<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis - Skilton, M - 2019 | Cochrane Library</title> <meta content="Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis - Skilton, M - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009841.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis - Skilton, M - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009841.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009841.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis" name="citation_title"/> <meta content="Mica Skilton" name="citation_author"/> <meta content="University of Liverpool, Institute in the Park" name="citation_author_institution"/> <meta content="Ashma Krishan" name="citation_author"/> <meta content="University of Liverpool, Alder Hey Children's NHS Foundation Trust" name="citation_author_institution"/> <meta content="Sanjay Patel" name="citation_author"/> <meta content="Stepping Hill Hopsital, Stockport NHS Foundation Trust" name="citation_author_institution"/> <meta content="Ian P Sinha" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Kevin W Southern" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="kwsouth@liverpool.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD009841.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009841.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009841.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009841.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Age Factors; Aminophenols [adverse effects, *therapeutic use]; Chloride Channel Agonists [adverse effects, *therapeutic use]; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cystic Fibrosis [*drug therapy, *genetics]; Cystic Fibrosis Transmembrane Conductance Regulator [drug effects, *genetics]; Forced Expiratory Volume [drug effects]; Molecular Targeted Therapy [methods]; Mucociliary Clearance; Mutation [*genetics]; Quality of Life; Quinolones [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009841.pub3&amp;doi=10.1002/14651858.CD009841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009841\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009841\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009841.pub3",title:"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis",firstPublishedDate:"Jan 7, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009841.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009841.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009841.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009841.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009841.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009841.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009841.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009841.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009841.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009841.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4059 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009841.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-sec-0123"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-sec-0117"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/appendices#CD009841-sec-0128"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/table_n/CD009841StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/table_n/CD009841StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information#CD009841-cr-0002">Mica Skilton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information#CD009841-cr-0003">Ashma Krishan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information#CD009841-cr-0004">Sanjay Patel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information#CD009841-cr-0005">Ian P Sinha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information#CD009841-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Kevin W Southern</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information/en#CD009841-sec-0133">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009841.pub3">https://doi.org/10.1002/14651858.CD009841.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009841-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009841-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009841-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009841-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009841-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009841-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009841-abs-0001" lang="en"> <section id="CD009841-sec-0001"> <h3 class="title" id="CD009841-sec-0001">Background</h3> <p>Cystic fibrosis (CF) is the commonest inherited life‐shortening illness in white populations, caused by a mutation in the gene that codes for the cystic fibrosis transmembrane regulator protein (CFTR), which functions as a salt transporter. This mutation mainly affects the airways where excess salt absorption dehydrates the airway lining leading to impaired mucociliary clearance. Consequently, thick, sticky mucus accumulates making the airway prone to chronic infection and progressive inflammation; respiratory failure often ensues. Other complications include malnutrition, diabetes and subfertility. </p> <p>Increased understanding of the condition has allowed pharmaceutical companies to design mutation‐specific therapies targeting the underlying molecular defect. CFTR potentiators target mutation classes III and IV and aim to normalise airway surface liquid and mucociliary clearance, which in turn impacts on the chronic infection and inflammation. This is an update of a previously published review. </p> </section> <section id="CD009841-sec-0002"> <h3 class="title" id="CD009841-sec-0002">Objectives</h3> <p>To evaluate the effects of CFTR potentiators on clinically important outcomes in children and adults with CF. </p> </section> <section id="CD009841-sec-0003"> <h3 class="title" id="CD009841-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles, reviews and online clinical trial registries. Last search: 21 November 2018. </p> </section> <section id="CD009841-sec-0004"> <h3 class="title" id="CD009841-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of parallel design comparing CFTR potentiators to placebo in people with CF. A separate review examines trials combining CFTR potentiators with other mutation‐specific therapies. </p> </section> <section id="CD009841-sec-0005"> <h3 class="title" id="CD009841-sec-0005">Data collection and analysis</h3> <p>The authors independently extracted data, assessed the risk of bias in included trials and used GRADE to assess evidence quality. Trial authors were contacted for additional data. </p> </section> <section id="CD009841-sec-0006"> <h3 class="title" id="CD009841-sec-0006">Main results</h3> <p>We included five RCTs (447 participants with different mutations) lasting from 28 days to 48 weeks, all assessing the CFTR potentiator ivacaftor. The quality of the evidence was moderate to low, mainly due to risk of bias (incomplete outcome data and selective reporting) and imprecision of results, particularly where few individuals experienced adverse events. Trial design was generally well‐documented. All trials were industry‐sponsored and supported by other non‐pharmaceutical funding bodies. </p> <p>F508del (class II) (140 participants) </p> <p>One 16‐week trial reported no deaths, or changes in quality of life (QoL) or lung function (either relative or absolute change in forced expiratory volume in one second (FEV1) (moderate‐quality evidence). Pulmonary exacerbations and cough were the most reported adverse events in ivacaftor and placebo groups, but there was no difference between groups (low‐quality evidence); there was also no difference between groups in participants interrupting or discontinuing treatment (low‐quality evidence). Number of days until the first exacerbation was not reported, but there was no difference between groups in how many participants developed pulmonary exacerbations. There was also no difference in weight. Sweat chloride concentration decreased, mean difference (MD) ‐2.90 mmol/L (95% confidence interval (CI) ‐5.60 to ‐0.20). </p> <p>G551D (class III) (238 participants) </p> <p>The 28‐day phase 2 trial (19 participants) and two 48‐week phase 3 trials (adult trial (167 adults), paediatric trial (52 children)) reported no deaths. QoL scores (respiratory domain) were higher with ivacaftor in the adult trial at 24 weeks, MD 8.10 (95% CI 4.77 to 11.43) and 48 weeks, MD 8.60 (95% CI 5.27 to 11.93 (moderate‐quality evidence). The adult trial reported a higher relative change in FEV1 with ivacaftor at 24 weeks, MD 16.90% (95% CI 13.60 to 20.20) and 48 weeks, MD 16.80% (95% CI 13.50 to 20.10); the paediatric trial reported this at 24 weeks, MD 17.4% (P &lt; 0.0001)) (moderate‐quality evidence). These trials demonstrated absolute improvements in FEV1 (% predicted) at 24 weeks, MD 10.80% (95% CI 8.91 to 12.69) and 48 weeks, MD 10.44% (95% CI 8.56 to 12.32). The phase 3 trials reported increased cough, odds ratio (OR) 0.57 (95% CI 0.33 to 1.00) and episodes of decreased pulmonary function, OR 0.29 (95% CI 0.10 to 0.82) in the placebo group; ivacaftor led to increased dizziness in adults, OR 10.55 (95% CI 1.32 to 84.47). There was no difference between groups in participants interrupting or discontinuing treatment (low‐quality evidence). Fewer participants taking ivacaftor developed serious pulmonary exacerbations; adults taking ivacaftor developed fewer exacerbations (serious or not), OR 0.54 (95% CI 0.29 to 1.01). A higher proportion of participants were exacerbation‐free at 24 weeks with ivacaftor (moderate‐quality evidence). Ivacaftor led to a greater absolute change from baseline in FEV1 (% predicted) at 24 weeks, MD 10.80% (95% CI 8.91 to 12.69) and 48 weeks, MD 10.44% (95% CI 8.56 to 12.32); weight also increased at 24 weeks, MD 2.37 kg (95% CI 1.68 to 3.06) and 48 weeks, MD 2.75 kg (95% CI 1.74 to 3.75). Sweat chloride concentration decreased at 24 weeks, MD ‐48.98 mmol/L (95% CI ‐52.07 to ‐45.89) and 48 weeks, MD ‐49.03 mmol/L (95% CI ‐52.11 to ‐45.94). </p> <p>R117H (class IV) (69 participants) </p> <p>One 24‐week trial reported no deaths. QoL scores (respiratory domain) were higher with ivacaftor at 24 weeks, MD 8.40 (95% CI 2.17 to 14.63), but no relative changes in lung function were reported (moderate‐quality evidence). Pulmonary exacerbations and cough were the most reported adverse events in both groups, but there was no difference between groups; there was no difference between groups in participants interrupting or discontinuing treatment (low‐quality evidence). Number of days until the first exacerbation was not reported, but there was no difference between groups in how many participants developed pulmonary exacerbations. No changes in absolute change in FEV1 or weight were reported. Sweat chloride concentration decreased, MD ‐24.00 mmol/L (CI 95% ‐24.69 to ‐23.31). </p> </section> <section id="CD009841-sec-0007"> <h3 class="title" id="CD009841-sec-0007">Authors' conclusions</h3> <p>There is no evidence supporting the use of ivacaftor in people with the F508del mutation. Both G551D phase 3 trials demonstrated a clinically relevant impact of ivacaftor on outcomes at 24 and 48 weeks in adults and children (over six years of age) with CF. The R117H trial demonstrated an improvement in the respiratory QoL score, but no improvement in respiratory function. </p> <p>As new mutation‐specific therapies emerge, it is important that trials examine outcomes relevant to people with CF and their families and that adverse events are reported robustly and consistently. Post‐market surveillance is essential and ongoing health economic evaluations are required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009841-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009841-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009841-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009841-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009841-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009841-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009841-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009841-abs-0004" lang="en"> <h3>Ivacaftor (marketed as Kalydeco®), a new specific therapy for cystic fibrosis</h3> <p><b>Review question</b> </p> <p>How does ivacaftor affect clinical outcomes (survival, quality of life and lung function) in people with cystic fibrosis (CF)? </p> <p><b>Background</b> </p> <p>In people with CF, airway surfaces do not have enough water because of an abnormal protein; this makes it difficult to clear thick and sticky mucus, which leads to lung infections. Ivacaftor works on the abnormal protein in people with some mutations to allow the airways retain more water and better clear mucus, so fewer lung infections develop. </p> <p>Ivacaftor was aimed at people with class III and IV mutations, and has been studied in people with G551D (class III), R117H (class IV) and F508del (class II) mutations. </p> <p><b>Trial characteristics</b> </p> <p>We included five trials (447 participants) comparing ivacaftor to placebo (dummy treatment with no active medication) lasting between four and 48 weeks. Three trials enrolled a total of 238 people with at least one copy of the G551D mutation, one trial enrolled 140 people with two copies of the F508del mutation and one enrolled 69 people with at least one copy of the R117H mutation. The evidence is up to date as of 21 November 2018. </p> <p><b>Key results</b> </p> <p>F508del mutation </p> <p>The trial did not report any deaths or show improvements in lung function, quality of life scores or weight. Cough and pulmonary exacerbations (flare ups of lung disease) were the most reported adverse events when taking both ivacaftor and placebo; there were a similar number of flare ups for both groups. Sweat chloride concentrations were reduced with ivacaftor. </p> <p>G551D mutation </p> <p>No deaths were reported. Both children and adults taking ivacaftor showed improvements in lung function, but only adults reported higher quality of life scores. People given placebo reported more coughing and experienced more episodes of decreased lung function; more adults taking ivacaftor reported episodes of dizziness. Similar numbers of people taking ivacaftor and placebo delayed the course of medication, or withdrew from the trial altogether, due to side effects (e.g. psychological issues, liver disease, severe breathing problems). There were more serious pulmonary exacerbations whilst taking placebo compared to ivacaftor. Adults taking ivacaftor were admitted to hospital less often and had fewer courses of intravenous antibiotics for exacerbations. Both children and adults and children increased their weight with ivacaftor. There was a drop in sweat chloride concentrations with ivacaftor. </p> <p>R117H mutation </p> <p>No deaths occurred in this trial. While quality of life scores improved with ivacaftor, lung function did not. Cough and pulmonary exacerbations (flare ups of lung disease) were the most reported adverse events when taking both ivacaftor and placebo; there were a similar number of flare ups for both groups. There was no difference in weight; but as for other mutations there was a reduction in sweat chloride concentration with ivacaftor.<br/> <br/> Evidence suggests that ivacaftor is an effective treatment for people (over six years of age) with cystic fibrosis and the G551D mutation, but not for those with the F508del or R117H mutations. </p> <p><b>Quality of the evidence</b> </p> <p>In most trials, individuals were put into different treatment groups at random with equal chances of being given either placebo or ivacaftor; no one could work out which treatment the next person would receive, so that healthier people did not receive ivacaftor and make the results seem better. We were not sure whether anyone involved in the trial knew who was receiving which treatment and how this might affect results. No trials reported all results clearly; sometimes they did not report them in a way that we could use in the review and sometimes they did not report the data at all. This affected our certainty regarding the overall results. Information about some side effects was limited as not many people experienced them, therefore, it is difficult to judge whether there was a difference between treatment groups </p> <p>We judged the evidence in this review to be moderate to low quality.</p> <p><b>Trial funding sources</b> </p> <p>All trials were sponsored by Vertex Pharmaceuticals Incorporated. The National Institute of Health (NIH), the Cystic Fibrosis Foundation (CFF) and other non‐pharmaceutical funding bodies also supported the trials. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009841-sec-0123" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009841-sec-0123"></div> <h3 class="title" id="CD009841-sec-0124">Implications for practice</h3> <section id="CD009841-sec-0124"> <p>The F508del trial demonstrated no evidence to support the use of ivacaftor in those with the F508del mutation (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). The two G551D phase 3 trials demonstrated a clinically relevant impact of ivacaftor on outcomes at 24 and 48 weeks in children (over six years of age) and adults with cystic fibrosis (CF) and the G551D mutation (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The R117H trial demonstrated an improvement in the respiratory domain of the CFQ‐R but no improvement in respiratory function (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). These trials were judged to have a moderate risk of bias. </p> </section> <h3 class="title" id="CD009841-sec-0125">Implications for research</h3> <section id="CD009841-sec-0125"> <p>Ivacaftor is the first intervention that corrects the underlying molecular defect in CF. It has demonstrated effectiveness in people with a class III mutation (G551D) and some effectiveness with class IV mutations (R117H) and has the potential to be used for other class III and IV mutations. Phase 3 trials examining ivacaftor in combination with a CFTR corrector (lumacaftor) in class II mutations (F508del) have been assessed in a separate Cochrane Review (<a href="./references#CD009841-bbs2-0086" title="SouthernKW , PatelS , SinhaIP , NevittSJ . Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD010966.pub2] ">Southern 2018</a>). </p> <p>As new mutation‐specific therapies emerge, it is important that the lessons learnt from this review are taken on board, in particular with respect to trial design (cross‐over trials are not appropriate given the potential for the therapies under consideration to fundamentally change the natural history of the condition), selective reporting and the details of participant blinding. It is important that these trials examine valid outcomes that are relevant to people with CF and their families. </p> <p>With novel therapies and approaches, such as ivacaftor, the reporting of adverse events is critical and this should be undertaken in a robust and consistent manner. Valid post‐market surveillance is also essential. </p> <p>In view of the cost implications for this therapy, ongoing health economic evaluations are required. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009841-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009841-sec-0029"></div> <div class="table" id="CD009841-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with the F508del CFTR mutation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ivacaftor compared with placebo for cystic fibrosis with the F508del CFTR mutation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis and with the F508del CFTR mutation<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> ivacaftor<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ivacaftor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Survival</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No deaths reported.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No deaths reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> <p><b>Total score</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL (CFQ‐R)</b> </p> <p><b>Respiratory domain</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b><br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no significant difference between groups at 16 weeks.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> % predicted Relative change from baseline</b> </p> <p>Follow‐up:16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported.<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean FEV<sub>1</sub> (% predicted) was 2.4% higher (0.95% lower to 5.75% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b><br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no significant difference between groups at 16 weeks.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> % predicted Absolute change from baseline</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported.<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean FEV<sub>1</sub> (% predicted) was 1.7% higher (0.65% lower to 4.05% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b><br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no significant difference between groups at 16 weeks.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Follow‐up:16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events in the placebo group were: pulmonary exacerbation, cough, oropharyngeal pain and fatigue. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events in the ivacaftor group were: cough, pulmonary exacerbation, upper respiratory tract infection and nasal congestion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b><br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no significant difference between groups in terms of any other adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to first pulmonary exacerbation</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean placebo group risk across studies, unless otherwise stated. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CFQ‐R:</b> Cystic Fibrosis Questionnaire‐Revised; <b>CFTR</b> : cystic fibrosis transmembrane regulator; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume at 1 second; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Presentation of the data prevented including data in analysis therefore results are presented narratively.<br/> 2. Only differences between placebo and ivacaftor groups were presented, results within the placebo group were not presented therefore an assumed risk cannot be calculated.<br/> 3. Downgraded once due to risk of bias from incomplete outcome data and/or selective reporting in all of the included studies.<br/> 4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specific events are very wide (also see <a href="./references#CD009841-fig-0005" title="">Analysis 1.2</a>) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009841-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with at least one G551D CFTR mutation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ivacaftor compared with placebo for cystic fibrosis with at least one G551D CFTR mutation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis and with at least one G551D CFTR mutation<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> ivacaftor<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ivacaftor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Survival</b> </p> <p>Follow‐up: 2 ‐ 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>238</b><br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> <p><b>Total score</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL (CFQ‐R)</b> </p> <p><b>Respiratory domain</b> </p> <p>Follow‐up: 2 ‐ 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>222</b> </p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small phase 2 trial (n = 19) showed no significant difference at 2 or 4 weeks.</p> <p>A phase 3 trial (n = 151) in adults showed significantly higher quality of life in the ivacaftor group compared to placebo at 48 weeks </p> <p>A phase 3 trial (n = 52) showed no significant difference at 24 or 48 weeks in the child version of the CFQ‐R. The same trial showed a significantly higher quality of life in the ivacaftor group compared to placebo at 48 weeks in the parent / caregiver version at 24 weeks but not at 48 weeks.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> % predicted Relative change from baseline</b> </p> <p>Follow‐up: 2 ‐ 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>232</b> </p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small phase 2 trial (n = 19) showed no significant difference at 2 or 4 weeks.</p> <p>Two phase 3 trials (n = 213) showed a significant improvement in FEV<sub>1</sub> at 24 weeks (MD ranged between 16.9% to 17.4%) </p> <p>One phase 3 trial (n = 161) showed a significant improvement in FEV<sub>1</sub> at 48 weeks (MD 16.8%). <sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> L and % predicted</b> </p> <p><b>Absolute change from baseline</b> </p> <p>Follow‐up: 2 to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>232</b> </p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small phase 2 trial (n = 19) showed no significant difference at 2 or 4 weeks.</p> <p>Two phase 3 trials (n = 213) showed a significant improvement in FEV<sub>1</sub> (L and % predicted) at 24 weeks and 48 weeks.<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Follow‐up: 2 ‐ 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events in the placebo group were: pulmonary exacerbation, cough, oropharyngeal pain and headache. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events in the ivacaftor group were: cough, pulmonary exacerbation, upper respiratory tract infection and headache. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>232</b> </p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary exacerbations were significantly more common in the placebo group. There was no significant difference between groups in terms of any other adverse events.<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to first pulmonary exacerbation</b> </p> <p>Follow‐up: 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>41% of the placebo group were exacerbation free at 48 weeks.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>67% of the ivacaftor group were exacerbation free at 48 weeks.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HR 0.46</b> (95% CI 0.29 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>161</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was also a statistically significant difference between groups at 24 weeks; 78% and 51% of the ivacaftor and placebo groups were exacerbation free respectively; HR 0.46 (95% CI 0.28 to 0.76). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean placebo group risk across studies, unless otherwise stated. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CFQ‐R:</b> Cystic Fibrosis Questionnaire‐Revised; <b>CFTR</b> : cystic fibrosis transmembrane regulator; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume at 1 second; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Presentation of the data prevented pooling the data from all three studies therefore results are summarised narratively.<br/> 2. Downgraded once due to risk of bias from incomplete outcome data and/or selective reporting in all of the included studies.<br/> 3. Downgraded once due to unexplained heterogeneity.<br/> 4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specific events are very wide (also see <a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>, <a href="./references#CD009841-fig-0016" title="">Analysis 2.6</a> and <a href="./references#CD009841-fig-0018" title="">Analysis 2.8</a>).<br/> 5. See analyses for numerical results (<a href="./references#CD009841-fig-0011" title="">Analysis 2.1;</a><a href="./references#CD009841-fig-0012" title="">Analysis 2.2</a>; <a href="./references#CD009841-fig-0013" title="">Analysis 2.3</a>).<br/> 6. See analysis for numerical results (<a href="./references#CD009841-fig-0014" title="">Analysis 2.4</a>).<br/> 7. See analyses for numerical results (<a href="./references#CD009841-fig-0024" title="">Analysis 2.14</a>; <a href="./references#CD009841-fig-0025" title="">Analysis 2.15</a>).<br/> 8. See analyses for numerical results (<a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>; <a href="./references#CD009841-fig-0016" title="">Analysis 2.6</a>; <a href="./references#CD009841-fig-0018" title="">Analysis 2.8</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009841-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with at least one R117H CFTR mutation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ivacaftor compared with placebo for cystic fibrosis with at least one R117H CFTR mutation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis and with at least one R117H CFTR mutation </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> ivacaftor </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ivacaftor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Survival</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p><b>Total score</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL (CFQ‐R)</b> </p> <p><b>Respiratory domain</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adjusted CFQ‐R respiratory domain score was 8.40% higher (2.17% higher to 14.63% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a significant</p> <p>improvement in CFQ‐R respiratory domain scores at 24 weeks.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted Relative change from baseline</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adjusted FEV<sub>1</sub> (% predicted) was 5.00% higher (0.24% lower to 10.24% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between groups at 24 weeks.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> L and</b> </p> <p><b>% predicted</b> </p> <p><b>Absolute change from baseline</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adjusted FEV<sub>1</sub> (% predicted) was 2.10% higher (1.13% lower to 5.33% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between groups at 24 weeks.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The most commonly reported adverse events in the placebo group were: pulmonary exacerbation and cough. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The most commonly reported adverse events in the ivacaftor group were: pulmonary exacerbation, cough, headache, nasal congestion, oropharyngeal pain, diarrhoea and increased sputum. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no</p> <p>significant difference between groups in terms of any other adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first</b> </p> <p><b>pulmonary</b> </p> <p><b>exacerbation</b> </p> <p>Follow‐up:</p> <p>24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63% of the placebo group were exacerbation free at 24 weeks.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68% of the ivacaftor group were exacerbation free at 24 weeks.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.93</b> (95% CI 0.42 to 2.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no</p> <p>significant difference between groups at 24 weeks.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CFQ‐R:</b> Cystic Fibrosis Questionnaire‐Revised; <b>CFTR</b> : cystic fibrosis transmembrane regulator; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume at 1 second; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Presentation of the data prevented including data in analysis therefore results are presented narratively.<br/> 2. Downgraded once due to risk of bias from selective reporting.<br/> 3. Treatment effect was adjusted for baseline values of age and % predicted FEV<sub>1</sub>.<br/> 4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specific events are very wide (also see <a href="./references#CD009841-fig-0034" title="">Analysis 3.4</a>) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009841-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009841-sec-0030"></div> <p>A glossary of terms specific to this review can be found in the appendices (<a href="./appendices#CD009841-sec-0129">Appendix 1</a>); a more general glossary of terms used in Cochrane Reviews can be accessed at <a href="http://www.cochrane.org/sites/default/files/uploads/glossary.pdf" target="_blank">Cochrane Glossary</a>. </p> <section id="CD009841-sec-0031"> <h3 class="title" id="CD009841-sec-0031">Description of the condition</h3> <p>Cystic fibrosis (CF) is the most common inherited life‐shortening illness in white populations, with a prevalence of 1 in 2000 at birth in Europeans (<a href="./references#CD009841-bbs2-0072" title="BobadillaJL , MacekM , FineJP , FarrellPM . Cystic fibrosis: a worldwide analysis of CFTR mutations‐‐correlation with incidence data and application to screening. Human Mutation2002;19(6):575‐606. ">Bobadilla 2002</a>) and varying prevalence in North American populations depending on ethnic composition (<a href="./references#CD009841-bbs2-0075" title="HamoshA , FitzSimmonsSC , Macek JrM , KnowlesMR , RosensteinBJ , CuttingGR . Comparison of the clinical manifestations of cystic fibrosis in black and white patients. Journal of Pediatrics1998;132(2):255‐9. ">Hamosh 1998</a>). According to the data report from the UK CF Registry which was published in July 2014, there were 10,338 people with a confirmed diagnosis of CF in the UK (<a href="./references#CD009841-bbs2-0087" title="UK CFTrust . Cystic fibrosis: our focus. www.cysticfibrosis.org.uk/media/598466/annual‐data‐report‐2013‐jul14.pdf (accessed 07 Jan 2015). ">UK CF Registry Report 2013</a>). The clinical features of CF arise from abnormalities in a protein called the cystic fibrosis transmembrane conductance regulator (CFTR) (<a href="./references#CD009841-bbs2-0082" title="RiordanJR , RommensJM , KeremB , AlonN , RozmahelR , GrzelczakZ , et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science1989;245(4922):1066. ">Riordan 1989</a>; <a href="./references#CD009841-bbs2-0084" title="SouthernKW . Delta F508 in cystic fibrosis: Willing but not able. Archives of Disease in Childhood1997;76(3):278‐82. ">Southern 1997</a>). Normally, CFTR protein is transported to the outer cell membrane, where it has a role in co‐ordinating the transport of the salt ions, sodium (Na<sup>+</sup>) and chloride (Cl<sup>‐</sup>), in and out of the cell. This salt transport role is particularly important in the airways, pancreas, sweat gland, and vas deferens.  </p> <p>In the lungs of people with CF, defective salt transport leads to a reduction in airway surface liquid volume. This, in turn, leads to compromised mucociliary clearance, which initiates a cycle of infection, inflammation and progressive lung damage, eventually causing respiratory failure and premature death. Other consequences of CFTR dysfunction, including those related to abnormalities in the inflammatory response, are probably important but not as well characterized. In addition, CFTR‐related ion transport abnormalities can lead to other systemic complications. These include malnutrition and diabetes (through pancreatic damage, salt depletion through excess loss in sweat) and subfertility (in men and women) caused by various factors. </p> <p>Over 1900 mutations have been identified in the CFTR gene, which can be categorised according to the impact they have on CFTR synthesis, processing, or function (<a href="./references#CD009841-bbs2-0073" title="Hospital for Sick Children in Toronto. Cystic Fibrosis Mutation Database. www.genet.sickkids.on.ca/StatisticsPage.html (accessed 01 March 2012). ">CFMD 2012</a>). These categories have been described (<a href="./references#CD009841-bbs2-0083" title="RowntreeRK , HarrisA . The phenotypic consequences of CFTR mutations. Annals of Human Genetics2003;67(5):471‐85. ">Rowntree 2003</a>; <a href="./references#CD009841-bbs2-0085" title="SouthernKW . Cystic fibrosis and formes frustes of CFTR‐related disease. Respiration: International Review of Thoracic Diseases2007;74(3):241‐51. ">Southern 2007</a>); and a summary is presented in the additional tables (<a href="#CD009841-tbl-0004">Table 1</a>). The most common mutation is the delta F508 (F508del) mutation (class II mutation) and is present on at least one allele in 7990 (90.8%) people with CF in the UK. The second most common mutation in the UK is the G551D mutation (class III mutation). This mutation exists in 514 (5.84%) people with CF in the UK. The R117H mutation (class IV mutation) is the third most common mutation, present in 398 (4.52%) people with CF in the UK (<a href="./references#CD009841-bbs2-0087" title="UK CFTrust . Cystic fibrosis: our focus. www.cysticfibrosis.org.uk/media/598466/annual‐data‐report‐2013‐jul14.pdf (accessed 07 Jan 2015). ">UK CF Registry Report 2013</a>). </p> <div class="table" id="CD009841-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of mutations affecting CFTR production, structure, and function</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Example mutation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Impact on CFTR structure and function</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G542X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthesis of CFTR is critically impaired, and no functional protein is produced. This is due to the presence of a premature stop codon in the nucleotide sequence. Individuals have minimal CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ΔF508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A full length of CFTR is produced, but this is structurally abnormal and destroyed by the cell before it reaches the cell membrane. This is called a defect in the intracellular trafficking pathway. Minimal amounts of CFTR can escape being destroyed and be transported to the cell membrane. However here, class II CFTR products display defective ion transport. Individuals have minimal CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G551D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CFTR is produced and embedded in the cell membrane, but the chloride channel does not respond (‘switch on’) to normal stimulation from the cell. This means there is no significant ion transport across the protein. Individuals have some residual CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R347P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CFTR is transported to the outer cell membrane, and responds to normal stimulation, but functions at a low level because chloride ions do not cross the channel appropriately. Individuals have some residual CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A455E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal CFTR is produced, but the amount of protein is reduced. Individuals have some residual CFTR function. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CFTR: cystic fibrosis transmembrane conductance regulator</p> </div> </div> </section> <section id="CD009841-sec-0032"> <h3 class="title" id="CD009841-sec-0032">Description of the intervention</h3> <p>Understanding how the mutations, which are described in the additional tables (<a href="#CD009841-tbl-0004">Table 1</a>), affect the production, structure, and function of CFTR has led to the concept of mutation‐specific therapies. One strategy, relating mainly to mutations classes III to V but also to class II, is to improve the function of CFTR that has reached the cell membrane, but whose function is compromised (<a href="./references#CD009841-bbs2-0080" title="McKoneEF , AitkenML . Cystic fibrosis: disease mechanisms and therapeutic targets. Drug Discovery Today: Disease Mechanisms2004;1(1):137‐43. ">McKone 2004</a>). Drugs that improve CFTR function in the cell membrane are called potentiators and have the potential to correct the abnormal salt transport that characterises CF. Potentiators can be administered orally, or as an inhaled preparation. </p> <p>Two distinct approaches have resulted in the recognition of candidate drugs with this mode of action (<a href="./references#CD009841-bbs2-0070" title="AmaralMD , KunzelmannK . Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends in Pharmacological Sciences2007;28(7):334‐41. ">Amaral 2007</a>): </p> <p> <ol id="CD009841-list-0001"> <li> <p>testing of compounds known to affect CFTR or other ion‐channels (either pharmaceutical drugs or chemicals which occur naturally in plants, herbs, fruits or food components); </p> </li> <li> <p>high throughput screening, which involves testing large numbers of diverse chemicals, on laboratory cell lines, to identify which of these may stimulate CFTR. </p> </li> </ol> </p> <p>In addition to potentiators, other drugs which aim to correct defects of the CFTR are also under investigation in clinical trials. These include correctors (which increase the amount of CFTR in the cell membrane by preventing early degradation ‐ class II mutations) and 'stop‐codon therapies' which act to prevent structural abnormalities of CFTR that occur when premature stop codons terminate protein synthesis too early ‐ class I mutations). Cochrane Reviews of trials assessing correctors and one assessing stop codon therapies have been published (<a href="./references#CD009841-bbs2-0071" title="AslamAA , HigginsC , SinhaIP , SouthernKW . Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012040.pub2] ">Aslam 2017</a>; <a href="./references#CD009841-bbs2-0086" title="SouthernKW , PatelS , SinhaIP , NevittSJ . Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD010966.pub2] ">Southern 2018</a>). </p> </section> <section id="CD009841-sec-0033"> <h3 class="title" id="CD009841-sec-0033">How the intervention might work</h3> <p>The CFTR potentiator ivacaftor was identified through high‐throughput screening by Vertex Pharmaceuticals Incorporated. In cell and animal models, it was able to restore CFTR function for class III mutations and correct the abnormal transmembrane salt transport (<a href="./references#CD009841-bbs2-0088" title="VanGoorF , HadidaS , GrootenhuisPD , BurtonB , CaoD , NeubergerT , et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX‐770.. Proceedings of the National Academy of Sciences of the United States of America2009;106(44):18825‐30. [DOI: 10.1073/pnas.0904709106] ">Van Goor 2009</a>). However, the precise mechanism of action of ivacaftor is unclear, owing to the limited amount of data. </p> <p>The correction of the basic defect in CF in the airways of the lung could lead to the normalization of airway surface liquid; the resulting re‐establishment of mucociliary clearance, would then have a beneficial impact on the chronic infection and inflammation that characterizes CF lung disease. </p> </section> <section id="CD009841-sec-0034"> <h3 class="title" id="CD009841-sec-0034">Why it is important to do this review</h3> <p>Since CFTR potentiators are novel therapies, it is important that randomised controlled trials (RCTs) testing these agents are critically appraised. This will enable examination of the evidence relating to the benefits and harms of CFTR potentiators. It is important that funding bodies have a clear evidence base on which to assess new therapies for CF that aim to correct the basic defect, particularly given the large prevalence of people with mutations that might be impacted by CFTR potentiators. It is likely that these therapies will represent a significant healthcare resource. In addition, critical appraisal of included trials will help inform future trial design. </p> <p>This review aims to collate evidence from RCTs that have evaluated the benefits and harms of CFTR potentiators in people with CF. This is an update of a previously published version (<a href="./references#CD009841-bbs2-0090" title="PatelS , SinhaIP , DwanK , EchevarriaC , SchechterM , SouthernKW . Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009841] ">Patel 2012</a>; <a href="./references#CD009841-bbs2-0091" title="PatelS , SinhaIP , DwanK , EchevarriaC , SchechterM , SouthernKW . Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009841.pub2] ">Patel 2015</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009841-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009841-sec-0035"></div> <p>To evaluate the effects of CFTR potentiators on clinically important outcomes in children and adults with CF. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009841-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009841-sec-0036"></div> <section id="CD009841-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009841-sec-0038"> <h4 class="title">Types of studies</h4> <p>RCTs of parallel design (published or unpublished). Cross‐over trials were considered inappropriate given the potential longer‐term impact of this therapy on outcomes. </p> </section> <section id="CD009841-sec-0039"> <h4 class="title">Types of participants</h4> <p>We have included trials involving children or adults with CF, as confirmed either by the presence of two disease‐causing mutations, or by a combination of a positive sweat test and recognised clinical features of CF. We included trials involving people with any level of disease severity and any relevant mutation class, where CFTR has been demonstrated to successfully embed within the cell membrane and display defective function. </p> </section> <section id="CD009841-sec-0040"> <h4 class="title">Types of interventions</h4> <p>In a post hoc change we have only included trials comparing CFTR potentiators to placebo or another intervention. Trials where CFTR potentiators are used in combination with other CFTR function modulators were excluded. There are many ongoing trials that use a CFTR potentiator alongside a CFTR corrector and we believe it would be more appropriate to conduct a separate systematic review for these trials (<a href="./references#CD009841-bbs2-0086" title="SouthernKW , PatelS , SinhaIP , NevittSJ . Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD010966.pub2] ">Southern 2018</a>). </p> </section> <section id="CD009841-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD009841-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009841-list-0002"> <li> <p>Survival (in a post hoc change mortality data were also considered)</p> </li> <li> <p>Quality of life (QoL) (measured using validated quantitative scales or scores (e.g. Cystic Fibrosis Questionnaire‐Revised (CFQ‐R) (<a href="./references#CD009841-bbs2-0081" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire‐Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610‐8. ">Quittner 2009</a>)) </p> <ol id="CD009841-list-0003"> <li> <p>total QoL score</p> </li> <li> <p>different sub‐domains which may be reported</p> </li> </ol> </li> <li> <p>Forced expiratory flow rate at one second (FEV<sub>1</sub>) (relative change from baseline) </p> </li> </ol> </p> </section> <section id="CD009841-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009841-list-0004"> <li> <p>Adverse effects</p> <ol id="CD009841-list-0005"> <li> <p>graded by review authors as mild (therapy does not need to be discontinued)</p> </li> <li> <p>graded by review authors as moderate (therapy is discontinued, and the adverse effect ceases) </p> </li> <li> <p>graded by review authors as severe (life‐threatening or debilitating, or which persists even after treatment is discontinued) </p> </li> <li> <p>other adverse effects of therapy (of any severity) that are not classifiable according to these categories, including pulmonary exacerbation (protocol defined or physician defined) and time‐to‐exacerbation data </p> </li> </ol> </li> <li> <p>Hospitalisation</p> <ol id="CD009841-list-0006"> <li> <p>number of days</p> </li> <li> <p>number of episodes</p> </li> </ol> </li> <li> <p>School or work attendance (i.e. number of days missed)</p> </li> <li> <p>Other physiological measures of lung function (litres or per cent (%) predicted for age, sex and height) </p> <ol id="CD009841-list-0007"> <li> <p>FEV<sub>1</sub> absolute values (rather than "relative change from baseline", which is specified as primary outcome) </p> </li> <li> <p>forced vital capacity (FVC) (absolute values and change from baseline)</p> </li> </ol> </li> <li> <p>Extra courses of antibiotics (measured as time‐to the next course of antibiotics and the total number of courses of antibiotics) </p> <ol id="CD009841-list-0008"> <li> <p>oral</p> </li> <li> <p>intravenous</p> </li> <li> <p>inhaled</p> </li> </ol> </li> <li> <p>Radiological measures of lung disease (assessed using any scoring system)</p> <ol id="CD009841-list-0009"> <li> <p>chest radiograph scores</p> </li> <li> <p>computerised tomogram (CT) score</p> </li> </ol> </li> <li> <p>Acquisition of respiratory pathogens</p> <ol id="CD009841-list-0010"> <li> <p><i>Pseudomonas aeruginosa</i> </p> </li> <li> <p><i>Staphylococcus aureus</i> </p> </li> <li> <p><i>Haemophilus influenzae</i> </p> </li> <li> <p>other significant pathogen</p> </li> </ol> </li> <li> <p>Eradication of respiratory pathogens (as defined by trial authors)</p> <ol id="CD009841-list-0011"> <li> <p><i>P aeruginosa</i> </p> </li> <li> <p><i>S aureus</i> </p> </li> <li> <p><i>H influenzae</i> </p> </li> <li> <p>other significant pathogen</p> </li> </ol> </li> <li> <p>Nutrition and growth (measured as relative change from baseline) (including z scores or centiles) </p> <ol id="CD009841-list-0012"> <li> <p>weight</p> </li> <li> <p>body mass index (BMI)</p> </li> <li> <p>height</p> </li> </ol> </li> <li> <p>Sweat chloride (change from baseline) as a measure of CFTR function</p> </li> <li> <p>Cost of treatment</p> </li> </ol> </p> </section> </section> </section> <section id="CD009841-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>There are no restrictions regarding language or publication status.</p> <section id="CD009841-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Group's Cystic Fibrosis Trials Register using the term: 'drugs that augment function of abnormal CFTR protein in the cell membrane'. Relevant trials have been tagged with this term for indexing purposes in the Group's Cystic Fibrosis Trials Register. </p> <p>This is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the handsearching of two journals – <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work was identified by searching through the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of latest search of the Group's Cystic Fibrosis Trials Register: 21 November 2018. </p> <p>We also searched online clinical trial registries (<a href="./appendices#CD009841-sec-0129">Appendix 1</a>). Date of last search of clinical trial registries: 21 November 2018. </p> </section> <section id="CD009841-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We screened references of included trials to identify other potentially relevant trials. We also contacted authors of included trials, leaders in the field, and companies known to be developing and investigating CFTR potentiators, to identify any trials that may have been missed by these searches. </p> </section> </section> <section id="CD009841-sec-0047"> <h3 class="title" id="CD009841-sec-0047">Data collection and analysis</h3> <section id="CD009841-sec-0048"> <h4 class="title">Selection of studies</h4> <p>For the original review, two authors (SP and IS) independently assessed the suitability of each trial identified by the search. From the 2018 update onwards MS and IS independently assessed the suitability of each trial and if disagreement arose regarding suitability for inclusion, we attempted to reach a consensus by discussion, failing which a third author (KWS) arbitrated. </p> </section> <section id="CD009841-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>For the updated review, two authors (MS and IS) independently extracted relevant data from each included trial using a standardised data extraction form. If disagreement arose on data extraction, we attempted to reach a consensus by discussion, failing which a fourth author (KWS) arbitrated. </p> <p>We intended to report on our primary outcome 'survival' as survival to time X (time‐to‐event data). However, these data were not available, so we considered mortality data (number of deaths) as an alternative outcome (post hoc change). For lung function, where possible we reported the relative change from baseline in FEV<sub>1</sub>, since this way of presenting FEV<sub>1</sub> is very important in clinical practice. If this was not possible, we reported absolute change from baseline in FEV<sub>1</sub> as a secondary outcome. We extracted QoL as the absolute change from baseline. </p> <p>With regards to the secondary outcome 'Adverse effects', we extracted the total number of participants who experienced adverse effects or required trial drug interruption or termination. When extracting data on pulmonary exacerbations, we noted whether they were protocol‐defined or physician‐defined. We reported the number of participants who experienced episodes of pulmonary exacerbation or reported time‐to‐exacerbation data. We extracted the number of participants who required hospitalisations. With regards to 'Extra courses of antibiotics', we reported on the total number of courses of antibiotics. </p> <p>For the secondary outcomes 'Change from baseline in weight' and 'Change from baseline in sweat chloride concentration', we extracted the absolute change from baseline results. </p> <p>For continuous outcomes, where standard deviations (SDs) were not provided, we calculated the standard error of the mean (SEM) from the 95% confidence intervals (CIs) and inserted the results into a generic inverse variance (GIV) analysis. </p> <p>If the trial author presented non‐parametric data, we reported results in the written text and not in the analysis. </p> <p>We have reported data at 4 weeks, 16 weeks, 24 weeks and 48 weeks.</p> </section> <section id="CD009841-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (MS and IS) assessed the risk of bias for each trial using the Cochrane risk of bias tool (<a href="./references#CD009841-bbs2-0077" title="HigginsJPT , Altman DG(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). This includes assessment of the following methodological aspects of the included trials: </p> <p> <ol id="CD009841-list-0013"> <li> <p>procedure for randomisation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>masking (blinding) of the intervention from participants, clinicians, and trial personnel evaluating outcomes (performance bias); </p> </li> <li> <p>missing outcome data (attrition bias);</p> </li> <li> <p>selective outcome reporting (reporting bias);</p> </li> <li> <p>other sources of bias.</p> </li> </ol> </p> <p>We also assessed whether all participants were included in an intention‐to‐treat analysis, regardless of whether they completed the treatment schedule or not. If disagreement arose on the assessment of risk of bias of a trial, we attempted to reach a consensus by discussion, failing which a third author (KWS) arbitrated.  </p> </section> <section id="CD009841-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, we calculated a pooled estimate of the treatment effect for each outcome using the pooled odds ratio (OR) and 95% CIs or 99% confidence intervals for analysis of separate adverse events. If calculating a pooled OR was not appropriate, we calculated an estimate of the treatment effect for each outcome using the OR and 95% CIs. </p> <p>For continuous outcomes, we calculated the mean change from baseline for each group or the mean post‐intervention values and 95% CIs for each group. We produced a pooled estimate of treatment effect by calculating the mean difference (MD) and 95% CIs. For QoL, CFQ‐R was the most frequently used questionnaire and so we calculated the MD and 95% CIs. No other questionnaire was used. </p> <p>For time‐to‐event outcomes, such as 'Time to first pulmonary exacerbation', we used measures of survival analysis, and calculated hazard ratios (HR) and 95% CIs between different arms of the trial. </p> <p>In future updates of this review, if different trials present data for the same outcomes in different forms (e.g. absolute values of lung function measures, or change in these measures from a baseline), we will combine these in a meta‐analysis where appropriate. </p> <p>Where the trials did not report change data, but instead presented absolute post‐treatment data without baseline data (so it was not possible to calculate change data), we planned to use absolute post‐treatment data instead of change from baseline. However, if the report presented baseline and post‐treatment data for any outcome, we calculated SDs for the change from baseline, for example if the CI was available. If there was not enough information available to calculate the SDs for the changes, we planned to impute them from other trials in the review, where data were available and trials were similar (i.e. when they used the same measurement scale, had the same degree of measurement error, had the same time periods between baseline and final value measurement and had conducted the randomisation process appropriately). If neither of these methods were possible, we planned to calculate a change‐from‐baseline SD, making use of an imputed correlation coefficient (methods described in chapter 16 in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD009841-bbs2-0078" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>)). </p> </section> <section id="CD009841-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>Within this review, we have only included results from RCTs of parallel design in which individual trial participants were randomised. We excluded cross‐over trials, because they are not appropriate for evaluating therapies that potentially correct the underlying defect (<a href="./references#CD009841-bbs2-0078" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). We did not identify any cluster RCTs. Further updates of this review will include any eligible cluster RCTs identified and these will be included and analysed as described in the <i>Cochrane Handbook for Systematic Reviews of Inteventions</i> (<a href="./references#CD009841-bbs2-0078" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> <p>Where trials with multiple intervention groups reported dichotomous data i.e. adverse effects, we pooled the data to form one intervention group and compared data to the placebo group as recommended in chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Inteventions</i> (<a href="./references#CD009841-bbs2-0078" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD009841-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>In order to allow an intention‐to‐treat analysis, we extracted data on the number of participants with each outcome event, by allocated treated group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow‐up. We calculated the number of participants with outcome data and checked if this was consistent with the number of originally randomised participants. We checked that this finding was consistent with findings on the online ongoing trials database (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). If there were any discrepancies or any uncertainty, we contacted the primary investigators for clarification. For more detail about what we requested and what information we were provided with, see the risk of bias section below (<a href="#CD009841-sec-0079">Incomplete outcome data (attrition bias)</a>). </p> </section> <section id="CD009841-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity through a visual examination of the forest plots, and by considering the I² statistic (<a href="./references#CD009841-bbs2-0076" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>) together with the Chi² test (P &lt; 0.1) (<a href="./references#CD009841-bbs2-0074" title="DeeksJ , HigginsJ , AltmanD . Chapter 9 Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). The I² statistic reflects the likelihood that the variation of results across trials is due to heterogeneity rather than chance, and we interpreted this statistic using the following classification: </p> <p> <ul id="CD009841-list-0014"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>If we had identified heterogeneity between trials, we would have conducted a sensitivity analysis including only homogenous trials to determine the effect of heterogeneity on the overall treatment effect of the intervention. </p> </section> <section id="CD009841-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>In order to identify selective outcome reporting, where possible we compared outcomes described in the trial protocol with those reported in the publication(s). We requested protocols for specific trials from the primary investigators, corresponding author, or relevant pharmaceutical company when they were not available<i>.</i> We have recorded the proportion of protocols that were available to us<i>.</i> If the protocol was not available, we checked published information on the trial registry databases. We also compared outcomes listed in the 'Methods' section of the final paper with those presented in the 'Results' section. If the published papers partially reported negative findings (i.e. P &gt; 0.05), we contacted the primary investigators for these data. </p> <p>We planned to assess publication bias by constructing and assessing the symmetry of a funnel plot. This would have been possible if we had included more than 10 trials in the review. </p> </section> <section id="CD009841-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model to analyse data from trials which we did not consider to be heterogeneous (see classifications above). If substantial or considerable heterogeneity had been present (I² greater than 50%), we used a random‐effects model to analyse data. </p> </section> <section id="CD009841-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to investigate any heterogeneity that we identified using subgroup analyses of potential confounding factors. For this review, we planned that these confounding factors would be: </p> <p> <ul id="CD009841-list-0015"> <li> <p>age (children (defined as younger than 18 years of age) versus adults);</p> </li> <li> <p>gender;</p> </li> <li> <p>different mutation classes (<a href="#CD009841-tbl-0004">Table 1</a>). </p> </li> </ul> </p> <p>As we did not seek individual patient data from trial investigators, we did not undertake a subgroup analysis on the basis of disease severity. Such an analysis may be incorporated in future updates of this review. </p> </section> <section id="CD009841-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>If we had been able to combine a sufficient number of trials (at least 10), we planned to examine the impact of risk of bias on the results examined by comparing meta‐analyses including and excluding trials with concerns of high risk of selection or reporting bias due to issues relating to randomisation, allocation concealment, or masking of interventions from participants or trial personnel. </p> <section id="CD009841-sec-0059"> <h5 class="title">Summary of findings and quality of the evidence (GRADE)</h5> <p>In a post hoc change from protocol, we have presented three summary of findings tables (<a href="./full#CD009841-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009841-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009841-tbl-0003">summary of findings Table 3</a>) under the comparison of 'Ivacaftor compared to placebo' according to mutation class (see <a href="#CD009841-tbl-0004">Table 1</a>). </p> <p>The following outcomes were reported in all tables (chosen based on relevance to clinicians and consumers): </p> <p> <ul id="CD009841-list-0016"> <li> <p>survival;</p> </li> <li> <p>QoL (total score);</p> </li> <li> <p>QoL (respiratory domain);</p> </li> <li> <p>FEV<sub>1</sub> (relative and absolute change); </p> </li> <li> <p>adverse events; and</p> </li> <li> <p>time to first pulmonary exacerbation.</p> </li> </ul> </p> <p>For clarity in the tables, adverse events are not presented according to the subdomains in <a href="#CD009841-sec-0082">Effects of interventions</a>; instead the authors have inserted a general statement about the summary of findings for these outcomes and the evidence is graded based on all of the subdomains combined. </p> <p>We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We evidence by one level if they considered the limitation to be serious and by two levels if very serious. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009841-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009841-sec-0060"></div> <section id="CD009841-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD009841-sec-0062"> <h4 class="title">Results of the search</h4> <p>The search of the Group's Cystic Fibrosis Trials Register identified a total of 201 publications (abstracts and full papers) representing 67 trials. A further 91 trials were identified from ongoing trials databases. Five trials (67 references) were included and 62 trials (115 references) were excluded. The two trials (two references) awaiting classification have both been published as conference abstracts; further details below (<a href="./references#CD009841-bbs2-0068" title="KazaniS , AlcantaraJ , DebonnettL , DoucetJ , JonesI , KulmatyckiK , et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2016;193(Meeting Abstracts):A7789. [CFGD Register: BD243] NCT02190604 . Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients.. clinicaltrials.gov/ct2/show/NCT02190604 (first received 15 July 2014). ">Kazani 2016</a>; <a href="./references#CD009841-bbs2-0069" title="UttamsinghV , PiljaL , BrummelCL , GrotbeckB , CassellaJV , BramanG . CTP‐656 multiple dose pharmacokinetic profile continues to support a once‐daily potentiator for cystic fibrosis patients with gating mutations. Pediatric Pulmonology2016;51 Suppl 45:277. [Abstract no.: 244; CFGD Register: BD241] ">Uttamsingh 2016</a>). In a post hoc change (2018), references to corrector and potentiator combination therapy trials have not been listed in the review, meaning 79 trials (110 references) identified have not been listed in the reference section of this review. The results of the search are displayed in the PRISMA diagram below (<a href="#CD009841-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009841-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009841-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>No additional trials were identified by screening references of included trials or by contacting authors of included trials, leaders in the field, and companies known to be developing and investigating CFTR potentiators. </p> </section> <section id="CD009841-sec-0063"> <h4 class="title">Included studies</h4> <p>We included five trials (67 references) with 447 participants in this review (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). All trials were available as full texts. </p> <section id="CD009841-sec-0064"> <h5 class="title">Trial design</h5> <p>All five included trials were RCTs of parallel design. The responsible funding body in all included trials was Vertex Pharmaceuticals Incorporated. The National Institute of Health (NIH), the Cystic Fibrosis Foundation (CFF) and other non‐pharmaceutical funding bodies were also involved in supporting the trials (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>The F508del trial (n = 140) was a phase 2 trial that lasted 16 weeks (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). Participants who met pre‐defined eligibility criteria and completed Part A of the trial were continued onto an open‐label extension phase (Part B) lasting 96 weeks (n = 48); data from this extension were not eligible for inclusion in this review (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). There were three trials of people with the G551D mutation; the phase 2 trial had three arms and lasted 28 days (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>); the two phase 3 trials lasted 48 weeks (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Participants in these trials who completed 48 weeks of treatment (n = 194) were entered into an open‐label extension phase, which lasted up to 96 weeks; participants from this trial were not eligible for inclusion in this review because they were not re‐randomised to treatment or control (<a href="./references#CD009841-bbs2-0056" title="McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory medicine2014;2(11):902‐10. [PUBMED: 25311995] ">PERSIST 2014</a>). The phase 3 R117H trial (n = 69) lasted for 24 weeks (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). Participants that completed 24 weeks of treatment were eligible to enrol into an open‐label extension phase which lasted up to 104 weeks with an interim analysis at 12 weeks (<a href="./references#CD009841-bbs2-0079" title="NCT01707290 . Rollover study of ivacaftor in subjects with cystic fibrosis and a non G551D CFTR mutation (KONTINUE) [A phase 3, two‐arm, rollover study to evaluate the safety of long term ivacaftor treatment in subjects 6 years of age and older with cystic fibrosis and a non‐G551D CFTR mutation]. clinicaltrials.gov/ct2/show/NCT01707290 (first received 16 October 2012). ">KONTINUE 2017</a>). Data from KONTINUE were not eligible for inclusion as participants were not re‐randomised (<a href="./references#CD009841-bbs2-0079" title="NCT01707290 . Rollover study of ivacaftor in subjects with cystic fibrosis and a non G551D CFTR mutation (KONTINUE) [A phase 3, two‐arm, rollover study to evaluate the safety of long term ivacaftor treatment in subjects 6 years of age and older with cystic fibrosis and a non‐G551D CFTR mutation]. clinicaltrials.gov/ct2/show/NCT01707290 (first received 16 October 2012). ">KONTINUE 2017</a>). </p> <p>All trials were conducted at multiple centres (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The F508del trial was run across 34 sites in North America (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). Although this trial recruited participants with a class II mutation, we included it in the initial version of the review on the basis that the trial evaluated ivacaftor and its effect of the minimal amount of CFTR reaching the cell surface in this mutation. The phase 2 G551D trial recruited participants from 13 sites in North America and Europe (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). The paediatric G551D trial (65 sites) and the adult G551D trial (29 sites) were conducted in North America, Europe and Australia (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The phase 3 R117H trial was conducted at 31 sites across Europe and North America (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>Outcome data were reported at time frames ranging from 2 to 48 weeks (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> <section id="CD009841-sec-0065"> <h5 class="title">Participants</h5> <p>All 447 participants in the included trials had a confirmed diagnosis of CF. The F508del trial examined the effect of ivacaftor on people homozygous for the F508del mutation (class II mutation) (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). In the three G551D trials (class III mutation), participants were required to possess at least one G551D‐CFTR allele (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The R117H trial required participants to have at least one R117H‐CFTR allele (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>Two trials recruited recruited participants aged 12 years and older (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>); participants in the F508del trial had a mean age of 25.5 years (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>) and participants in the adult G551D trial had a mean age of 23.2 years (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The phase 2 G551D trial recruited participants aged 18 years and over and participants had a median 21 age of years (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). The paediatric phase 3 G551D trial enrolled participants aged 6 to 11 years of age and participants had a mean age of 8.9 years (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). The R117H trial recruited those over 6 years of age and participants had a mean age of 31 years (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>In the F508del trial 140 participants were allocated in a 4:1 ratio to either intervention or placebo (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). Sample sizes in the G551D trials ranged between 19 participants (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) and 167 participants (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The phase 2 G551D trial allocated 19 participants in a 2:2:1 ratio to either one of two intervention groups or a placebo group respectively (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). In the phase 3 G551D trials, 52 children and 167 adults were allocated in a 1:1 ratio to either intervention or placebo (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). During randomisation, the adults were stratified according to age (less than 18 years versus 18 years and over) and pulmonary function (less than 70% versus 70% and over of the predicted FEV<sub>1</sub>) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Similarly, a 1:1 ratio was used to allocate participants to intervention or placebo groups in the R117H trial; participants were stratified by age (6 to 11 years, 12 to 17 years, and 18 years and over) and % predicted FEV<sub>1</sub> (&lt; 70%, ≥ 70% to ≤ 90% and &gt; 90%) during randomisation (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>All participants had a baseline FEV<sub>1</sub> reading of 40% or over for age, sex and height and where baseline information was available, similar characteristics were seen (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> <section id="CD009841-sec-0066"> <h5 class="title">Interventions</h5> <p>Ivacaftor was the intervention drug in all included trials (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Four trials compared 150 mg of ivacaftor every 12 hours to placebo (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The phase 2 G551D trial compared 150 mg and 250 mg of ivacaftor every 12 hours to placebo (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). </p> <p>To determine the doses to be used, two G551D trials (the phase 2 trial and the paediatric phase 3 trial) conducted earlier investigations (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). Ivacaftor dose levels used in the phase 2 G551D trial were determined based on pharmacokinetic modelling of data from a previous cross‐over trial (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). Pre‐trial single‐dose pharmacokinetic analysis and phase 2a data were used to determine doses in the paediatric phase 3 G551D trial (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). </p> <p>Participants in four of the five included trials continued on prescribed medications, that were approved for CF, during the trial period (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). No information was provided for the R117H trial regarding how drug dosage was determined or whether participants continued taking prescribed medications (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> </section> <section id="CD009841-sec-0067"> <h5 class="title">Outcomes</h5> <p>The primary end points in the trials were safety (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) or absolute change in FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) or both (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). </p> <p>All trials employed the CFQ‐R respiratory domain to measure QoL (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). One trial reported data for all domains (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). In the adult phase 3 G551D trial, data for other CFQ‐R domains were reported where improvements were seen in the ivacaftor group (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Relative change from baseline in FEV<sub>1</sub> was reported in the full text by four trials (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) and in a conference abstract by the fifth trial (24‐week interim data only) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). </p> <p>All trials reported on the safety profile of ivacaftor and the total number of participants who developed pulmonary exacerbations (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The adult G551D trial and R117H trial also reported data for hospitalisation and number of days of hospitalisation (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Three trials reported on the number of participants who required extra courses of antibiotics (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>All trials examined the effect of ivacaftor on absolute change in FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Two trials reported on absolute change from baseline in FEV<sub>1</sub> for subgroups, according to pulmonary function, geographic region and gender (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>Three trials reported on weight (change from baseline), BMI and BMI as z score for age (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) and one trial reported change in BMI from baseline (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). Two trials reported on height z scores (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>All included trials reported on change from baseline in sweat chloride concentration (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>Nasal potential difference, a primary outcome in the Accurso trial, was not included in this review, as it is not yet a validated outcome measure (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). </p> </section> </section> <section id="CD009841-sec-0068"> <h4 class="title">Excluded studies</h4> <p>A total of 62 trials (115 references) were listed as excluded. We excluded 12 trials which were of cross‐over design (<a href="./references#CD009841-bbs2-0008" title="AltesT , JohnsonM , HigginsM , FidlerM , BotfieldM , Mugler IIIJP , et al. The effect of ivacaftor treatment on lung ventilation defects, as measured by hyperpolarized helium‐3 MRI, on patients with cystic fibrosis and a G551D‐CFTR mutation. Journal of Cystic Fibrosis2014;13 Suppl 2:S6. [Abstract no.: WS3.2; CENTRAL: 1000056; CFGD Register: BD172d; CRS: 5500131000000009] AltesT , JohnsonM , HigginsM , FidlerM , BotfieldM , TustisonN , Leiva‐SalinasC . Use of hyperpolarized helium‐3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis. Journal of Cystic Fibrosis2017;16:267‐274. AltesT , JohnsonMA , MillerGW , MuglerJP , FlorsL , MataJ , et al. Hyperpolarized Gas MRI of ivacaftor therapy in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 46; CFGD Register: BD172b; ] AltesT , JohnsonMA , MillerGW , MuglerJP , FlorsL , MataJ , et al. Hyperpolarized gas MRI of ivacaftor therapy in persons with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:291. [Abstract no.: 196; CFGD Register: BD172c; ] AltesT , JohnsonMA , MillerGW , MuglerJP , FlorsL , MataJ , et al. Hyperpolarized helium‐3 magnetic resonance imaging of CFTR potentiator therapy in subjects with cystic fibrosis and the G551D mutation. Pediatric Pulmonology2011;46(S34):284. [Abstract no.: 205; CFGD Register: BD172a; MEDLINE: 98135729] ">Altes 2011</a>; <a href="./references#CD009841-bbs2-0010" title="BerkersG , vanMourikP , DekkersJF , KruisselbrinkE , VonkAM , Heida‐MichelS , et al. Correlation between individual clinical responses and forskolin‐induced swelling of paired intestinal organoids upon CFTR modulator treatment. Pediatric Pulmonology2017;52 Suppl 47:295. [CFGD Register: BD242] ">Berkers 2017</a>; <a href="./references#CD009841-bbs2-0015" title="ButtonBM , EdgeworthD , FinlaysonF , FantidisM , WilsonL , TalbotA , et al. Effect of ivacaftor on wellness, quality of life and cognitive function in adults with cystic fibrosis and G551D mutation. Journal of Cystic Fibrosis2015;14 Suppl 1:S18. [Abstract no.: WS09.5; CENTRAL: 1081475; CFGD Register: BD222a; CRS: 5500135000000012] ButtonBM , EdgeworthD , WilsonLM , SayerJ , TierneyA , FinlaysonF , et al. Ivacaftor improves wellness, quality of life and cognitive function in G551D cystic fibrosis. Pediatric Pulmonology2015;50 Suppl 41:437. [Abstract no.: 643; CENTRAL: 1092211; CFGD Register: BD222e; CRS: 5500135000001400] EdgeworthD , KeatingD , EllisM , ButtonB , WilliamsE , ClarkD , et al. Improvement in exercise duration, lung function and well‐being in G551D‐cystic fibrosis patients: a double‐blind, placebo‐controlled, randomized, cross‐over study with ivacaftor treatment. Clinical Science2017;131(15):2037‐45. [CFGD Register: BD222f] EdgeworthD , KeatingD , WilliamsE , ClarkD , ButtonB , TierneyA , et al. Exercise improvements in ivacaftor treated G551D cystic fibrosis patients are not solely related to FEV1 and sweat changes. European Respiratory Journal2015;46 Suppl:PA2047. [CFGD Register: BD222j; DOI: 10.1183/13993003.congress2015.PA2047] EdgeworthD , KeatingD , WilliamsE , ClarkD , ButtonBM , TierneyAC , et al. Ivacaftor improves exercise capacity in patients with G551D CF gene mutations. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S27. [Abstract no.: WS14.1; CENTRAL: 1081478; CFGD Register: BD222b; CRS: 5500135000000015] KeatingD , EdgeworthD , HeretierS , DeniseC , TierneyA , KotsimbosT , et al. Sweat chloride response does not reliably correlate with clinical parameters: a placebo controlled crossover trial of ivacaftor in G551D CF patients. Journal of Cystic Fibrosis2017;16 Suppl 1:S75. [CFGD Register: BD222g] TierneyAC , EdgeworthD , WilliamsE , FinlaysonF , KeatingD , ClarkD , et al. Ivacaftor and its effects on body composition in adults with G551D related cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S50. [Abstract no.: ePS05.1; CENTRAL: 1081476; CFGD Register: BD222d; CRS: 5500135000000013] WilliamsE , EdgeworthD , FantidisM , FinlaysonF , ButtonBM , ClarkD , et al. Patient reported adherence to ivacaftor. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2015;14 Suppl 1:S46. [Abstract no.: ePS03.4; CENTRAL: 1081477; CFGD Register: BD222c; CRS: 5500135000000014] WilsonJ , KeatingD , ClarkD , EdgeworthD , Allen‐GrahamJ , FinlaysonF , et al. The effect of ivacaftor CFTR gene‐potentiating therapy on cytokine levels in CF patients with the G551D mutation. Journal of Cystic Fibrosis2017;16 Suppl 1:S83. [CFGD Register: BD222h] WilsonJ , len‐GrahamJ , TalbotA , FinlaysonF , ClarkD , KeatingD , et al. Treatment with ivacaftor in CF patients with the G551D mutation is associated with improvement in cognition. Journal of Cystic Fibrosis2018;17(Suppl 3):S57. [CFGD Register: BD222k] WilsonJW , KeatingD , ClarkD , EdgeworthD , Allen‐GrahamJ , FinlaysonF , et al. Ivacaftor CFTR gene‐potentiating therapy reduces inflammatory cytokine levels in CF patients with G551D mutation. Pediatric Pulmonology2017;52 Suppl 47:236‐7. [CFGD Register: BD222i] ">Edgeworth 2017</a>; <a href="./references#CD009841-bbs2-0013" title="AccursoFJ , RatjenF , AltesT , LubarskyB , DongQ , KangL , et al. Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 56; CFGD Register: BD189//BD190b//BD188c; ] DaviesJ , SheridanH , BellN , CunninghamS , DavisSD , ElbornJS , et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D‐CFTR mutation and preserved spirometry: a randomised controlled trial. The Lancet. Respiratory Medicine2013;1(8):630‐8. [CFGD Register: BD188f] DaviesJC , SheridanH , LeeP , SongT , StoneA , RatjenF . Lung clearance index to evaluate the effect of ivacaftor on lung function in subjects with CF who have the G551D‐CFTR mutation and mild lung disease. Pediatric Pulmonology2012;47 Suppl 35:311. [Abstract no.: 249; CFGD Register: BD188b; ] DaviesJC , SheridanH , LeePS , SongT , StoneA , RatjenF , et al. Effect of ivacaftor on lung function in subjects with CF who have the G551D‐CFTR mutation and mild lung disease: a comparison of lung clearance index (LCI) vs. spirometry. Journal of Cystic Fibrosis2012;11 Suppl 1:S15. [Abstract no.: WS7.6; CFGD Register: BD188a; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD188e // BD170m // BD171k; CRS: 5500125000000401] RatjenF , SheridanH , LeeP , SongT , StoneA , DaviesJC . Lung clearance index as an outcome measure in cystic fibrosis clinical trials. Pediatric Pulmonology2011;46 Suppl 34:282. [Abstract no.: 201; CENTRAL: 921614; CFGD Register: BD188d; CRS: 5500125000000389] RatjenFA , SheridanH , LeeP‐S , SongT , StoneA , DaviesJ . Lung clearance index as an endpoint in a multicenter randomized control trial of ivacaftor in subjects with cystic fibrosis who have mild lung disease. American Journal of Respiratory and Critical Care Medicine2012;185:A2819. [CENTRAL: 1107525; CFGD Register: BD188g; CRS: 5500050000000279; EMBASE: 71987408] ">Davies 2012</a>; <a href="./references#CD009841-bbs2-0024" title="DeBoeckK , MunckA , WalkerS , FaroA , HiattP , ChanJ , et al. The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non‐G551D‐CFTR gating mutation, the KONNECTION study. Journal of Cystic Fibrosis2014;13 Suppl 2:S1. [Abstract no.: WS1.1; CENTRAL: 998097; CFGD Register: BD201b; CRS: 5500125000000707] DeBoeckK , PaskavitzJ , ChenX , HigginsM . Ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non‐G551D‐CFTR gating mutation: phase 3, part 1 results. Pediatric Pulmonology2013;48 Suppl 36:292. [Abstract no.: 241; CENTRAL: 962356; CFGD Register: BD201a; CRS: 5500125000000421] ">KONNECTION 2013</a>; <a href="./references#CD009841-bbs2-0018" title="EudraCT Number:2016‐001619‐19 . Genistein as an add‐on treatment for CF?. clinicaltrialsregister.eu/ctr‐search/trial/2016‐001619‐19/NL (first received 27 March 2016). ">EudraCT Number: 2016‐001619‐19</a>; <a href="./references#CD009841-bbs2-0026" title="McGarryME , FinkbeinerWE , IllekB , FischerH , ZlockLT , OlshanskyS , et al. Ivacaftor response is not predicted by signs of residual CFTR function. Pediatric Pulmonology2015;50 Suppl 41:292. [Abstract no.: 266; CENTRAL: 1092198; CFGD Register: BD224a; CRS: 5500135000001387] McGarryME , IllekB , LyNP , ZlockL , OlshanskyS , MorenoC , et al. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: n‐of‐1 studies. Pediatric Pulmonology2017;52(4):472‐9. [CFGD Register: BD224c] NielsonDW , MorenoC , McGarryME , LyN . Sweat chloride as an outcome measure in n‐of‐one CF drug testing. Pediatric Pulmonology2015;50 Suppl 41:298. [Abstract no.: 284; CENTRAL: 1092201; CFGD Register: BD224b; CRS: 5500135000001390] ">McGarry 2015</a>; <a href="./references#CD009841-bbs2-0028" title="NCT01685801 . Pilot study testing the effect of ivacaftor on lung function in subjects with cystic fibrosis and residual CFTR function [A pilot study testing the effect of ivacaftor on lung function in subjects with cystic fibrosis, residual CFTR function, and FEV1 ≥40% predicted]. clinicaltrials.gov/ct2/show/NCT01685801 (first received 14 September 2012). ">NCT01685801</a>; <a href="./references#CD009841-bbs2-0029" title="NCT01784419 . Short term effects of ivacaftor in non‐G551D cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT01784419 (first received 05 February 2013). ">NCT01784419</a>; <a href="./references#CD009841-bbs2-0041" title="NCT02709109 . A study to evaluate the safety and efficacy of VX‐371 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. clinicaltrials.gov/ct2/show/NCT02709109 (first received 15 March 2016). ">NCT02709109</a>; <a href="./references#CD009841-bbs2-0045" title="NCT02742519 . A study to evaluate efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 3 through 5 years who have a specified CFTR gating mutation. clinicaltrials.gov/ct2/show/NCT02742519 (first received 19 April 2015). ">NCT02742519</a>; <a href="./references#CD009841-bbs2-0048" title="NCT03068312 . A study to evaluate efficacy of ivacaftor in subjects with cystic fibrosis who have a 3849 + 10KB C→T or D1152H CFTR mutation. clinicaltrials.gov/ct2/show/NCT03068312 (first received 01 March 2017). ">NCT03068312</a>) and one trial which carried out secondary analysis on trials of cross‐over design (<a href="./references#CD009841-bbs2-0006" title="AccursoFJ , RatjenF , AltesT , LubarskyB , DongQ , KangL , et al. Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 56; CFGD Register: BD189//BD188c; ] ">Accurso 2013</a>). Eleven trials were excluded as they used treatments to correct the molecular defect and were not potentiators (<a href="./references#CD009841-bbs2-0007" title="BellS , DeBoeckK , DrevinekP , PlantB , BarryP , ElbornS , et al. GLPG2222 in subjects with cystic fibrosis and the F508del/Class III mutation on stable treatment with ivacaftor: results from a phase II study (ALBATROSS). Journal of cystic fibrosis2018;17(Suppl 3):S2. [CFGD Register: BD247a; clinicaltrials.gov: NCT03045523] BellSC , DeBoeckK , DrevinekP , PlantBJ , ElbornJ , DeKockH , et al. Results from a phase ii study ‐ albatross ‐ evaluation of glpg2222 in subjects with cf and the f508del/class iii mutation on stable treatment with ivacaftor. Pediatric Pulmonology2018;53(S2):249. [CFGD Register: BD247b; clinicaltrials.gov: NCT03045523] ">ALBATROSS 2017</a>; <a href="./references#CD009841-bbs2-0011" title="ChadwickS , BrowningJE , SternM , ChengSH , GruenertDC , GeddesDM , et al. Nasal application of glycerol in DF508 cystic fibrosis patients. Pediatric Pulmonology1998;26 Suppl 17:278. [CFGD Register: BD147] ">Chadwick 1998</a>; <a href="./references#CD009841-bbs2-0012" title="ClancyJP , RoweSM , AccursoFJ , AitkenML , AminRS , AshlockMA , et al. Results of a phase IIa study of VX‐809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del‐CFTR mutation. Thorax2012;67(1):12‐8. [CFGD Register: BD166c; MEDLINE: 98135729] ClancyJP , RoweSM , AccursoFJ , BallmannM , BoyleMP , DeBoeckC , et al. A phase II, randomized, placebo‐controlled, clinical trial of four doses of VX‐809 in CF patients homozygous for the F508del CFTR mutation. Pediatric Pulmonology2010;45 Suppl 33:298. [Abstract no.: 224; CFGD Register: BD166b; MEDLINE: 98135729] ClancyJP , RoweSM , LiuB , HathorneH , DongQ , WissehS , et al. Variability of nasal potential difference measurements in clinical testing of CFTR modulators [abstract]. Pediatric Pulmonology2011;46 Suppl 34:283, Abstract no: 202. [CFGD Register: BD165n, BD166d; MEDLINE: 98135729] ClancyJP , Spencer‐GreenG , for the VX‐809‐101 Study Group. Clinical evaluation of VX‐809, a novel investigational oral F508del‐CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 73; CFGD Register: BD166a; MEDLINE: 98135729] ">Clancy 2012</a>; <a href="./references#CD009841-bbs2-0020" title="van derEntKC , MinicP , VerhulstS , VanBraeckelE , FlumeP , BoasS , et al. GLPG2222 in subjects with cystic fibrosis homozygous for F508del: results from a phase II study (FLAMINGO). Journal of Cystic Fibrosis2018;17(Suppl 3):S42. [CFGD Register: BD254a] van derEntKC , MinicP , VerhulstS , VanBraeckelE , FlumeP , BoasS , et al. Glpg2222 in CF subjects homozygous for f508del: results from a phase ii study (Flamingo). Pediatric Pulmonology2018;53(S2):250. [CFGD Register: BD254b] ">FLAMINGO 2017</a>; <a href="./references#CD009841-bbs2-0021" title="HorsleyA , BurrL , KotsimbosT , LedsonM , SchwarzC , SimmondsN , et al. Safety, pharmacokinetics and pharmacodynamics of the CFTR corrector FDL169. Journal of Cystic Fibrosis2018;17(Suppl 3):S42. [CFGD Register: BD250a] HorsleyAR , BlaasS , BurrL , CarrollM , DowneyDG , DrevinekP , et al. Novel CFTR corrector FDL169: safety, pharmacokinetics and pharmacodynamics. Pediatric Pulmonology2018;53(S2):252. [CFGD Register: BD250b] ">Horsley 2018</a>; <a href="./references#CD009841-bbs2-0025" title="AhrensRC , StandaertTA , LaunspachJ , HanSH , TeresiME , AitkenML , et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatric Pulmonology2002;33(2):142‐50. [CFGD Register: BD136d] AitkenML , AhrensRC , KarlinDA , KonstanMW , McNamaraSC , RegelmanWE , et al. Safety of a phase I double‐blind placebo‐controlled dose escalation trial of oral CPX in adult CF patients. Pediatric Pulmonology1998;26(S17):276. [CFGD Register: BD136b] McCartyNA , StandaertTA , TeresiM , TuthillC , LaunspachJ , KelleyTJ , et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatric Pulmonology2002;33(2):90‐8. [CFGD Register: BD136c] McCartyNA , WeatherlyMR , KelleyTJ , KonstanMW , MilgramLJH , TeresiM , et al. Multicenter phase I trial of CPX in adults patients with mild CF: results of nasal potential difference measurements. Pediatric Pulmonology1998;Suppl 17:276. [CFGD Register: BD136a] ">McCarty 2002</a>; <a href="./references#CD009841-bbs2-0054" title="NCT03474042 . GLPG2737 on top of Orkambi in subjects with cystic fibrosis (PELICAN). clinicaltrials.gov/ct2/show/NCT03474042 (first received 22 March 2018). ">NCT03474042</a>; <a href="./references#CD009841-bbs2-0036" title="NCT02323100 . Glycerol phenylbutyrate corrector therapy for CF (Cystic Fibrosis). clinicaltrials.gov/show/nct02323100 (first posted 23 December 2014). ">NCT02323100</a>; <a href="./references#CD009841-bbs2-0060" title="RubensteinRC , ZeitlinPL . A pilot clinical trial of oral sodium 4‐phenylbutyrate (Buphenyl) in deltaF508‐homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. American Journal of Respiratory and Critical Care Medicine1998;157(2):484‐90. [CFGD Register: BD146b; MEDLINE: 98135729] RubensteinRC , ZeitlinPL . A randomized, double blind, placebo‐controlled trial of sodium 4‐phenylbutyrate (Buphenyl) in deltaF508‐homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Pediatric Pulmonology1997;24 Suppl 14:272. [CFGD Register: BD146a] ">Rubenstein 1998</a>; <a href="./references#CD009841-bbs2-0061" title="RubensteinRC , PropertKJ , ReenstraWW , SkotleskiML . A pilot trial of the combination of phenylbutyrate and genistein. Pediatric Pulmonology2006;41 Suppl 29:294. [CFGD Register: BD149] ">Rubenstein 2006</a>; <a href="./references#CD009841-bbs2-0067" title="ZeitlinPL , Diener‐WestM , RubensteinRC , BoyleMP , LeeCK , Brass‐ErnstL . Evidence of CFTR function in cystic fibrosis after systemic administration of 4‐phenylbutyrate. Molecular Therapy2002;6(1):119‐26. [CFGD Register: BD148] ">Zeitlin 2002</a>). Six trials were excluded as they examined stop codon therapies for class I mutations (<a href="./references#CD009841-bbs2-0023" title="AjayiT , KonstanM , AccursoFJ , DeBoeckK , KeremE , RoweS , et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [Abstract no.: 63; CENTRAL: 921666; CFGD Register: BD167h; CRS: 5500100000011670] DaviesJC , TiddensHAWM , MalfrootA , HeijermanHGM , KeremE , HjelteL , SunJ , et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis2016;15 Suppl 1:S21. [Abstract no.: WS13.11; CFGD Register: BD167q] DeBoeckK , HeijermanHGM , DaviesJC , Sermet‐GaudelusI , HjelteL , KeremE , et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis2016;15 Suppl 1:S20. [Abstract no.: WS13.1; CFGD Register: BD167p] KeremE , KonstanMW , DeBoeckK , AccursoFJ , Sermet‐GaudelusI , WilschanskiM , et al. Ataluren for the treatment of nonsense‐mutation cystic fibrosis: a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet Respiratory Medicine2014;2(7):539‐47. [DOI: 10.1016/S2213‐2600(14)70100‐6; PUBMED: 24836205] KeremE , Sermet‐GaudelusI , HjelteL , DeBoeckK . Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo‐treated patients from the 009 study. Journal of cystic fibrosis2016;15 Suppl 1:S118. [Abstract no.: 264; CFGD Register: BD167o] KeremE , WilschanskiM , AccursoF , DeBoeckK , KonstanM , RowsS , et al. Natural history of cystic fibrosis in patients with nonsense‐mutation‐mediated disease. Pediatric Pulmonology2012;47 Suppl 35:312. [Abstract no.: 252; CENTRAL: 921643; CFGD Register: BD167e; CRS: 5500125000000035] KeremE , WilschanskiM , DeBoeckK , Sermet‐GaudelusI , ConstantineS , ElfringGL , et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis2011;10 Suppl 1:S17. [Abstract no.: 65; CFGD Register: BD167c; MEDLINE: 98135729] KeremE , WilschanskiM , MelottiP , Sermet‐GaudelusI , DeBoeckK , RoweSM , et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic &amp; other baseline data. Pediatric Pulmonology2010;45 Suppl 33:314. [Abstract no.: 314; CFGD Register: BD167a; MEDLINE: 98135729] KeremE , WilschanskiM , Sermet‐GaudelusI , DeBoeckK , AccursoFJ , KonstanMW , et al. The effect of Pseusdomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis2014;13 Suppl 2:S70. [Abstract no.: 94; CENTRAL: 996543; CFGD Register: BD167k ; CRS: 5500129000000008] KeremE , WilschasnskiM , Sermet‐GaudelausI , deBoeckK , AccursoFJ , KonstanM , et al. Interim results of the phase 3 open‐ label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis2013;12 Suppl 1:S15. [Abstract no.: WS7.5; CENTRAL: 921641; CFGD Register: BD167g; CRS: 5500100000011653] KonstanMW , AccursoFJ , DeBoeckK , KeremE , RoweSM , Sermet‐GaudelusI , et al. Pretreatment data from phase 3 study of Ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2011;46 Suppl 34:295. [Abstract no.: 232; CFGD Register: BD167d; MEDLINE: 98135729] KonstanMW , RoweSM , AccursoFJ , KeremE , WilschanskiM , DeBoeckK , et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 258; CENTRAL: 921688; CFGD Register: BD167i; CRS: 5500125000000400] RoweS , Sermet‐GaudelusI , KonstanM , KeremE , WilschanskiM , DeBoeckK , et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology2012;47 Suppl 35:290. [Abstract no.: 193; CENTRAL: 921642; CFGD Register: BD167f; CRS: 5500125000000027] RoweSM , KonstanMW , AccursoFJ , DeBoeckK , Sermet‐GaudelusI , KeremE , et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense‐mutation cystic fibrosis. Pediatric Pulmonology2013;48 Suppl 36:279. [Abstract no.: 207; CENTRAL: 921748; CFGD Register: BD167j; CRS: 5500125000000409] ">Kerem 2014</a>; <a href="./references#CD009841-bbs2-0057" title="PradalU , CasottiV , DelmarcoA , NicolisE , LivraghiA , ConeseM , et al. Effects of gentamicin on ion transport, MRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study. Pediatric Pulmonology2002;34 Suppl 24:263. [CFGD Register: BD145] ">Pradal 2002</a>; <a href="./references#CD009841-bbs2-0059" title="RomanoL , CasciaroR , VaniniP , Zegarra‐MoranO , NegroI , MinutoN , et al. Reduction of sweat ion concentrations following topical application of gentamicin in CF patients carrying nonsense mutations. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6‐9; Vienna, Austria. 2001:P11. [CFGD Register: BD144b] RomanoL , SacchiR , Zegarra‐MoranO , VaniniP , GuerrieroF , CasciaroR , et al. Effects of topical applications of gentamicin on sweat test in CF patients carrying nonsense‐mutations. Pediatric Pulmonology2000;30 Suppl 20:250. [CFGD Register: BD144a] ">Romano 2000</a>; <a href="./references#CD009841-bbs2-0063" title="Sermet‐GaudelusI , DeBoeckK , CasimirGJ , VermeulenF , LealT , MogenetA , et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. American Journal of Respiratory &amp; Critical Care Medicine2010;182(10):1262‐72. [CFGD Register: BD167b; MEDLINE: 98135729] ">Sermet‐Gaudelus 2010</a>; <a href="./references#CD009841-bbs2-0065" title="WilschanskiM , VirgilisD , Strauss‐LiviatanN , TalA , BenturL , BlauH , et al. Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: a double‐blind placebo controlled trial. Pediatric Pulmonology2000;30 Suppl 20:244. [CFGD Register: BD143a; MEDLINE: 98135729] WilschanskiM , YahavJ , BlauH , BenturL , RivlinJ , AviramM , et al. Restoration of CFTR function by gentamicin in cystic fibrosis patients carrying stop mutations: a double blind placebo controlled trial. Gastroenterology2003;124(4 Suppl 1):A582. [CFGD Register: BD143c] WilschanskiM , YahavY , YaacovY , BlauH , BenturL , RivlinJ , et al. Gentamicin‐induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine2003;349(15):1433‐41. [CFGD Register: BD143b] ">Wilschanski 2003</a>; <a href="./references#CD009841-bbs2-0066" title="KeremE , YaakovY , ArmoniS , PugatschT , ShoseyovD , CohenM , et al. PTC124 induces time‐dependent improvements in chloride conductance and clinical parameters in patients with nonsense‐mutation‐mediated cystic fibrosis. Pediatric Pulmonology2008;43 Suppl 31:294. [CFGD Register: BD22d; MEDLINE: 98135729] Sermet‐GaudelusI , DeBoeckK , CasimirG , LealT , VermeulenF , MogenetA , et al. Children with nonsense‐mutation‐mediated cystic fibrosis respond to investigational treatment with PTC124. Pediatric Pulmonology2008;43 Suppl 31:313. [CFGD Register: BD22c; MEDLINE: 98135729] Sermet‐GaudelusI , LealT , DeBoeckK , CasimirG , HanssensL , HageP , et al. PTC124 induces CFTR full‐length production and activity in children with nonsense‐mutation‐mediated CF. Journal of Cystic Fibrosis2008;7 Suppl 2:S22. [CFGD Register: BD22a; MEDLINE: 98135729] WilschanskiM , ArmoniS , YaakovY , BlauH , ShoseyovD , CohenM , et al. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense ‐mutation‐mediated CF. Journal of Cystic Fibrosis2008;7 Suppl 2:S22. [CFGD Register: BD22b; MEDLINE: 98135729] ">Wilschanski 2008</a>). We excluded 12 trials due to an observational study design (<a href="./references#CD009841-bbs2-0017" title="EudraCT Number:2016‐001440‐18 . Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls. clinicaltrialsregister.eu/ctr‐search/trial/2016‐001440‐18/NL (first received 16 January 2018). ">EudraCT Number: 2016‐001440‐18</a>; <a href="./references#CD009841-bbs2-0022" title="HubertD , DehillotteC , MunckA , DavidV , BaekJ , MelyL , et al. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp‐CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real‐world setting. Journal of Cystic Fibrosis2018;17(1):89‐95. [PUBMED: 28711222] ">Hubert 2018</a>; <a href="./references#CD009841-bbs2-0027" title="NCT01549314 . Cystic Fibrosis Related Bone Disease: the Role of CFTR. clinicaltrials.gov/ct2/show/NCT01549314 (first received 9 March 2012). ">NCT01549314</a>; <a href="./references#CD009841-bbs2-0030" title="NCT01863238 . An ocular safety study of ivacaftor‐treated pediatric patients 11 years of age or younger with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01863238 (first received 27 May 2013). ">NCT01863238</a>; <a href="./references#CD009841-bbs2-0032" title="NCT02039986 . Ivacaftor (Kalydeco) and insulin in cystic fibrosis (CF) [Effects of ivacaftor (Kalydeco) treatment upon insulin and incretin secretion in patients with cystic fibrosis]. clinicaltrials.gov/ct2/show/NCT02039986 (first received 20 January 2014). ">NCT02039986</a>; <a href="./references#CD009841-bbs2-0033" title="NCT02141464 . Energy balance and weight gain with ivacaftor treatment. clinicaltrials.gov/ct2/show/NCT02141464 (first received 19 May 2014). ">NCT02141464</a>; <a href="./references#CD009841-bbs2-0035" title="NCT02311140 . Effects of Kalydeco on upper airway and paranasal sinus inflammation measured by nasal lavage and on symptoms (KPNSI). clinicaltrials.gov/ct2/show/NCT02311140 (first received 8 December 2014). ">NCT02311140</a>; <a href="./references#CD009841-bbs2-0038" title="NCT02445053 . Observational study of outcomes in cystic fibrosis patients with selected gating mutations on a CFTR allele (The VOCAL Study) (VOCAL). clinicaltrials.gov/ct2/show/NCT02445053 (first received 15 May 2015). ">NCT02445053</a>; <a href="./references#CD009841-bbs2-0043" title="NCT02722057 . A study to confirm the long‐term safety and effectiveness of Kalydeco in patients with cystic fibrosis who have an R117H‐CFTR mutation, including pediatric patients. clinicaltrials.gov/ct2/show/NCT02722057 (first received 29 March 2016). ">NCT02722057</a>; <a href="./references#CD009841-bbs2-0053" title="NCT03390985 . Canadian observation trial in CF patients undergoing treatment with ivacaftor (G551D). clinicaltrials.gov/ct2/show/NCT03390985 (first received 5 January 2018). ">NCT03390985</a>; <a href="./references#CD009841-bbs2-0055" title="NCT03652090 . Evaluation of the Primary Human Nasal Epithelial Cell Culture Model in the Context of Personalized Therapy in Cystic Fibrosis. clinicaltrials.gov/ct2/show/NCT03652090 (first received 29 August 2018). ">NCT03652090</a>; <a href="./references#CD009841-bbs2-0062" title="SeligerV , BaiY , VolkovaN , TianS , Waltz . Prevalance of cataracts in a population of cystic fibrosis patients homozygous for the F508del mutation. Journal of Cystic Fibrosis2015;14 Suppl 1:S108. [Abstract no.: 196; CFGD Register: BD213d // BD214c] ">Seliger 2015</a>) and a further 12 trials were excluded as they had a single interventional arm with no comparator (<a href="./references#CD009841-bbs2-0009" title="RosenfeldM , WainwrightCE , HigginsM , WangLT , McKeeC , CampbellD , et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to &lt;24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single‐arm study. The Lancet. Respiratory Medicine2018;6(7):545‐53. [PUBMED: 29886024] ">ARRIVAL 2018</a>; <a href="./references#CD009841-bbs2-0014" title="DaviesJC , CunninghamS , HarrisWT , LapeyA , RegelmannWE , SawickiGS , et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2‐5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open‐label, single‐arm study. The Lancet. Respiratory medicine2016;4(2):107‐15. [PUBMED: 26803277] ">Davies 2016</a>; <a href="./references#CD009841-bbs2-0016" title="EudraCT Number:2014‐000817‐30 . Comparing the effect of curcumin and genistein to treatment with Ivacaftor in CF patients with a class III mutation. clinicaltrialsregister.eu/ctr‐search/trial/2014‐000817‐30/NL (first received 22 May 2014). ">EudraCT Number: 2014‐000817‐30</a>; <a href="./references#CD009841-bbs2-0031" title="NCT01946412 . Roll‐over study of ivacaftor in cystic fibrosis pediatric subjects with a CF transmembrane conductance regulator gene (CFTR) gating mutation. clinicaltrials.gov/ct2/show/NCT01946412 (first received 19 September 2013). ">NCT01946412</a>; <a href="./references#CD009841-bbs2-0034" title="NCT02310789 . Does ivacaftor alter wild type CFTR‐open probability in the sweat gland secretory coil?. clinicaltrials.gov/ct2/show/NCT02310789 (first received 8 December 2014). ">NCT02310789</a>; <a href="./references#CD009841-bbs2-0039" title="NCT02690519 . Study of GLPG1837 in subjects with cystic fibrosis (S1251N mutation) (SAPHIRA2). clinicaltrials.gov/ct2/show/NCT02690519 (first received 24 February 2016). ">NCT02690519</a>; <a href="./references#CD009841-bbs2-0040" title="NCT02707562 . Study of GLPG1837 in subjects with cystic fibrosis (G551D Mutation) (SAPHIRA1). clinicaltrials.gov/ct2/show/NCT02707562 (first received 14 March 2016). ">NCT02707562</a>; <a href="./references#CD009841-bbs2-0047" title="NCT02934698 . An efficacy and safety study of ivacaftor in patients with cystic fibrosis and two splicing mutations. clinicaltrials.gov/ct2/show/NCT02934698 (first received 17 October 2016). ">NCT02934698</a>; <a href="./references#CD009841-bbs2-0049" title="NCT03256799 . Evaluation of ivacaftor in patients using ataluren for nonsense mutations. clinicaltrials.gov/ct2/show/NCT03256799 (first received 22 August 2017). ">NCT03256799</a>; <a href="./references#CD009841-bbs2-0050" title="NCT03256968 . PTC study to evaluate ataluren in combination with ivacaftor. clinicaltrials.gov/ct2/show/NCT03256968 (first received 22 August 2017). ">NCT03256968</a>; <a href="./references#CD009841-bbs2-0052" title="NCT03277196 . A phase 3, 2‐arm, open‐label study to evaluate the safety and pharmacodynamics of long‐term ivacaftor treatment in subjects with cystic fibrosis who are less than 24 months of age at treatment initiation and have an approved ivacaftor‐responsive mutation. clinicaltrials.gov/ct2/show/NCT03277196 (first received 08 September 2017). ">NCT03277196</a>; <a href="./references#CD009841-bbs2-0056" title="McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory medicine2014;2(11):902‐10. [PUBMED: 25311995] ">PERSIST 2014</a>). Three trials used treatments to amplify or modify the molecular defect rather than potentiate it (<a href="./references#CD009841-bbs2-0042" title="NCT02718495 . Study assessing PTI‐428 safety, tolerability, and pharmacokinetics in subjects with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02718495 (first received 24 March 2016). ">NCT02718495</a>; <a href="./references#CD009841-bbs2-0044" title="NCT02724527 . Study of cavosonstat (N91115) in CF patients who are heterozygous for F508del‐CFTR and a gating mutation and being treated with ivacaftor (SNO‐7). clinicaltrials.gov/ct2/show/NCT02724527 (first received 31 March 2016). ">NCT02724527</a>; <a href="./references#CD009841-bbs2-0051" title="NCT03258424 . Study assessing PTI‐428 safety, tolerability, and pharmacokinetics in subjects with cystic fibrosis on KALYDECO® as background therapy. clinicaltrials.gov/ct2/show/NCT03258424 (first received 23 August 2017). ">NCT03258424</a>). Four trials did not use mutation‐specific treatments e.g. antibiotic therapy (<a href="./references#CD009841-bbs2-0019" title="EudraCT Number:2016‐001785‐29 . Combined effect of CFTR modifiers and intensive antibiotic treatment. clinicaltrialsregister.eu/ctr‐search/trial/2016‐001785‐29/IE (first received 10 May 2016). ">EUudraCT Number: 2016‐001785‐29</a>; <a href="./references#CD009841-bbs2-0037" title="NCT02443688 . A phase 2 study to evaluate the efficacy, safety, and tolerability of CTX‐4430 in adult CF patients. clinicaltrials.gov/ct2/show/NCT02443688 (first received 14 May 2015). ">NCT02443688</a>; <a href="./references#CD009841-bbs2-0046" title="NCT02759562 . Effect of andecaliximab on FEV1 in adults with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02759562 (first received 03 May 2016). ">NCT02759562</a>; <a href="./references#CD009841-bbs2-0058" title="DerichsN , Taylor‐CousarJ , TullisE , DaviesJ , NazarethD , DowneyDG , et al. Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio‐CF study. Journal of Cystic Fibrosis2017;16(Supplement 1):S36. [CFGD Register: BD246b] Taylor‐CousarJL , DerichsN , TullisDE , DaviesJC , NazarethD , DowneyD , et al. Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: safety data from the rio‐CF study. Pediatric Pulmonology2017;52(Supplement 47):307. [CFGD Register: BD246c] Taylor‐CousarJL , TullisE , DerichsN , DaviesJC , NazarethD , DowneyD , et al. Riociguat for the treatment of adult Phe508del homozygous cystic fibrosis: efficacy data from the Phase II Rio‐CF study. Journal of Cystic Fibrosis2018;17(Suppl 3):S67. [CFGD Register: BD246a] ">RIO‐CF 2017</a>). One trial excluded people with CF (<a href="./references#CD009841-bbs2-0064" title="NCT03085485 . The Topic Trial ‐ Study to Determine the Safety and Efficacy of Ivacaftor. clinicaltrials.gov/ct2/show/NCT03085485 (first received 21 March 2017). ">TOPIC 2018</a>). </p> <p>We excluded 79 trials (110 references) comparing potentiator and corrector combination therapy to placebo, but these have not been referenced within the list of excluded studies as a separate systematic review has been conducted which focuses on combination therapy (<a href="./references#CD009841-bbs2-0086" title="SouthernKW , PatelS , SinhaIP , NevittSJ . Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD010966.pub2] ">Southern 2018</a>). </p> <section id="CD009841-sec-0069"> <h5 class="title">Studies awaiting classification</h5> <p>Two trials are listed as awaiting classification (<a href="./references#CD009841-bbs2-0068" title="KazaniS , AlcantaraJ , DebonnettL , DoucetJ , JonesI , KulmatyckiK , et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2016;193(Meeting Abstracts):A7789. [CFGD Register: BD243] NCT02190604 . Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients.. clinicaltrials.gov/ct2/show/NCT02190604 (first received 15 July 2014). ">Kazani 2016</a>; <a href="./references#CD009841-bbs2-0069" title="UttamsinghV , PiljaL , BrummelCL , GrotbeckB , CassellaJV , BramanG . CTP‐656 multiple dose pharmacokinetic profile continues to support a once‐daily potentiator for cystic fibrosis patients with gating mutations. Pediatric Pulmonology2016;51 Suppl 45:277. [Abstract no.: 244; CFGD Register: BD241] ">Uttamsingh 2016</a>), one of which has been terminated according to the record on clinicaltrials.gov (<a href="./references#CD009841-bbs2-0068" title="KazaniS , AlcantaraJ , DebonnettL , DoucetJ , JonesI , KulmatyckiK , et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2016;193(Meeting Abstracts):A7789. [CFGD Register: BD243] NCT02190604 . Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients.. clinicaltrials.gov/ct2/show/NCT02190604 (first received 15 July 2014). ">Kazani 2016</a>). </p> <section id="CD009841-sec-0070"> <h6 class="title">Trial design</h6> <p>Both trials are double‐blind RCTs of parallel design, but one is a phase 1 trial (<a href="./references#CD009841-bbs2-0069" title="UttamsinghV , PiljaL , BrummelCL , GrotbeckB , CassellaJV , BramanG . CTP‐656 multiple dose pharmacokinetic profile continues to support a once‐daily potentiator for cystic fibrosis patients with gating mutations. Pediatric Pulmonology2016;51 Suppl 45:277. [Abstract no.: 244; CFGD Register: BD241] ">Uttamsingh 2016</a>) and the second is a phase 2 trial (<a href="./references#CD009841-bbs2-0068" title="KazaniS , AlcantaraJ , DebonnettL , DoucetJ , JonesI , KulmatyckiK , et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2016;193(Meeting Abstracts):A7789. [CFGD Register: BD243] NCT02190604 . Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients.. clinicaltrials.gov/ct2/show/NCT02190604 (first received 15 July 2014). ">Kazani 2016</a>). The phase 1 trial lasted for seven days with no additional follow‐up (<a href="./references#CD009841-bbs2-0069" title="UttamsinghV , PiljaL , BrummelCL , GrotbeckB , CassellaJV , BramanG . CTP‐656 multiple dose pharmacokinetic profile continues to support a once‐daily potentiator for cystic fibrosis patients with gating mutations. Pediatric Pulmonology2016;51 Suppl 45:277. [Abstract no.: 244; CFGD Register: BD241] ">Uttamsingh 2016</a>). The phase 2 trial had a duration of 14 days with a follow‐up to 42 days (<a href="./references#CD009841-bbs2-0068" title="KazaniS , AlcantaraJ , DebonnettL , DoucetJ , JonesI , KulmatyckiK , et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2016;193(Meeting Abstracts):A7789. [CFGD Register: BD243] NCT02190604 . Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients.. clinicaltrials.gov/ct2/show/NCT02190604 (first received 15 July 2014). ">Kazani 2016</a>). </p> </section> <section id="CD009841-sec-0071"> <h6 class="title">Participants</h6> <p>In the phase 1 trial, investigators enrolled 40 participants with a confirmed diagnosis of CF, but no details of participants' baseline characteristics are available (<a href="./references#CD009841-bbs2-0069" title="UttamsinghV , PiljaL , BrummelCL , GrotbeckB , CassellaJV , BramanG . CTP‐656 multiple dose pharmacokinetic profile continues to support a once‐daily potentiator for cystic fibrosis patients with gating mutations. Pediatric Pulmonology2016;51 Suppl 45:277. [Abstract no.: 244; CFGD Register: BD241] ">Uttamsingh 2016</a>). </p> <p>In the three‐arm phase 2 trial, only the third phase of the trial was eligible which randomised 49 adults with CF heterozygous with one allele represented as any CFTR mutation and the other allele must represent a class III, IV, V, VI CFTR mutation (<a href="./references#CD009841-bbs2-0068" title="KazaniS , AlcantaraJ , DebonnettL , DoucetJ , JonesI , KulmatyckiK , et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2016;193(Meeting Abstracts):A7789. [CFGD Register: BD243] NCT02190604 . Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients.. clinicaltrials.gov/ct2/show/NCT02190604 (first received 15 July 2014). ">Kazani 2016</a>). In the phase 2 trial the mean age of participants was 31.7 years. With regards to gender split the trial randomised more males (n = 30) than females (n = 19). </p> </section> <section id="CD009841-sec-0072"> <h6 class="title">Intervention</h6> <p>Investigators enrolled 40 participants and allocated them in a 4:1 ratio to either intervention or placebo (<a href="./references#CD009841-bbs2-0069" title="UttamsinghV , PiljaL , BrummelCL , GrotbeckB , CassellaJV , BramanG . CTP‐656 multiple dose pharmacokinetic profile continues to support a once‐daily potentiator for cystic fibrosis patients with gating mutations. Pediatric Pulmonology2016;51 Suppl 45:277. [Abstract no.: 244; CFGD Register: BD241] ">Uttamsingh 2016</a>). CTP‐656 (a deuterated analogue of ivacaftor) was used as the intervention drug. Participants received either 75mg, 150mg, or 225mg of CTP‐656. Dose escalation was initiated only after safety and tolerability were found to support proceeding to the higher dose. All participants were dosed under fed conditions; a high‐fat breakfast was provided on Day 1 through Day 7 approximately 30 minutes prior to dosing (<a href="./references#CD009841-bbs2-0069" title="UttamsinghV , PiljaL , BrummelCL , GrotbeckB , CassellaJV , BramanG . CTP‐656 multiple dose pharmacokinetic profile continues to support a once‐daily potentiator for cystic fibrosis patients with gating mutations. Pediatric Pulmonology2016;51 Suppl 45:277. [Abstract no.: 244; CFGD Register: BD241] ">Uttamsingh 2016</a>). (Since this trial was undertaken CTP‐656 has been sold by its developers (Concert Pharmaceuticals Inc.) to Vertex and has been renamed VX‐561.) </p> <p>The phase 2 trial compared QBW251 (a membrane‐associated wild‐type CFTR potentiator) at two doses ‐ 150 mg twice daily and 450 mg twice daily ‐ to placebo. The 450 mg daily dose group was split into participants with a number of different mutations (n = 12) and a second group who were homozygous for F508del (n = 19) (<a href="./references#CD009841-bbs2-0068" title="KazaniS , AlcantaraJ , DebonnettL , DoucetJ , JonesI , KulmatyckiK , et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2016;193(Meeting Abstracts):A7789. [CFGD Register: BD243] NCT02190604 . Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients.. clinicaltrials.gov/ct2/show/NCT02190604 (first received 15 July 2014). ">Kazani 2016</a>). </p> </section> <section id="CD009841-sec-0073"> <h6 class="title">Outcomes</h6> <p>The phase 1 trial's main outcome was the pharmacokinetic (PK) profile and PK blood samples were collected at several time points post‐dose on Day 1 and Day 7, and at 12 and 24 hours post‐dose on Day 2 through Day 6. The plasma concentrations of CTP‐656 and its metabolites, (D‐M1 and D‐M6) were analysed by a combination of liquid chromatography with mass spectrometry for all three dose cohorts (<a href="./references#CD009841-bbs2-0069" title="UttamsinghV , PiljaL , BrummelCL , GrotbeckB , CassellaJV , BramanG . CTP‐656 multiple dose pharmacokinetic profile continues to support a once‐daily potentiator for cystic fibrosis patients with gating mutations. Pediatric Pulmonology2016;51 Suppl 45:277. [Abstract no.: 244; CFGD Register: BD241] ">Uttamsingh 2016</a>). </p> <p>In the phase 2 trial, the primary outcomes were the change in LCI and adverse events; secondary outcomes included the change in FEV<sub>1</sub>, the change in CFQR reported outcomes and the change in sweat chloride. Some limited results have been published on clinicaltrials.gov (<a href="./references#CD009841-bbs2-0068" title="KazaniS , AlcantaraJ , DebonnettL , DoucetJ , JonesI , KulmatyckiK , et al. QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2016;193(Meeting Abstracts):A7789. [CFGD Register: BD243] NCT02190604 . Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients.. clinicaltrials.gov/ct2/show/NCT02190604 (first received 15 July 2014). ">Kazani 2016</a>). </p> </section> </section> </section> </section> <section id="CD009841-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risk of bias judgements can be found in the figures (<a href="#CD009841-fig-0002">Figure 2</a>; <a href="#CD009841-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD009841-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. This Figure demonstrates the high proportion of trials that were judged to have a high risk of attrition bias (incomplete outcome data addressed) and selective reporting bias." data-id="CD009841-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. This Figure demonstrates the high proportion of trials that were judged to have a high risk of attrition bias (incomplete outcome data addressed) and selective reporting bias. </p> </div> </div> </div> <div class="figure" id="CD009841-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009841-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009841-sec-0075"> <h4 class="title">Allocation</h4> <section id="CD009841-sec-0076"> <h5 class="title">Sequence generation</h5> <p>Four trials reported on random sequence generation; all four employed an unblinded statistician (not otherwise associated with the trial) to produce the final randomisation list using a code produced by the trial sponsor and we judged these to have a low risk of bias for sequence generation (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). One phase 3 G551D trial did not report on how the children were randomised and we judged this to have an unclear risk of bias (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). </p> </section> <section id="CD009841-sec-0077"> <h5 class="title">Allocation concealment</h5> <p>Four trials reported on allocation concealment (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Participants were allocated to groups using an interactive voice response system (IVRS) according to the concealed randomisation list and we judged these to have a low risk of bias with regards to allocation concealment (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The paediatric phase 3 G551D trial did not report on allocation concealment and we judged this to have an unclear risk of bias (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). </p> </section> </section> <section id="CD009841-sec-0078"> <h4 class="title">Blinding</h4> <p>Three trials reported on the blinding of trial personnel (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). All trial personnel were blinded to participant treatment assignments. Tasks requiring unblinded personnel were conducted by people not otherwise involved in the trials; hence we judged these three trials to have a low risk of bias for blinding of personnel (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Two trials stated that they were 'double‐blinded' but did not provide sufficient information to allow a clear judgement giving an unclear risk of bias (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>With regards to the blinding of participants, none of the included trials reported details of the oral tablets such as colour, size, consistency or taste; therefore we judge them all to have an unclear risk of bias with regards to the blinding of participants (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> <section id="CD009841-sec-0079"> <h4 class="title">Incomplete outcome data</h4> <p>There was low attrition (less than 15%) in all included trials (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>In the phase 2 G551D trial, one participant withdrew consent prior to dosing, but all 19 remaining participants completed the trial and were included in the analysis of reported outcomes; therefore, we judged this trial to have a low risk of attrition bias (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). In the R117H trial, two participants from the ivacaftor group withdrew after dosing due to one participant becoming pregnant and one for non‐compliance. All 69 participants who received at least one dose of the trial drug were included in the analysis. We judged this trial to also have a low risk of attrition bias (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>In the remaining three trials, some participant data were excluded from the analysis and these trials were judged to have a high risk of attrition bias (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>A total of 10 participants (7.1%) withdrew from the F508del trial (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>); eight out of 112 (7.1%) participants withdrew from the ivacaftor group (three due to adverse events, two for non‐compliance, one refused medication, one was lost to follow up; and one due to "early termination per sponsor decision") and two participants out of 28 (7.1%) withdrew from the placebo group due to adverse events (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). Participant data were excluded from the analysis of the change from baseline in sweat chloride concentration (one participant excluded from the ivacaftor group) and the absolute change from baseline in FEV<sub>1</sub> (one participant excluded from the ivacaftor group). The author was approached for information on these missing data (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). </p> <p>In the paediatric phase 3 G551D trial, 4 out of 52 children (7.7%) withdrew from the placebo group, one for each of the following reasons: adverse events; refusal of medication; withdrawal of consent; and wrong genotype. Participant data were excluded from the analysis for absolute change from baseline in % predicted FEV<sub>1</sub> (one child excluded from placebo group), change from baseline in sweat chloride concentration (three children excluded from ivacaftor group and three children excluded from the placebo group) and CFQ‐R respiratory domain paediatric version (one child excluded from placebo group). The author was approached for information on these missing data and revealed that a modified intention‐to‐treat analysis (not per protocol) was employed, where data were excluded from the analysis (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). </p> <p>In the adult phase 3 G551D trial, 10 out of 167 participants (6.0%) withdrew from the placebo group; four due to adverse events, one on the physician's decision, two required prohibited medication; one withdrew consent; one was the wrong genotype; and one had "Increased Lab Draws/Difficult Lab Stick". Six out of 167 participants (3.6%) withdrew from the ivacaftor group; one due to adverse events; two for non‐compliance; one became pregnant; one refused medication; and one withdrew consent. After these 16 randomised participants (9.6%) withdrew, a total of 161 participants (78 in the placebo group and 83 in the ivacaftor group) were included in the analysis. However, in the analysis of change from baseline in CFQ‐R respiratory domain scores, data from 10 participants (seven participants from the placebo group and three participants from the ivacaftor group) were excluded; and data from nine participants (four participants from the placebo group and five participants from the ivacaftor group) were excluded from the analysis of the change from baseline in sweat chloride concentration. The author was approached for information on these missing data (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> <section id="CD009841-sec-0080"> <h4 class="title">Selective reporting</h4> <p>Trial protocols were available for the phase 2 G551D and the adult phase 3 G551D trials (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). In the phase 2 trial, weight was measured at days 1, 3, 14, 21 and 28, but not reported. In such a trial, the change in weight of participants from baseline is a key outcome and by not reporting this outcome, the trial is at high risk of selective reporting bias (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). In the adult trial, the following tertiary outcomes were not reported in the full text: change from baseline in oxygen saturation; change from baseline in EuroQol Questionnaire (EQ‐5D); and outpatient sick visits to the clinic or hospital for CF–related complications. Also CFQ‐R domain scores were reported for domains where improvements were seen in the ivacaftor group only. Hence, this trial was also judged to have a high risk of selective reporting bias (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>Full protocols were not available, either online or upon request, for the remaining three trials (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). In the paediatric phase 3 G551D trial, FVC was measured at days 1 and 15, then at weeks 8, 16, 24, 32, 40 and 48; but results were not reported in the full text; also, relative change in FEV<sub>1</sub> from baseline was reported at 24 weeks, but not at any other time point (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). In such trials, the change from baseline in FVC and relative change from baseline in FEV<sub>1</sub> are key outcomes and by not reporting these outcomes, the trial is at high risk of selective reporting (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). In the F508del trial, there were missing data for change from baseline in FEV<sub>1</sub> score (at day 15 and week 8) and in change from baseline in FVC or mid‐forced expiratory flow (FEF25‐75%) measured throughout the trial. Also, one withdrawal from the ivacaftor group was due to "early termination per sponsor decision" and attempts to illicit further information about this were unsuccessful; we therefore found the risk of selective reporting in this trial to be high (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). In the R117H trial, a protocol synopsis was made available by the trial sponsor which reported a number of tertiary outcomes; however, no results were made available for these outcomes. We therefore judged the trial to be at high risk of selective reporting bias (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> </section> <section id="CD009841-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <p>The baseline characteristics of participants were similar in all included trials (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>In the phase 2 G551D trial, drug dosing was monitored by clinical staff via returned dosage units and dosing diaries; an adherence rate of 100% (range 92.6 to 100) was achieved (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). In the paediatric phase 3 G551D trial, reviewing dosing with participants and caregivers ensured correct doses were taken; mean rates of compliance of 94.4% in the ivacaftor group and of 95.7% in the placebo group were reported (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). Two trials ensured adherence by drug accountability (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). No information was provided regarding drug adherence for the R117H trial (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>In the R117H trial additional age subgroup analyses were performed for participants aged 6 to 11 years and ≥ 18 years, however, there were only two participants between 12 to 17 years of age so no statistical analysis was performed for this group (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). No reason was provided for the low numbers in 12 to 17 age group (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>All trials were funded by a single company, Vertex Pharmaceuticals Incorporated (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> </section> <section id="CD009841-sec-0082"> <h3 class="title" id="CD009841-sec-0082">Effects of interventions</h3> <p>See: <a href="./full#CD009841-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with the F508del CFTR mutation</a>; <a href="./full#CD009841-tbl-0002"><b>Summary of findings 2</b> Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with at least one G551D CFTR mutation</a>; <a href="./full#CD009841-tbl-0003"><b>Summary of findings 3</b> Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with at least one R117H CFTR mutation</a> </p> <p>In the summary of findings tables, the quality of the evidence has been graded for pre‐defined outcomes (see above) and definitions of these gradings provided. </p> <section id="CD009841-sec-0083"> <h4 class="title">Ivacaftor versus placebo</h4> <section id="CD009841-sec-0084"> <h5 class="title">Primary outcomes</h5> <section id="CD009841-sec-0085"> <h6 class="title">1. Survival</h6> <p>No survival data or deaths were reported by any of the included trials (n = 447) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> <section id="CD009841-sec-0086"> <h6 class="title">2. QoL</h6> <section id="CD009841-sec-0087"> <p><b>a. total QoL score</b></p> <p>None of the trials reported on total QoL scores (n = 447) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> </section> <section id="CD009841-sec-0088"> <h6 class="title">b. different sub‐domains</h6> <p>All five trials reported the CFQ‐R respiratory domain scores (n = 447) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The phase 2 G551D trial also reported scores for all other CFQ‐R domains (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) and the adult phase 3 G551D trial reported scores for CFQ‐R domains where improvements were reported in the ivacaftor group (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>In the F508del trial, investigators reported lower scores on the CFQ‐R respiratory domain score in the ivacaftor group (MD ‐1.3) at 16 weeks, but this difference was not significant (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>) (moderate‐quality evidence). Insufficient data for this outcome were reported for inclusion in the analysis. </p> <p>Data from both phase 3 G551D trials have not been combined as the paediatric trial reported individual change from baseline respiratory domain scores, for both children and parents or caregivers (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>), but the adult trial pooled the CFQ‐R respiratory domain scores from adult and child questionnaires (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). In the paediatric trial, at 24 weeks children in the ivacaftor group reported higher CFQ‐R respiratory domain scores, MD 6.10 (95% CI ‐1.35 to 13.55), but the difference between groups was not significant (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>) (<a href="./references#CD009841-fig-0011" title="">Analysis 2.1</a>) (moderate‐quality evidence). In the same trial at 24 weeks, the parents or caregivers of children in the ivacaftor group reported significantly higher CFQ‐R respiratory domain scores, MD 5.90 (95% CI 0.41 to 11.39) (<a href="./references#CD009841-fig-0012" title="">Analysis 2.2</a>) (moderate‐quality evidence). In the adult trial, at 24 weeks participants reported significantly higher CFQ‐R respiratory domain scores in the ivacaftor group, MD 8.10 (95% CI 4.77 to 11.43) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (<a href="./references#CD009841-fig-0013" title="">Analysis 2.3</a>) (moderate‐quality evidence). </p> <p>At 48 weeks, both children and and parents or caregivers reported higher CFQ‐R respiratory domain scores in the ivacaftor group, MD 5.10 (95% CI ‐1.56 to 11.76) and MD 4.90 (95% CI ‐0.39 to 10.19) respectively (<a href="./references#CD009841-fig-0011" title="">Analysis 2.1</a>; <a href="./references#CD009841-fig-0012" title="">Analysis 2.2</a>) (moderate‐quality evidence); in neither case were treatment differences significant (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). In the adult trial at 48 weeks, investigators reported significantly higher CFQ‐R respiratory domain scores in the ivacaftor group, MD 8.60 (95% CI 5.27 to 11.93) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (<a href="./references#CD009841-fig-0013" title="">Analysis 2.3</a>) (moderate‐quality evidence). At the same time‐point, significantly higher CRQ‐R scores in the physical functioning scale (P &lt; 0.001), social functioning scale (P = 0.0026), eating disturbances scale (P = 0.0021) and treatment burden scale (P = 0.0419) were observed (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Higher scores for the body, emotion and digestive scales were also seen but the treatment differences between groups for these domains were not significant (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>Accurso reported on improvement in the respiratory domain score at two weeks and four weeks using medians and ranges, precluding the analysis of these data in RevMan (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). At two weeks, a median (range) increase of 5.6 (0.0 to 16.7) points was achieved in the 150 mg ivacaftor group and 5.6 (‐11.1 to 11.1) in the 250 mg ivacaftor group. The median (range) change of 2.8 (‐5.6 to 11.1) in the placebo group meant the difference between the two treatment and the placebo groups was not significant. At four weeks, there were no significant differences between treatment groups and the placebo group; the 150 mg group reported a median (range) improvement of 8.3 (0.0 to 16.7) points, the 250 mg group reported a median (range) improvement of 11.1 (‐5.6 to 33.3) points and the placebo group reported a median (range) improvement of 2.8 (‐5.6 to 11.1) points (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). Accurso also presented median (range) scores for all other CFQ‐R domains which are shown in the additional tables (<a href="#CD009841-tbl-0005">Table 2</a>). None of the improvements were significant (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) (moderate‐quality evidence). </p> <div class="table" id="CD009841-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">CFQ‐R domain scores in the phase 2 G551D study at 4 weeks (median (range))</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Domain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Day 14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Day 28</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (n = 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐770 150 mg (n = 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐770 250 mg (n = 7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (n = 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐770 150 mg (n = 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐770 250 mg (n = 7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body image</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (‐11.1 to 22.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.2 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐11.1 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐22.2 to 11.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 44.4) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Digestive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐22.2 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> <p>(0 to 22.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 33.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eating disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐11.1 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 0) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3<br/> (‐6.7 to 20.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐26.7 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐20.0 to 26.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3<br/> (0 to 20.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐6.7 to 6.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7<br/> (‐6.7 to 20.0) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health perceptions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.2 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐33.3 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐22.2 to 22.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 11.1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 4.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1<br/> (‐4.2 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2<br/> (0 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> <p>(0 to 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> <p>(‐8.3 to 25.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 to 12.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8<br/> (‐5.6 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6<br/> (0 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8<br/> (‐5.6 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3<br/> (0 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1<br/> (‐5.6 to 33.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Role</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐8.3 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐8.3 to 8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐8.3 to 8.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Social</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8<br/> (‐5.6 to 5.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐44.4 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐16.7 to 5.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8<br/> (‐11.1 to 5.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐11.1 to 5.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐16.7 to 11.1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment burden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐22.2 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.2 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐22.2 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.2 to 11.1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2<br/> (‐16.7 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2<br/> (‐8.3 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐8.3 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐8.3<br/> (‐16.7 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐16.7 to 25.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 16.7) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 33.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 33.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐33.3 to 33.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 to 33.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 to 33.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐33.3 to 33.3)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CFQ‐R: Cystic Fibrosis Questionnaire‐Revised</p> </div> </div> <p>In the R117H trial, investigators reported a significant improvement in the CFQ‐R respiratory domain scores in the ivacaftor group, MD 8.40 (95% CI 2.17 to 14.63) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>) (<a href="./references#CD009841-fig-0031" title="">Analysis 3.1</a>) (moderate‐quality evidence). The treatment effect was adjusted for continuous baseline values of age and % predicted FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). The R117H trial conducted a further subgroup analysis by age, which only showed a significant improvement in the respiratory domain score for adults in the ivacaftor group and not children (<a href="#CD009841-tbl-0006">Table 3</a>). </p> <div class="table" id="CD009841-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Outcomes for age subgroups in R117H study at 24 weeks</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Overall</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>6 ‐ 11 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>≥18 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life (CFQ‐R) ‐ respiratory domain (pooled)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% predicted FEV<sub>1</sub> ‐ absolute change from baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% predicted FEV<sub>1</sub> ‐ relative change from baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ‐ absolute change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweat chloride ‐ absolute change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐24.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐21.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Treatment difference was adjusted for age and % predicted FEV<sub>1</sub> </p> <p>BMI: body mass index<br/> CFQ‐R: cystic fibrosis questionnaire ‐ revised<br/> FEV<sub>1</sub>: forced expiratory volume in one second </p> </div> </div> </section> </section> <section id="CD009841-sec-0089"> <h5 class="title">3. FEV<sub>1</sub> (relative change from baseline) </h5> <p>All included trials reported this outcome (n = 447) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>At 16 weeks investigators reported no significant difference in the relative change from baseline in FEV<sub>1</sub> between groups in the F508del trial, MD 2.40% (95% CI ‐0.95 to 5.75) (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>) (<a href="./references#CD009841-fig-0004" title="">Analysis 1.1</a>) (moderate‐quality evidence). </p> <p>At 24 weeks in the phase 3 G551D trials, both children and adults in the ivacaftor group reported significant improvements in the relative change from baseline in FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). For the paediatric trial, only interim data were reported in a conference abstract which were insufficient for inclusion into the meta‐analysis, MD 17.4% (P &lt; 0.0001) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>); but for the adult trial investigators reported MD 16.90% (95% CI 13.60 to 20.20) (<a href="./references#CD009841-fig-0014" title="">Analysis 2.4</a>). Data at 48 weeks were not reported in the paediatric trial (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>); however, the adult trial reported a significant improvement in the relative change from baseline in FEV<sub>1</sub> in the ivacaftor group at 48 weeks, MD 16.80% (95% CI 13.50 to 20.10) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (<a href="./references#CD009841-fig-0014" title="">Analysis 2.4</a>) (moderate‐quality evidence). </p> <p>Again Accurso reported medians (range) from the phase 2 G551D trial; at four weeks there was a relative improvement from baseline in % predicted FEV<sub>1</sub> of 8.7% (2.3 to 31.3) in the 150 mg group, 4.4% (0.0 to 18.3) in the 250 mg group and 7.3% (5.2 to 8.2) in the placebo group (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). Treatment differences between ivacaftor arms and the placebo group were not significant (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) (moderate‐quality evidence). </p> <p>In the R117H trial, investigators included the relative change from baseline in FEV<sub>1</sub> data in a results table; however, the absolute change in FEV<sub>1</sub> was a primary outcome and this was the focus of the text (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). At 24 weeks investigators reported no significant difference in the relative change from baseline in FEV<sub>1</sub> between treatment groups MD 5.00% (95% CI ‐0.24 to 10.24) (<a href="./references#CD009841-fig-0032" title="">Analysis 3.2</a>) (moderate‐quality evidence). Treatment effect was adjusted for continuous baseline values of age and % predicted FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> </section> </section> <section id="CD009841-sec-0090"> <h4 class="title">Secondary outcomes</h4> <section id="CD009841-sec-0091"> <h5 class="title">1. Adverse effects</h5> <p>All included trials reported the number of participants who experienced adverse effects (n = 447) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>The F508del trial reported the number of participants who experienced adverse effects that occurred in at least 5% of participants taking ivacaftor (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>) (<a href="./references#CD009841-fig-0005" title="">Analysis 1.2</a>). Accurso reported the number of participants who experienced any adverse effect in the phase 2 G551D trial (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>); we have pooled data for the 150 mg group and 250 mg group and compared these to the placebo group (<a href="./references#CD009841-fig-0016" title="">Analysis 2.6</a>). Both phase 3 G551D trials reported the number of participants who experienced any serious adverse effect and the number of participants who experienced all adverse effects that occurred in more than 5% of participants in either treatment arm (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). We have combined the data from both trials (<a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>). Serious adverse effects were defined as life‐threatening or debilitating, which is consistent with our definition of severe. The R117H trial reported the number of participants with any adverse event, serious adverse events (the authors' definition of a serious adverse event was not present in the text), adverse events leading to discontinuation and adverse events occurring in 15% of participants in any ivacaftor treatment group (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>) (<a href="./references#CD009841-fig-0033" title="">Analysis 3.3</a>; <a href="./references#CD009841-fig-0034" title="">Analysis 3.4</a>). </p> <p>For the F508del trial, phase 3 G551D trials and the R117H trial, we have reported on adverse effects that occurred more frequently in either the ivacaftor or placebo groups where there was greater or equal to 5% incidental difference between groups in the number of participants affected (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Given the small sample size in the phase 2 G551D trial by Accurso (n = 19), we have not reported on the most common adverse effects from this trial (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). For all trials we have present below the results that were statistically significant in trial reports. Where numerical data were not provided, we have discussed the results narratively. </p> <section id="CD009841-sec-0092"> <h6 class="title">a. mild (therapy does not need to be discontinued)</h6> <p>In the F508del trial, episodes of cough, nausea, rash and contact dermatitis were experienced by more participants assigned to ivacaftor compared to those assigned to placebo. Pulmonary exacerbations were more common in participants in the placebo group (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>) (<a href="./references#CD009841-fig-0005" title="">Analysis 1.2</a>) (low‐quality evidence). In the adult phase 3 G551D trial, more adults in the placebo group experienced episodes of pulmonary exacerbation, cough, haemoptysis, and decreased pulmonary function in comparison to participants in the ivacaftor group. Adverse effects that occurred in more adults in the ivacaftor group were headache, upper respiratory tract infection, nasal congestion, rash, and dizziness (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (<a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>) (low‐quality evidence). In the paediatric phase 3 G551D trial, episodes of cough, productive cough, vomiting, rales, and decreased pulmonary function were experienced by more children in the placebo group in comparison to children in the ivacaftor group. Episodes of oropharyngeal pain, headache, nasopharyngitis, upper respiratory tract infection, otitis media, diarrhoea, and an increased blood eosinophil count were reported in more children in the ivacaftor group (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>) (<a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>) (low‐quality evidence). In the R117H trial more episodes of nasal congestion, oropharyngeal pain, abdominal pain, wheeze and CF lung pathogen colonisation were experienced in the ivacaftor group compared to the placebo group (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>) (<a href="./references#CD009841-fig-0034" title="">Analysis 3.4</a>) (low‐quality evidence). </p> <p>There were no statistically significant differences at the 1% significance level to allow for multiple analyses related to adverse events in any of the included trials (<a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>; <a href="./references#CD009841-fig-0016" title="">Analysis 2.6</a>, <a href="./references#CD009841-fig-0005" title="">Analysis 1.2</a>; <a href="./references#CD009841-fig-0034" title="">Analysis 3.4</a>). </p> </section> <section id="CD009841-sec-0093"> <h6 class="title">b. moderate (therapy is discontinued and the adverse effect ceases)</h6> <p>The F508del trial and both phase 3 G551D trials reported the number of participants who experienced adverse effects that required interruption of the intervention (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The R117H trial did not report any participants requiring interruption of the intervention (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>In the F508del trial, two participants in the ivacaftor group (1.8%) stopped receiving the intervention due to elevated liver enzyme values; but the intervention was subsequently restarted as both cases were found to be caused by concurrent pathology (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). No trial drug interruption occurred in the placebo group. The difference between groups in number of participants who required trial interruption was not significant, OR 1.29 (95% CI 0.06 to 27.62) (<a href="./references#CD009841-fig-0006" title="">Analysis 1.3</a>) (low‐quality evidence). In the paediatric phase 3 G551D trial, three participants from the placebo group experienced adverse effects requiring interruption of the intervention compared to one participant in the ivacaftor group; but the details of these adverse events were not reported (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>) (low‐quality evidence). In the adult trial, 11 adverse events in the ivacaftor group (13.3%) compared to four in the placebo group (5.1%) required trial drug interruption. Adverse events in the ivacaftor group were: haemoptysis (n = 1); migraine (n = 1); upper respiratory tract infection (n = 1); pulmonary exacerbation (n = 1); increased hepatic enzyme (n = 2); pulmonary exacerbation and anaphylactic shock (n = 1); lymph node pain and gynaecomastia (n = 1); myalgia and diarrhoea (n = 1); decreased weight and pulmonary exacerbation (n = 1); and vulvovaginal mycotic infection, oral candidiasis and two episodes of pulmonary exacerbation (n = 1). Adverse events in the placebo group were: migraine (n = 1); pulmonary exacerbation (n = 1); increased blood lactate dehydrogenase and increased hepatic enzymes (n = 1); and rash, nephrolithiasis and renal colic (n = 1). Investigators reported that five participants in the placebo group required drug interruption; however, one of these participants subsequently withdrew from the trial and will be discussed under 'severe' adverse events (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (low‐quality evidence). Combined data for both phase 3 G551D trials showed no significant difference between treatment arms, OR 1.18 (95% CI 0.14 to 9.92) (<a href="./references#CD009841-fig-0017" title="">Analysis 2.7</a>) (low‐quality evidence). Heterogeneity was substantial (I² = 64%) which is possibly due to the difference in ages between the adult and paediatric trials. </p> </section> <section id="CD009841-sec-0094"> <h6 class="title">c. severe (life‐threatening or debilitating, or which persists even after treatment is discontinued) </h6> <p>All included trials reported the number of participants who developed adverse effects that required discontinuation of the intervention (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>In the F508del trial, three participants in the ivacaftor group (2.7%) discontinued due to asthenia, fatigue and headache (n = 1), arthritis (n = 1) and myopathy (n = 1); a further participant in this group developed fatigue, depression and suicidal ideation that was considered to be life‐threatening (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). In comparison, two participants in the placebo group (7.1%) discontinued medication because of abnormal feelings of cognitive disorder (n = 1) and elevated liver enzymes and increased lactate dehydrogenase levels (n = 1). The abnormal liver enzyme profile was considered to be caused by concomitant use of an anabolic steroid like a nutritional supplement (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). The number of participants requiring trial drug discontinuation between treatment arms was not significant, OR 0.36 (95% CI 0.06 to 2.25) (<a href="./references#CD009841-fig-0006" title="">Analysis 1.3</a>) (low‐quality evidence). </p> <p>In the paediatric phase 3 G551D trial, one participant from the placebo group withdrew due to anxiety and psychological issues (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). In the adult trial, four participants from the placebo group withdrew from the trial; one each due to increased hepatic enzyme levels, atrioventricular block, panic attack and respiratory failure. There was one dropout from the ivacaftor group due to increased hepatic enzymes (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Combined data for the phase 3 G551D trials showed no significant difference between treatment arms in the number of participants discontinuing the trial drug, OR 0.25 (95% CI 0.04 to 1.57) (<a href="./references#CD009841-fig-0017" title="">Analysis 2.7</a>) (low‐quality evidence). Likewise, combined data from the two trials for serious adverse effects, did not show an increase with ivacaftor compared with placebo (<a href="./references#CD009841-fig-0018" title="">Analysis 2.8</a>), with the exception of pulmonary exacerbation which will be discussed under other adverse effects of therapy (below). </p> <p>No severe adverse effects were reported in any of the participants in the phase 2 G551D trial and all adverse events resolved without discontinuation of the intervention (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) (low‐quality evidence). </p> <p>The R117H trial reported six (17%) severe adverse events in the placebo group and four (12%) in the ivacaftor group with no participants discontinuing the intervention due to adverse events (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). There was no significant difference in the number of serious adverse events between treatment arms, OR 0.64 (95% CI 0.16 to 2.52) (<a href="./references#CD009841-fig-0033" title="">Analysis 3.3</a>) (low‐quality evidence). </p> </section> <section id="CD009841-sec-0095"> <h6 class="title">d. other adverse effects of therapy (of any severity) that are not classifiable according to these categories </h6> <p>The number of participants who experienced episodes of pulmonary exacerbation was reported by all trials (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (low‐quality evidence). In all cases pulmonary exacerbations were protocol‐defined; both phase 3 G551D trials and also the F508del trial employed the same definition (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>), but this was different to the definition employed by the phase 2 G551D trial (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). The R117H trial reported protocol‐defined pulmonary exacerbations, but the full protocol was not available to determine this definition (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). Data for all G551D participants in this review are shown separately (<a href="./references#CD009841-fig-0019" title="">Analysis 2.9</a>). In the adult phase 3 G551D trial, there were minor differences in the number of participants experiencing episodes of pulmonary exacerbations between the full text, supplementary appendix and an online trials database (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). Data were extracted from the online trials database where data for serious and other cases of pulmonary events were reported. </p> <p>In the phase 2 G551D trial, one participant from each of the treatment arms experienced an exacerbation compared to none in the placebo group (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>); when analysed, there was no significant difference in the number of participants who experienced pulmonary exacerbations between the ivacaftor group (combined data from 150 mg and 250 mg groups) and the placebo group at one month, OR 1.67 (95% CI 0.07 to 41.64) (<a href="./references#CD009841-fig-0019" title="">Analysis 2.9</a>). In the phase 3 G551D trials, at 48 weeks significantly fewer participants in the ivacaftor group experienced serious episodes of pulmonary exacerbations compared to participants in the placebo group, OR 0.34 (99% CI 0.13 to 0.88) (<a href="./references#CD009841-fig-0018" title="">Analysis 2.8</a>). Combined data for all exacerbations in these trials was not significant between groups at this time‐point, OR 0.64; 95% CI 0.36 to 1.12) (<a href="./references#CD009841-fig-0019" title="">Analysis 2.9</a>). In the adult trial, the meta‐analysis of all exacerbations shows significantly fewer participants in the ivacaftor group experienced exacerbations than in the placebo group, OR 0.54 (95% CI 0.29 to 1.01) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (<a href="./references#CD009841-fig-0019" title="">Analysis 2.9</a>). In the F508del trial, investigators reported a non‐significant lower frequency of pulmonary exacerbations in the ivacaftor group, OR 0.44 (99% CI 0.14 to 1.41) (<a href="./references#CD009841-fig-0005" title="">Analysis 1.2</a>). </p> <p>The adult phase 3 G551D trial reported data for the time‐to‐first pulmonary exacerbation (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). At 24 weeks, a significantly greater proportion of participants in the ivacaftor group (78%) were exacerbation‐free in comparison to participants in the placebo group (51%). This corresponds to a hazard ratio (HR) of 0.46 (95% CI 0.28 to 0.76) (P = 0.002) so within the first 24 weeks, adults receiving ivacaftor were 54% less likely to experience an exacerbation than those assigned to placebo (<a href="./references#CD009841-fig-0020" title="">Analysis 2.10</a>). At 48 weeks, 67% of participants in the ivacaftor group and 41% of participants in the placebo group were exacerbation‐free, HR 0.46 (95% CI 0.29 to 0.73), and the difference between groups remained significant (P &lt; 0.001) (<a href="./references#CD009841-fig-0020" title="">Analysis 2.10</a>) (moderate‐quality evidence). Therefore during the 48‐week trial period, participants receiving ivacaftor were 54% less likely to experience an exacerbation than those assigned to placebo (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>The R117H trial reported that at 24 weeks there was no significant difference between treatment groups for the time‐to‐first pulmonary exacerbation, HR 0.93 (95% CI 0.42 to 2.08) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>) (<a href="./references#CD009841-fig-0036" title="">Analysis 3.6</a>) (moderate‐quality evidence). Additionally, there was no significant difference between the ivacaftor and placebo groups in the number of participants experiencing a pulmonary exacerbation, OR 0.81 (95% CI 0.30 to 2.19) (<a href="./references#CD009841-fig-0035" title="">Analysis 3.5</a>). </p> <p>There was no significant difference in the hepatic enzyme profile between groups in either phase 3 G551D trial (<a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>; <a href="./references#CD009841-fig-0021" title="">Analysis 2.11</a>). The majority of participants in the F508del trial had aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin values less than or equal to two times ULN (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). </p> </section> </section> <section id="CD009841-sec-0096"> <h5 class="title">2. Hospitalisation</h5> <p>The adult phase 3 G551D trial (n = 167) reported on the number of hospitalisations for episodes of pulmonary exacerbation and also on the number of days admitted (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The R117H trial reported the number of hospital admissions for episodes of pulmonary exacerbation (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <section id="CD009841-sec-0097"> <h6 class="title">a. number of days</h6> <p>In the G551D trial, of the episodes of pulmonary exacerbation that required hospitalisations, those occurring in participants in the ivacaftor group required less time in hospital, MD ‐0.23 days (95% CI ‐3.74 to 3.28) (<a href="./references#CD009841-fig-0022" title="">Analysis 2.12</a>). We note this non‐significant summary statistic conflicts with the trial report. The Supplementary table 2B of the supplementary appendix reports a P value of 0.0275 for this difference; however, this has been calculated from a Wilcoxon rank‐sum test, stratified by baseline % predicted FEV<sub>1</sub> severity and age group (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). This is a non‐parametric test used when data are skewed and where values are usually given as medians and ranges. In this trial, however, mean and SDs have been reported. As stated above, after entering these data into Review Manager, we have calculated a different P value of 0.90 which was not significant (<a href="./references#CD009841-fig-0022" title="">Analysis 2.12</a>). </p> </section> <section id="CD009841-sec-0098"> <h6 class="title">b. number of episodes</h6> <p>Similarly, in the G551D trial significantly fewer episodes of pulmonary exacerbation required hospitalisation in participants in the ivacaftor group, OR 0.37 (95% CI 0.16 to 0.81) (<a href="./references#CD009841-fig-0023" title="">Analysis 2.13</a>) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The R117H trial did not show a significant difference between treatment groups in the number of participants requiring hospital admission for pulmonary exacerbations (<a href="./references#CD009841-fig-0035" title="">Analysis 3.5</a>) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> </section> </section> <section id="CD009841-sec-0099"> <h5 class="title">3. School or work attendance</h5> <p>No individual data for school or work attendance was reported by any trial (n = 447) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> <section id="CD009841-sec-0100"> <h5 class="title">4. Other physiological measures of lung function</h5> <section id="CD009841-sec-0101"> <h6 class="title">a. FEV<sub>1</sub> (absolute values) </h6> <p>All included trials reported on the absolute change from baseline in FEV<sub>1</sub> (n = 447) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). For the four phase three trials, this outcome was a primary endpoint (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The data in the paediatric phase 3 G551D trial were adjusted based on the continuous baseline value of % of predicted FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). Data in the R117H trial were adjusted for continuous baseline values of age and % predicted FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>Investigators reported no significant differences between groups in the F508del trial for change from baseline of % predicted FEV<sub>1</sub> at 16 weeks, MD 1.70% (95% CI ‐0.65 to 4.05) (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>) (<a href="./references#CD009841-fig-0007" title="">Analysis 1.4</a>) (moderate‐quality evidence). </p> <p>Both phase 3 G551D trials reported results early (day 15), but we are unable to include these results in our analysis (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). At this time point, an estimated MD of 13.0% points can be deduced from the graph (Figure 2 in the full paper) for the paediatric trial (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>) and the adult trial reported a significant MD of 9.2% points (P &lt; 0.001) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). At 24 weeks combined data from both of these trials show a significant increase in FEV<sub>1</sub> (% predicted) from baseline in the ivacaftor group, MD 10.80% (95% CI 8.91 to 12.69) (P &lt; 0.00001) with no heterogeneity (I² = 0%) (<a href="./references#CD009841-fig-0024" title="">Analysis 2.14</a>) (low‐quality evidence). Combined data at 48 weeks still demonstrate a significant change from baseline in FEV<sub>1</sub> (% predicted), MD 10.44% (95% CI 8.56 to 12.32), again with no heterogeneity (I² = 0%) (<a href="./references#CD009841-fig-0024" title="">Analysis 2.14</a>) (low‐quality evidence). For the change from baseline in FEV<sub>1</sub> (L), combined data at 24 weeks show a significant increase in in the ivacaftor group, MD 0.33 L (95% CI 0.17 to 0.49), but with considerable heterogeneity (I² = 85%) (<a href="./references#CD009841-fig-0025" title="">Analysis 2.15</a>) (low‐quality evidence). At 48 weeks the combined data still demonstrate a significant improvement, MD 0.31 L (95% CI 0.11 to 0.50), but again with considerable heterogeneity (I² = 90%) (<a href="./references#CD009841-fig-0025" title="">Analysis 2.15</a>) (low‐quality evidence). We do not know why the I² values are different between the meta‐analyses of % predicted FEV<sub>1</sub> and FEV<sub>1</sub> (L); we are not able to infer anything from it as there are only two trials in the analysis (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>At four weeks, in the phase 2 G551D trial, investigators reported a median (range) change from baseline in FEV<sub>1</sub> of 0.25 L (0.05 to 0.75) in the 150 mg group, 0.17 L (0 to 0.37) in the 250 mg group and 0.20 L (0.12 to 0.33) in the placebo group (low‐quality evidence). Treatment differences between the ivacaftor arms and the placebo arm were not significant (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). </p> <section id="CD009841-sec-0102"> <p><b>Subgroup analysis of the G551D trials</b></p> <p>Improvements in the absolute change from baseline in FEV<sub>1</sub> amongst pre‐defined subgroups were reported at 48 weeks by the phase 3 G551D trials (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>In the paediatric trial at 48 weeks, children in three subgroups demonstrated significant improvements in the change from baseline in % predicted FEV<sub>1</sub> in the ivacaftor group compared to the placebo group: </p> <p> <ul id="CD009841-list-0017"> <li> <p>a baseline % predicted FEV<sub>1</sub> below 90%, MD 14.90 (95% CI 7.30 to 22.50); </p> </li> <li> <p>were from Europe, MD 24.60 (95% CI 6.40 to 42.80); and</p> </li> <li> <p>were female, MD 13.80 (95% CI 4.20 to 23.40) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). </p> </li> </ul> </p> <p>However, there was no significant difference in the change from baseline in % predicted FEV<sub>1</sub> between treatment and placebo in the following subgroups: </p> <p> <ul id="CD009841-list-0018"> <li> <p>baseline % predicted FEV<sub>1</sub> over 90%, MD 6.90% (95% CI ‐3.80 to 17.60); </p> </li> <li> <p>from North America, MD 5.80% (95% CI ‐2.60 to 14.20);</p> </li> <li> <p>from Australia, MD 4.20% (95% CI ‐3.70 to 12.10); and</p> </li> <li> <p>male, MD 5.20% (95% CI ‐2.20 to 12.60) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>) (<a href="./references#CD009841-fig-0026" title="">Analysis 2.16</a>). </p> </li> </ul> </p> <p>The adult phase 3 G551D trial reported significant improvements in FEV<sub>1</sub> % predicted favouring ivacaftor over placebo in all subgroups (<a href="#CD009841-tbl-0007">Table 4</a>); insufficient data precludes inclusion of these results in a meta‐analysis (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <div class="table" id="CD009841-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Absolute change in FEV1 % predicted amongst pre‐defined subgroups in the adult phase 3 G551D study at 48 weeks.</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subgroup</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline percent of predicted FEV<sub>1</sub> of less than 70% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline percent of predicted FEV<sub>1</sub> of greater or equal to 70% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants from North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants from Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants from Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less than 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greater than or equal to 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The treatment effect represents the difference between the ivacaftor group and the placebo group with respect to the absolute change from baseline through week 48. </p> <p>FEV<sub>1</sub>: forced expiratory volume at one second </p> </div> </div> <p>The R117H trial reported that at 24 weeks there was no significant treatment differences in absolute % predicted FEV<sub>1</sub> between the ivacaftor and placebo groups, MD 2.10% (95% CI ‐1.13 to 5.33) (<a href="./references#CD009841-fig-0037" title="">Analysis 3.7</a>) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>) (low‐quality evidence). </p> </section> </section> <section id="CD009841-sec-0103"> <h6 class="title">b. FVC (absolute values and change from baseline)</h6> <p>Three trials reported on the change from baseline in FVC (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). None of the data were included in a meta‐analysis as they were either non‐parametric data (reported as median and ranges) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) or insufficient data were provided (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>The F508del trial reported no significant differences between groups in FVC, but no numerical data were provided (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). </p> <p>The phase 2 G551D trial reported a relative improvement from baseline FVC at two weeks in all three groups; there was a 9.0% improvement in the 150 mg ivacaftor group, a 7.4% improvement in the 250 mg ivacaftor group and a 1.0% improvement in the placebo group (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). Treatment differences between the ivacaftor groups and the placebo group were not significant. At four weeks a median (range) change from baseline of 0.18 L (‐0.29 to 0.48) in the 150 mg group, 0.09 L (‐0.09 to 0.43) in the 250 mg group and 0.10 L in the placebo group were reported. These values corresponded to relative changes from baseline of 4.6% in the 150 mg group, 2.6% in the 250 mg group and 2.3% in the placebo group. Treatment differences between the ivacaftor groups and the placebo group were not significant (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). </p> <p>The adult phase 3 G551D trial reported on the absolute change from baseline in FVC in the form of a graph (supplemental figure 4B of the supplementary appendix) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). From the graph, an estimated MD between intervention and placebo arms of 11.5% at 24 weeks and 7.0% at 48 weeks can be deduced. These results should be interpreted with caution, as they are not accurate (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> </section> <section id="CD009841-sec-0104"> <h5 class="title">5. Extra courses of antibiotics</h5> <p>Three trials reported on extra courses of antibiotics required by participants (n = 376) (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>The F508del trial reported on the number of new sinopulmonary signs or symptom events that required new or changed antibiotic therapy; however, the route of administration was not stated (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). Investigators reported proportionately fewer episodes of new sinopulmonary signs or symptom events requiring antibiotic treatment in the ivacaftor group, OR 0.56 (95% CI 0.24 to 1.30); however, the difference was not significant (<a href="./references#CD009841-fig-0008" title="">Analysis 1.5</a>). </p> <p>The adult phase 3 G551D trial reported firstly the number of episodes of pulmonary exacerbation that required intravenous antibiotics and secondly the number of days on intravenous antibiotics to treat pulmonary exacerbations (see below) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The R117H trial reported the number of episodes of pulmonary exacerbation requiring intravenous antibiotics (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <section id="CD009841-sec-0105"> <h6 class="title">a. oral</h6> <p>This outcome was not reported in any trial.</p> </section> <section id="CD009841-sec-0106"> <h6 class="title">b. intravenous</h6> <p>In the adult phase 3 G551D trial, Ramsey reported significantly fewer episodes of pulmonary exacerbations requiring intravenous antibiotics occurred in participants in the ivacaftor group, OR 0.34 (95% CI 0.18 to 0.64) (P = 0.0009) (<a href="./references#CD009841-fig-0027" title="">Analysis 2.17</a>). In addition, more days of intravenous antibiotic administration were required for exacerbations occurring in participants in the placebo group, MD ‐4.35 (95% CI ‐10.51 to 1.81) (<a href="./references#CD009841-fig-0028" title="">Analysis 2.18</a>). Supplementary table 2B of the supplementary appendix reports a P value of 0.0183 for this difference; however, this has been calculated from a Wilcoxon rank‐sum test, stratified by baseline % predicted FEV<sub>1</sub> severity and age group (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). This is a non‐parametric test used when data are skewed and where values are usually given as medians and ranges. In this trial however, mean and SDs have been reported. After entering these data into Review Manager, we have calculated a different P value of 0.17 which was not significant (<a href="./references#CD009841-fig-0028" title="">Analysis 2.18</a>). </p> <p>In the R117H trial, investigators reported fewer episodes of pulmonary exacerbation requiring intravenous antibiotics in the ivacaftor group, OR 0.30 (95% CI 0.06 to 1.62), however, this result was not significant (P = 0.16) (<a href="./references#CD009841-fig-0035" title="">Analysis 3.5</a>) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> </section> <section id="CD009841-sec-0107"> <h6 class="title">c. inhaled</h6> <p>This outcome was not reported in either trial.</p> </section> </section> <section id="CD009841-sec-0108"> <h5 class="title">6. Radiological measures of lung disease</h5> <p>No trials reported chest radiograph scores or CT scores.</p> </section> <section id="CD009841-sec-0109"> <h5 class="title">7. Acquisition of respiratory pathogen</h5> <p>No trial reported on the acquisition of any respiratory pathogens (e.g. <i>P aeruginosa</i> , <i>S aureus</i> , <i>H influenzae</i>). </p> </section> <section id="CD009841-sec-0110"> <h5 class="title">8. Eradication of respiratory pathogens</h5> <p>No trial reported on the eradication of any respiratory pathogens (e.g. <i>P aeruginosa</i> , <i>S aureus</i> , <i>H influenzae</i>). </p> </section> <section id="CD009841-sec-0111"> <h5 class="title">9. Nutrition and growth</h5> <section id="CD009841-sec-0112"> <h6 class="title">a. weight</h6> <p>Three trials (n = 359) reported the absolute change from baseline in weight (kg) (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>); one of these additionally reported on weight‐for‐age z score (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). </p> <p>The F508del trial, reported no significant difference in weight gain between the ivacaftor group and the placebo group at 16 weeks, MD ‐0.20 kg (95% CI ‐1.18 to 0.78) (<a href="./references#CD009841-fig-0009" title="">Analysis 1.6</a>). There was also no significance difference between groups in weight‐for‐age z scores (MD 0.43), but insufficient data prevented inclusion of this outcome in the analysis (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). </p> <p>Combined data from the phase 3 G551D trials at 24 weeks demonstrated significant weight gain in the ivacaftor group, MD 2.37 kg (95% CI 1.68 to 3.06) with moderate heterogeneity (I² = 38%) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (<a href="./references#CD009841-fig-0029" title="">Analysis 2.19</a>). Combined data from the same trials at 48 weeks also demonstrated significant weight gain in the ivacaftor group compared to placebo, MD 2.75 kg (95% CI 1.74 to 3.75), but with no heterogeneity (I² = 0%) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (<a href="./references#CD009841-fig-0029" title="">Analysis 2.19</a>). </p> </section> <section id="CD009841-sec-0113"> <h6 class="title">b. BMI</h6> <p>Four trials reported on the change from baseline in BMI (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) and three additionally reported BMI for age z score (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>), but none of them provided sufficient information for inclusion into a meta‐analysis (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>In the F508del trial, a lower BMI score was reported in the ivacaftor group in comparison to the placebo group at 16 weeks, MD ‐0.04 mg/m², but the difference between groups was not significant (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). In the phase 3 G551D trials, both children and adults in the ivacaftor group scored significantly higher BMI values at 48 weeks, MD 1.09 kg/m² (P = 0.0003) and MD 0.93 kg/m² (P &lt; 0.0001) respectively (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>In the F508del trial, at 16 weeks there was no significant difference between the ivacaftor group and the placebo group in BMI‐for‐age z score amongst a subgroup of participants aged 20 years or below, MD 0.75 (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). The paediatric phase 3 G551D trial reported significantly higher BMI‐for‐age‐z scores in the ivacaftor group compared to placebo at 24 weeks, MD 0.34 (P ≤ 0.001), and 48 weeks, MD 0.45 (P &lt; 0.001) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). At 48 weeks, the adult phase 3 G551D trial reported significantly higher BMI‐for‐age‐z scores in the ivacaftor group amongst a subgroup of 47 participants aged 12 to 20 years, MD 0.33 (P = 0.0490) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>The R117H trial reported a higher BMI score in the ivacaftor group compared to placebo at 24 weeks, MD 0.26 kg/m² (95% CI ‐1.57 to 2.09), but this was not significant (P = 0.1) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>) (<a href="./references#CD009841-fig-0038" title="">Analysis 3.8</a>). Treatment effect was adjusted for age and categorical % predicted FEV<sub>1</sub> at baseline (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> </section> <section id="CD009841-sec-0114"> <h6 class="title">c. height</h6> <p>Two trials reported on height z scores (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The paediatric phase 3 G551D trial reported improvements in the ivacaftor group at both 24 weeks (MD 0.06) and 48 weeks (MD 0.12) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). In the adult phase 3 G551D trial reported improvements in the ivacaftor group at 24 weeks (MD 0.05) and 48 weeks (MD 0.06) amongst a subset of 47 participants aged 12 to 20 years (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> </section> </section> <section id="CD009841-sec-0115"> <h5 class="title">10. Sweat chloride (change from baseline)</h5> <p>The change from baseline in sweat chloride concentration was reported by all trials (n = 447) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>In the F508del trial, investigators reported significant reductions in sweat chloride concentration at 16 weeks in the ivacaftor group compared to the placebo group, MD ‐2.90 mmol/L (95% CI ‐5.60 to ‐0.20) (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>) (<a href="./references#CD009841-fig-0010" title="">Analysis 1.7</a>). </p> <p>In the phase 2 G551D trial, at four weeks there was a significant difference in the median (range) change from baseline in sweat chloride concentration between the 150 mg group (within group change ‐59.5 mmol/L (‐66.0 to ‐19.0) and the placebo group (within group change 5.0 mmol/L (‐2.0 to 11.0) (P = 0.02); a similar significant difference was seen between the 250 mg group (within group change ‐38.0 mmol/L (‐47.0 to ‐10.5) and placebo group (within group change 5.0 mmol/L (‐2.0 to 11.0) (P = 0.03) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>).<br/> <br/> In the phase 3 G551D trials, reduced sweat chloride concentrations were reported early (day 15) in children, MD ‐50 mmol/L (estimated from a graph) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>) and in adults, MD ‐47.1 mmol/L (P &lt; 0.001) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Combined data from these trials demonstrated significant reductions in sweat chloride concentration at 24 weeks, MD ‐50.19 mmol/L (95% CI ‐56.20 to ‐44.18) with a moderate level of heterogeneity (I² = 57%) (<a href="./references#CD009841-fig-0030" title="">Analysis 2.20</a>), and at 48 weeks, MD ‐49.74 mmol/L (95% CI ‐54.61 to ‐44.87) with a moderate level of heterogeneity (I² = 40%) (<a href="./references#CD009841-fig-0030" title="">Analysis 2.20</a>). Secondary analysis of combined data from these trials reported that the number needed to treat (NNT) for a reduction of 20 mmol/L in sweat chloride concentration was 1.03. Data from each phase 3 G551D trial demonstrated that significant changes in sweat chloride were reported regardless of whether participants were FEV<sub>1</sub> responders (5% point improvement) or minimal responders (less than 5% point improvement) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) (<a href="#CD009841-tbl-0008">Table 5</a>). </p> <div class="table" id="CD009841-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change from baseline in sweat chloride concentration in FEV1 responders and FEV1 non‐responders in the phase 3 G551D studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Paediatric phase 3 G551D study</b> <b>(</b><a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Adult phase 3 G551D study</b> <b>(</b><a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference (mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference (mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimal responders (less than 5% point improvement)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐55.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐46.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> responders (5% point improvement) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐53.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐49.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.0001</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FEV<sub>1</sub>: forced expiratory volume at one second </p> </div> </div> <p>In the R117H trial, at 24 weeks a significant reduction in sweat chloride concentrations was reported in the ivacaftor group compared to placebo group, MD ‐24.00 mmol/L (95% CI ‐28.01 to ‐19.99) (P = &lt;0.0001) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>) (<a href="./references#CD009841-fig-0039" title="">Analysis 3.9</a>). Treatment effect was adjusted for continuous baseline values of age and % predicted FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). In addition, age subgroup analysis showed significant reductions in sweat chloride concentrations for both participants aged 6 to 11 years and 18 years and over (<a href="#CD009841-tbl-0006">Table 3</a>). </p> </section> <section id="CD009841-sec-0116"> <h5 class="title">11. Cost of treatment</h5> <p>No trials reported on the cost of ivacaftor treatment.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009841-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009841-sec-0117"></div> <section id="CD009841-sec-0118"> <h3 class="title" id="CD009841-sec-0118">Summary of main results</h3> <p>The CFTR protein product of a class III mutation is transported to the cell membrane, but displays defective chloride ion gating and dysregulation of sodium channels resulting in a severe CF phenotype; characterised by chronic airway infection and inflammation and pancreatic insufficiency. Agents that repair the underlying gating defects (CFTR potentiators) restore CFTR function for class III mutations and correct the abnormal transmembrane salt transport in cell and animal models (<a href="./references#CD009841-bbs2-0088" title="VanGoorF , HadidaS , GrootenhuisPD , BurtonB , CaoD , NeubergerT , et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX‐770.. Proceedings of the National Academy of Sciences of the United States of America2009;106(44):18825‐30. [DOI: 10.1073/pnas.0904709106] ">Van Goor 2009</a>). These CFTR potentiators may also have a role in repairing the underlying gating defect in the minimal amounts of class II CFTR that are transported to the cell membrane and for the restrictive movement of chloride ions in class IV CFTR. </p> <p>This review examines whether CFTR potentiators improve clinically relevant endpoints in CF. Five trials with 447 participants met the inclusion criteria for this review; one compared 150 mg and 250 mg doses of ivacaftor (a potentiator) to placebo (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) and four compared 150 mg of ivacaftor to placebo (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Three trials examined the impact of ivacaftor on people with a class III mutation (G551D) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). One trial enrolled participants with a class II mutation (F508del) (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>) and one enrolled participants with a class IV mutation (R117H) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>The trial that evaluated ivacaftor for people with F508del enrolled participants aged 12 years or over (n = 140) for a duration of 16 weeks (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). The first G551D trial was a phase 2 trial enrolling participants 18 years and over and measuring a number of outcomes at 14 and 28 days (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). This was followed by two phase 3 trials, the first enrolling participants aged 12 years and older (n = 167) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) and the second enrolled participants aged 6 to 11 years (n = 52) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). These trials reported outcomes at 24 and 48 weeks. The R117H trial enrolled participants over six years of age (n = 69) and measured outcomes at 24 weeks (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>The primary end points for these trials were safety (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>) or change in FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>) or both (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). With respect to this review's primary outcomes, there were no deaths reported in any of the trials and the length and size of the trials precluded valid assessment of the impact of ivacaftor on survival. For CFQ‐R scores, no significant difference was reported in the F508del trial (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). The adults randomised to ivacaftor in the phase 2 G551D trial did not report significantly higher CFQ‐R respiratory domain scores 28 days (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). However, adults in the phase 3 G551D trial reported significantly higher CFQ‐R respiratory scores at 24 weeks, MD 8.10 (95% CI 4.63 to 11.57) and at 48 weeks, MD 8.70 (95% CI 5.51 to 11.89) (<a href="./references#CD009841-fig-0013" title="">Analysis 2.3</a>). This finding was not reproduced in the paediatric participants (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). The R117H trial reported significantly higher CFQ‐R scores at 24 weeks in participants randomised to ivacaftor, MD 8.40 (95% CI 2.17 to 14.63) (<a href="./references#CD009841-fig-0031" title="">Analysis 3.1</a>) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). Again, for relative change in FEV<sub>1</sub>, no significant improvement was reported in the F508del trial (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). The phase 2 G551D trial did not report treatment with ivacaftor resulted in a significant improvement in relative change in FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). However, in the adult G551D phase 3 trial, significant improvements in relative change in FEV<sub>1</sub> were seen early (after 15 days) and maintained through to 48 weeks, MD 16.80% (95% CI 13.50 to 20.10) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). Significant improvements in this outcome were also seen at 24 weeks in the paediatric trial, MD 17.4% (P &lt; 0.0001), but results at 48 weeks were not published (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). The R117H did not report any significant improvement in relative change in FEV<sub>1</sub> (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>We compared the number of participants experiencing adverse effects between the ivacaftor group and the placebo group. Combined data from both G551D phase 3 trials demonstrated a reduced reporting of cough, OR 0.57 (95% CI 0.33 to 1.00) and reduced episodes of decreased pulmonary function, OR 0.29 (95% CI 0.10 to 0.82) in the ivacaftor group (<a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>). Increased reports of dizziness were recorded in participants receiving ivacaftor in the adult G551D trial (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>), but this adverse effect was not reported by any other trial (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). Data from the R117H trial showed increased reporting of adverse effects in the ivacaftor group except for pulmonary exacerbation, OR 0.93 (95% CI 0.35 to 2.44), however, these results were not significant (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>) (<a href="./references#CD009841-fig-0034" title="">Analysis 3.4</a>). No trial reported a significant increase in adverse effects leading to interruption or termination of the trial drug (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>Combined data from the phase 3 G551D trials demonstrated significantly fewer participants experienced 'serious' cases of pulmonary exacerbation in the ivacaftor group, OR 0.34 (95% CI 0.17 to 0.70) (<a href="./references#CD009841-fig-0023" title="">Analysis 2.13</a>). When considering all data for exacerbations, fewer adults in the ivacaftor group reported exacerbations in the adult phase 3 G551D trial, OR 0.54 (95% CI 0.29 to 1.01) (<a href="./references#CD009841-fig-0019" title="">Analysis 2.9</a>); also, more participants in the placebo group required hospitalisation and IV antibiotics for pulmonary exacerbations and a greater proportion of participants in the ivacaftor group were exacerbation‐free at the 24 and 48 week time points (<a href="./references#CD009841-fig-0020" title="">Analysis 2.10</a>) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). In the R117H trial fewer participants in the ivacaftor group experienced pulmonary exacerbations, hospitalisation and IV antibiotics for the exacerbation, but results were not significant (<a href="./references#CD009841-fig-0035" title="">Analysis 3.5</a>) (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). This effect was not reported by the remaining three trials (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). </p> <p>The adverse effects profile of ivacaftor should be interpreted with caution as it was based on small numbers of participants. Furthermore, none of the included trials were powered to assess this outcome (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>No significant weight gain or change in BMI scores were reported in the F508del or R117H trials (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). Participants in both phase 3 G551D trials demonstrated significant weight gain on ivacaftor at 24 weeks, MD 2.37 kg (95% CI 1.68 to 3.06) and 48 weeks, MD 2.75 kg (95% CI 1.74 to 3.75) (<a href="./references#CD009841-fig-0029" title="">Analysis 2.19</a>). These two trials also reported that significantly higher BMI scores were achieved in the ivacaftor group; for children, MD 1.09 kg/m² (P = 0.0003) and for adults, MD 0.93 kg/m² (P &lt; 0.0001). Significantly higher BMI for age z scores were reported for children in the ivacaftor group at 24 weeks, MD 0.34 (P ≤ 0.001) and at 48 weeks, MD 0.45 (P &lt; 0.001) (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). In a subset of participants aged 12 to 20 years old from the adult trial, a higher BMI for age Z score was reported at 48 weeks, MD 0.33 (P = 0.0490) (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>All trials reported significant reductions in sweat chloride concentrations (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The F508del trial reported a MD of ‐2.90 mmol/L (95% CI ‐5.60 to ‐0.20) (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). The phase 2 G551D trial reported median values at 28 days; in the 150 mg ivacaftor group, median ‐64.5 mmol/L (P = 0.02) and in the 250 mg ivacaftor group, median ‐43.0 mmol/L (P = 0.03) (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>). Combined data from the phase 3 G551D trials demonstrated significant reductions in sweat chloride concentration in participants on ivacaftor at 24 weeks, MD ‐50.19 mmol/L (95% CI ‐56.20 to ‐44.18) and 48 weeks, MD ‐49.74 mmol/L (95% CI ‐54.61 to ‐44.87) (<a href="./references#CD009841-fig-0030" title="">Analysis 2.20</a>). Similarly, the ivacaftor group in the R117H trial reported a significant reduction in sweat chloride concentration at 24 weeks, MD ‐24.00 mmol/L (95% CI ‐28.01 to ‐19.99) (<a href="./references#CD009841-fig-0039" title="">Analysis 3.9</a>). </p> </section> <section id="CD009841-sec-0119"> <h3 class="title" id="CD009841-sec-0119">Overall completeness and applicability of evidence</h3> <p>The DISCOVER trial recruited 140 participants homozygous for the F508del mutation, who were a representative sample for people with this mutation aged from 12 years upwards. This trial was included because it evaluated ivacaftor, although on a population with class II mutations in which a minimal amount of CFTR is able to reach the cell surface. In light of the results that failed to reach statistical significance in this population, trials with younger participants with F508del are not appropriate (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>). </p> <p>Three trials recruited 238 participants with the G551D mutation representing a significant proportion of all people with this mutation in the countries where the trials were undertaken (<a href="./references#CD009841-bbs2-0001" title='AccursoF , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickD , et al. Improvement in sweat chloride concentration by the CFTR potentiator VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):296. [Abstract no.: 240; CFGD Register: BD165c; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine2010;363(21):1991‐2003. [CFGD Register: BD165i; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary appendix to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐33 online. [CFGD Register: BD165j; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (disclosure forms) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1991‐2003 online. [CFGD Register: BD165k; MEDLINE: 98135729] AccursoFJ , RoweSM , ClancyJP , BoyleMP , DunitzJM , DuriePR , et al. Online supplementary material (protocol) to "Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation" [online]. New England Journal of Medicine2010;363(21):1‐121 online. [CFGD Register: BD165l; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Final results of a 14‐and 28‐day study of VX‐770 in subjects with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S25. [Abstract no.: 97; CFGD Register: BD165d; MEDLINE: 98135729] AccursoFJ , RoweSM , DuriePR , KonstanMW , DunitzJ , HornickDB , et al. Interim results of phase 2a study of VX‐770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology2008;43(S1):295. [Abstract no.: 267; CFGD Register: BD165b; MEDLINE: 98135729] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis2014;13(2):139‐147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025] AccursoFJ , VanGoorF , ZhaJ , StoneAJ , DongQ , OrdonezCL , et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis2014;13(2):139‐47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288] AntoniuSA . Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX‐770 in persons with cystic fibrosis and the G551D‐CFTR mutation. New England Journal of Medicine 2010;363(21):1991‐2003. Expert Opinion on Investigational Drugs2011;20(3):423‐5. [CFGD Register: BD165m; MEDLINE: 98135729] BoyleM , ClancyJP , RoweSM , DurieP , DunitzJ , KonstanMW , et al. Effect of VX‐770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D‐CFTR mutation. Pediatric Pulmonology2009;44(S32):287. [Abstract no.: 217; CFGD Register: BD165f] ClancyJP , RoweSM , DurieP , FreedmanS , DongQ , OrdonezC , et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology2009;44(S32):288. [Abstract no.: 222; CFGD Register: BD165e; MEDLINE: 98135729] DonaldsonS , AccursoF , RoweS , ClancyJ , BoyleM , DunitzJ , et al. Improved CFTR and lung function with VX‐770, a novel investigational potentiator of CFTR, in subjects with the G551D‐CFTR mutation. European Respiratory Society Annual Congress; 2010 Sep 18‐22; Barcelona, Spain. 2010:34s. [Abstract no.: 359; CENTRAL: 777402; CFGD Register: BD165s; CRS: 5500050000000276] KonstanMW , AccursoFJ , BoyleMP , ClancyJP , OrdonezCL , ZhaJetal . Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D‐CFTR Mutation Treated With VX‐770, An Investigational Oral Potentiator Of CFTR. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A2336. [CENTRAL: 758845; CFGD Register: BD165t; CRS: 5500050000000280] RoweSM , ClancyJP , BoyleM , vanGoorF , OrdonezC , DongQ , et al. Parallel effects of VX‐770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [Abstract no.: 74; CFGD Register: BD165h; MEDLINE: 98135729] RoweSM , LiuB , HillA , HathorneH , CohenM , BeamerJR , et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D‐CFTR mutation. PloS One2013;8(7):e66955. [CFGD Register: BD165o; ] RoweSM , vanGoorF , ClancyJJP , DuriePR , KonstanMW , DunitzJ , et al. Corresponding effects of VW‐770 on NPD in vivo &amp; human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology2010;45 Suppl 33:319. [Abstract no.: 281; CFGD Register: BD165g] vanGoorF , HadidaS , NegulescuP , ClancyJP , AccursoFJ , AshlockMA , et al. Relationship of VX‐770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX‐770. Pediatric Pulmonology2008;43(S31):314.. [Abstract no.: 319; CFGD Register: BD165a; MEDLINE: 98135729] '>Accurso 2010</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). It can be assumed that the results are applicable to those with the G551D mutation not included in the trials; however, current trials have not enrolled children under six years of age or pregnant women. There are insufficient data for some outcomes, which we considered to be important for this review: school or work attendance; radiological measures of lung disease; acquisition of respiratory pathogens; and cost of treatment. One G551D trial reported on hospitalisations and extra courses of antibiotics (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). </p> <p>The R117H trial recruited 69 participants with the R117H mutation. Results are not applicable to individuals with other class IV mutations and the small sample size reduces the applicability of this evidence to people with cystic fibrosis who carry the R117H mutation (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). </p> <p>There is no current evidence to support the use of CFTR potentiators in people with other class III to V mutations (not G551D). While there are trials recruiting people with other class III to V mutations, these have not be included in this review due to their cross‐over trial design (<a href="./references#CD009841-bbs2-0024" title="DeBoeckK , MunckA , WalkerS , FaroA , HiattP , ChanJ , et al. The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non‐G551D‐CFTR gating mutation, the KONNECTION study. Journal of Cystic Fibrosis2014;13 Suppl 2:S1. [Abstract no.: WS1.1; CENTRAL: 998097; CFGD Register: BD201b; CRS: 5500125000000707] DeBoeckK , PaskavitzJ , ChenX , HigginsM . Ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non‐G551D‐CFTR gating mutation: phase 3, part 1 results. Pediatric Pulmonology2013;48 Suppl 36:292. [Abstract no.: 241; CENTRAL: 962356; CFGD Register: BD201a; CRS: 5500125000000421] ">KONNECTION 2013</a>; <a href="./references#CD009841-bbs2-0028" title="NCT01685801 . Pilot study testing the effect of ivacaftor on lung function in subjects with cystic fibrosis and residual CFTR function [A pilot study testing the effect of ivacaftor on lung function in subjects with cystic fibrosis, residual CFTR function, and FEV1 ≥40% predicted]. clinicaltrials.gov/ct2/show/NCT01685801 (first received 14 September 2012). ">NCT01685801</a>; <a href="./references#CD009841-bbs2-0029" title="NCT01784419 . Short term effects of ivacaftor in non‐G551D cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT01784419 (first received 05 February 2013). ">NCT01784419</a>). </p> </section> <section id="CD009841-sec-0120"> <h3 class="title" id="CD009841-sec-0120">Quality of the evidence</h3> <p>All the included trials were RCTs which represent the highest quality with regards to trial design. </p> <p>The overall risk of bias across the included trials was judged to be moderate. Random sequence generation, allocation concealment and blinding of trial personnel were well‐documented. Blinding of participants was less clear, as details of ivacaftor and placebo tablets (such as taste, colour and consistency) were not provided. Participant data were excluded from the analysis in four trials (<a href="./references#CD009841-bbs2-0002" title="FlumePA , BorowitzD , LiouT , LiH , YenK , OrdonezC , et al. VX‐770 in subjects with CF and homozygous for the F508del‐CFTR mutation. Pediatric Pulmonology2011;46 Suppl 34:284. [Abstract no.: 206; CFGD Register: BD168b; MEDLINE: 98135729] FlumePA , BorowitzDS , LiouTG , LiH , YenK , OrdonezCL , et al. VX‐770 in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Journal of Cystic Fibrosis2011;10 Suppl 1:S16. [Abstract no.: 61; CFGD Register: BD168a; MEDLINE: 98135729] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24. [CFGD Register: BD168c; ] FlumePA , LiouTG , BorowitzDS , LiH , YenK , OrdonezCL , et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del‐CFTR mutation. Chest2012;142(3):718‐24 online. [CFGD Register: BD168d] ">DISCOVER 2011</a>; <a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>; <a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>; <a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). The risk of selective reporting was generally high as trials did not always report on outcomes outlined in the protocol, or present data for all outcomes and report on outcomes considered important by the review authors. </p> <p>The quality of the evidence in this review is judged to be moderate to low, mainly due to risk of bias from incomplete outcome data and selective reporting and imprecision of results, particularly where few individuals have experienced adverse events (<a href="./full#CD009841-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009841-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009841-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD009841-sec-0121"> <h3 class="title" id="CD009841-sec-0121">Potential biases in the review process</h3> <p>The review authors conducted a comprehensive literature search of online journal databases using the Cystic Fibrosis and Genetic Disorders Review Group's Cystic Fibrosis Trials Register and online trials databases (<a href="./appendices#CD009841-sec-0129">Appendix 1</a>) and also of manual searching of journal conference abstracts. Two authors independently applied the inclusion and exclusion criteria to the resultant literature and extracted relevant trials. The authors independently extracted data and assessed the risk of bias of the included trials. If they failed to reach a consensus on the risk of bias in a trial, a third author (KWS) arbitrated. The initial analyses were undertaken by one review author (SP) and checked for appropriateness by the review statistician (KD). MS completed the analysis for the update of the review. This methodological approach ensured that risks of bias in the review process were kept to a minimum. </p> <p>This review has assessed all available published trial data. Trial authors were contacted for relevant unpublished information and individual participant data. To date, a protocol synopsis and summary of product characteristics have been provided with regards to information requested for the R117H trial (<a href="./references#CD009841-bbs2-0004" title="MossR . Study of ivacaftor in subjects with cystic fibrosis who have the R117H‐CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014)2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199; NCT01614457] MossR , FlumePA , ElbornJ , CookeJ , RoweSM , McColleySA , et al. Effects of ivacaftor in CF patients with R117H‐CFTR. Pediatric Pulmonology2014;49 Suppl 38:221. [Abstract no.: 17; CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His‐CFTR mutation: a double‐blind, randomised controlled trial. The Lancet. Respiratory Medicine2015;3(7):524‐33. [CFGD Register: BD204d] MossRB , FlumePA , ElbornJS , CookeJ , RoweSM , McColleySA , et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H‐CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis2014;13 Suppl 2:S44. [Abstract no.: WS23.6; CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012] ">KONDUCT 2015</a>). We are not aware of any unpublished trials, although we have highlighted issues with selective reporting in the included trials. </p> </section> <section id="CD009841-sec-0122"> <h3 class="title" id="CD009841-sec-0122">Agreements and disagreements with other studies or reviews</h3> <p>We are aware of one other published review of ivacaftor for people with CF which included the phase 3 G551D trials and data from the open‐label extensions to these trials (<a href="./references#CD009841-bbs2-0089" title="WhitingP , AlM , BurgersL , WestwoodM , RyderS , HoogendoornM , ArmstrongN , et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost‐effectiveness analysis. Health Technology Assessment (Winchester, England)2014;18(18):1‐106. [DOI: 10.3310/hta18180] ">Whiting 2014</a>). In line with this Cochrane Review, the Whiting review also concluded that ivacaftor has a clinically relevant impact on people with CF with the G551D mutation. We identified disagreements between the two reviews concerning the methodological quality and risk of bias assessments for the phase 3 G551D trials, although both reviews have used the Cochrane risk of bias tool. In the Whiting review, the authors judged the risk of bias for all methodological aspects of the adult phase 3 G551D trial to be low; whereas we judged this trial to have an unclear risk of detection bias and high risks of attrition bias and selective reporting bias (<a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a>). With regards to the paediatric phase 3 G551D trial, disagreements were identified for participant and outcome assessor blinding, incomplete outcome data and selective reporting. The Whiting review judged this trial to have a low risk of detection bias, performance bias and selective outcome reporting bias and an unclear risk of attrition bias; while we judged the trial to have an unclear risk of detection and performance bias and a high risk of attrition bias and selective outcome reporting bias (<a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a>). The overall methodological quality of the phase 3 G551D trials was assessed to be higher in the Whiting review than in this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009841-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009841-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. This Figure demonstrates the high proportion of trials that were judged to have a high risk of attrition bias (incomplete outcome data addressed) and selective reporting bias." data-id="CD009841-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. This Figure demonstrates the high proportion of trials that were judged to have a high risk of attrition bias (incomplete outcome data addressed) and selective reporting bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009841-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 1 FEV1 ‐ relative change from baseline." data-id="CD009841-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 1 FEV<sub>1</sub> ‐ relative change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 2 Adverse effects." data-id="CD009841-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 2 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 3 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or discontinuation (severe)." data-id="CD009841-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 3 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or discontinuation (severe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 4 FEV1 % predicted ‐ absolute change from baseline." data-id="CD009841-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 4 FEV<sub>1</sub> % predicted ‐ absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 5 Antibiotic treatment of sinopulmonary signs or symptoms." data-id="CD009841-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 5 Antibiotic treatment of sinopulmonary signs or symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 6 Weight (kg) ‐ change from baseline." data-id="CD009841-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 6 Weight (kg) ‐ change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 7 Sweat chloride concentration ‐ change from baseline." data-id="CD009841-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation, Outcome 7 Sweat chloride concentration ‐ change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 1 CFQ‐R score (respiratory domain, child version) ‐ adjusted change from baseline." data-id="CD009841-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 1 CFQ‐R score (respiratory domain, child version) ‐ adjusted change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 2 CFQ‐R score (respiratory domain score, parent/caregiver version) ‐ adjusted change from baseline." data-id="CD009841-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 2 CFQ‐R score (respiratory domain score, parent/caregiver version) ‐ adjusted change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 3 CFQ‐R score (respiratory domain score, pooled) ‐ absolute change from baseline." data-id="CD009841-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 3 CFQ‐R score (respiratory domain score, pooled) ‐ absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 4 FEV1 ‐ mean relative change from baseline." data-id="CD009841-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 4 FEV<sub>1</sub> ‐ mean relative change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 5 Adverse events occurring in greater than or equal to 5% of trial participants." data-id="CD009841-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 5 Adverse events occurring in greater than or equal to 5% of trial participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 6 All adverse events." data-id="CD009841-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 6 All adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 7 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or discontinuation (severe)." data-id="CD009841-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 7 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or discontinuation (severe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 8 Serious adverse events." data-id="CD009841-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 8 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 9 The number of G551D participants who developed episodes of pulmonary exacerbation." data-id="CD009841-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 9 The number of G551D participants who developed episodes of pulmonary exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 10 Time to first pulmonary exacerbation." data-id="CD009841-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 10 Time to first pulmonary exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 11 Maximum liver function test abnormalities in adolescents/adults at 48 weeks." data-id="CD009841-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 11 Maximum liver function test abnormalities in adolescents/adults at 48 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 12 Duration of hospitalisation for pulmonary exacerbation." data-id="CD009841-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 12 Duration of hospitalisation for pulmonary exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 13 Number of hospitalisations for pulmonary exacerbations." data-id="CD009841-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 13 Number of hospitalisations for pulmonary exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 14 FEV1 (% predicted) ‐ mean absolute change from baseline." data-id="CD009841-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 14 FEV<sub>1</sub> (% predicted) ‐ mean absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 15 FEV1 (litres) ‐ mean absolute change from baseline." data-id="CD009841-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 15 FEV<sub>1</sub> (litres) ‐ mean absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 16 Change from baseline through week 24 in percent of predicted FEV1 according to subgroup." data-id="CD009841-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 16 Change from baseline through week 24 in percent of predicted FEV<sub>1</sub> according to subgroup. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 17 Number of pulmonary exacerbations requiring intravenous antibiotics." data-id="CD009841-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 17 Number of pulmonary exacerbations requiring intravenous antibiotics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 18 Days with intravenous antibiotics administered for pulmonary exacerbations." data-id="CD009841-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 18 Days with intravenous antibiotics administered for pulmonary exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 19 Weight ‐ change from baseline (kg)." data-id="CD009841-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 19 Weight ‐ change from baseline (kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 20 Sweat chloride level ‐ change from baseline." data-id="CD009841-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation, Outcome 20 Sweat chloride level ‐ change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 1 CFQ‐R score (respiratory domain score, pooled) ‐ absolute change from baseline." data-id="CD009841-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 1 CFQ‐R score (respiratory domain score, pooled) ‐ absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 2 FEV1 relative change from baseline." data-id="CD009841-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 2 FEV<sub>1</sub> relative change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 3 Adverse events." data-id="CD009841-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 3 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 4 Adverse events in &gt; 15% of participants." data-id="CD009841-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 4 Adverse events in &gt; 15% of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 5 Summary of pulmonary exacerbations." data-id="CD009841-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 5 Summary of pulmonary exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 6 Time to first pulmonary exacerbation." data-id="CD009841-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 6 Time to first pulmonary exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 7 FEV1 predicted % absolute change from baseline." data-id="CD009841-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 7 FEV<sub>1</sub> predicted % absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 8 BMI absolute change from baseline." data-id="CD009841-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 8 BMI absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009841-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/urn:x-wiley:14651858:media:CD009841:CD009841-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_t/tCD009841-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 9 Sweat chloride concentration ‐ change from baseline." data-id="CD009841-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation, Outcome 9 Sweat chloride concentration ‐ change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/media/CDSR/CD009841/image_n/nCD009841-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009841-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with the F508del CFTR mutation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ivacaftor compared with placebo for cystic fibrosis with the F508del CFTR mutation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis and with the F508del CFTR mutation<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> ivacaftor<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ivacaftor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Survival</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No deaths reported.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No deaths reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> <p><b>Total score</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL (CFQ‐R)</b> </p> <p><b>Respiratory domain</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b><br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no significant difference between groups at 16 weeks.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> % predicted Relative change from baseline</b> </p> <p>Follow‐up:16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported.<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean FEV<sub>1</sub> (% predicted) was 2.4% higher (0.95% lower to 5.75% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b><br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no significant difference between groups at 16 weeks.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> % predicted Absolute change from baseline</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported.<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean FEV<sub>1</sub> (% predicted) was 1.7% higher (0.65% lower to 4.05% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b><br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no significant difference between groups at 16 weeks.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Follow‐up:16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events in the placebo group were: pulmonary exacerbation, cough, oropharyngeal pain and fatigue. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events in the ivacaftor group were: cough, pulmonary exacerbation, upper respiratory tract infection and nasal congestion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>140</b><br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no significant difference between groups in terms of any other adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to first pulmonary exacerbation</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean placebo group risk across studies, unless otherwise stated. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CFQ‐R:</b> Cystic Fibrosis Questionnaire‐Revised; <b>CFTR</b> : cystic fibrosis transmembrane regulator; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume at 1 second; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Presentation of the data prevented including data in analysis therefore results are presented narratively.<br/> 2. Only differences between placebo and ivacaftor groups were presented, results within the placebo group were not presented therefore an assumed risk cannot be calculated.<br/> 3. Downgraded once due to risk of bias from incomplete outcome data and/or selective reporting in all of the included studies.<br/> 4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specific events are very wide (also see <a href="./references#CD009841-fig-0005" title="">Analysis 1.2</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with the F508del CFTR mutation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009841-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with at least one G551D CFTR mutation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ivacaftor compared with placebo for cystic fibrosis with at least one G551D CFTR mutation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis and with at least one G551D CFTR mutation<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> ivacaftor<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ivacaftor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Survival</b> </p> <p>Follow‐up: 2 ‐ 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>238</b><br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> <p><b>Total score</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL (CFQ‐R)</b> </p> <p><b>Respiratory domain</b> </p> <p>Follow‐up: 2 ‐ 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>222</b> </p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small phase 2 trial (n = 19) showed no significant difference at 2 or 4 weeks.</p> <p>A phase 3 trial (n = 151) in adults showed significantly higher quality of life in the ivacaftor group compared to placebo at 48 weeks </p> <p>A phase 3 trial (n = 52) showed no significant difference at 24 or 48 weeks in the child version of the CFQ‐R. The same trial showed a significantly higher quality of life in the ivacaftor group compared to placebo at 48 weeks in the parent / caregiver version at 24 weeks but not at 48 weeks.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> % predicted Relative change from baseline</b> </p> <p>Follow‐up: 2 ‐ 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>232</b> </p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small phase 2 trial (n = 19) showed no significant difference at 2 or 4 weeks.</p> <p>Two phase 3 trials (n = 213) showed a significant improvement in FEV<sub>1</sub> at 24 weeks (MD ranged between 16.9% to 17.4%) </p> <p>One phase 3 trial (n = 161) showed a significant improvement in FEV<sub>1</sub> at 48 weeks (MD 16.8%). <sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FEV<sub>1</sub> L and % predicted</b> </p> <p><b>Absolute change from baseline</b> </p> <p>Follow‐up: 2 to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment.<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>232</b> </p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A small phase 2 trial (n = 19) showed no significant difference at 2 or 4 weeks.</p> <p>Two phase 3 trials (n = 213) showed a significant improvement in FEV<sub>1</sub> (L and % predicted) at 24 weeks and 48 weeks.<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Follow‐up: 2 ‐ 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events in the placebo group were: pulmonary exacerbation, cough, oropharyngeal pain and headache. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The most commonly reported adverse events in the ivacaftor group were: cough, pulmonary exacerbation, upper respiratory tract infection and headache. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>232</b> </p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary exacerbations were significantly more common in the placebo group. There was no significant difference between groups in terms of any other adverse events.<sup>8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to first pulmonary exacerbation</b> </p> <p>Follow‐up: 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>41% of the placebo group were exacerbation free at 48 weeks.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>67% of the ivacaftor group were exacerbation free at 48 weeks.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HR 0.46</b> (95% CI 0.29 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>161</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was also a statistically significant difference between groups at 24 weeks; 78% and 51% of the ivacaftor and placebo groups were exacerbation free respectively; HR 0.46 (95% CI 0.28 to 0.76). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean placebo group risk across studies, unless otherwise stated. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CFQ‐R:</b> Cystic Fibrosis Questionnaire‐Revised; <b>CFTR</b> : cystic fibrosis transmembrane regulator; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume at 1 second; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Presentation of the data prevented pooling the data from all three studies therefore results are summarised narratively.<br/> 2. Downgraded once due to risk of bias from incomplete outcome data and/or selective reporting in all of the included studies.<br/> 3. Downgraded once due to unexplained heterogeneity.<br/> 4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specific events are very wide (also see <a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>, <a href="./references#CD009841-fig-0016" title="">Analysis 2.6</a> and <a href="./references#CD009841-fig-0018" title="">Analysis 2.8</a>).<br/> 5. See analyses for numerical results (<a href="./references#CD009841-fig-0011" title="">Analysis 2.1;</a><a href="./references#CD009841-fig-0012" title="">Analysis 2.2</a>; <a href="./references#CD009841-fig-0013" title="">Analysis 2.3</a>).<br/> 6. See analysis for numerical results (<a href="./references#CD009841-fig-0014" title="">Analysis 2.4</a>).<br/> 7. See analyses for numerical results (<a href="./references#CD009841-fig-0024" title="">Analysis 2.14</a>; <a href="./references#CD009841-fig-0025" title="">Analysis 2.15</a>).<br/> 8. See analyses for numerical results (<a href="./references#CD009841-fig-0015" title="">Analysis 2.5</a>; <a href="./references#CD009841-fig-0016" title="">Analysis 2.6</a>; <a href="./references#CD009841-fig-0018" title="">Analysis 2.8</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with at least one G551D CFTR mutation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009841-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with at least one R117H CFTR mutation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ivacaftor compared with placebo for cystic fibrosis with at least one R117H CFTR mutation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis and with at least one R117H CFTR mutation </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> ivacaftor </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ivacaftor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Survival</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p><b>Total score</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL (CFQ‐R)</b> </p> <p><b>Respiratory domain</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adjusted CFQ‐R respiratory domain score was 8.40% higher (2.17% higher to 14.63% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a significant</p> <p>improvement in CFQ‐R respiratory domain scores at 24 weeks.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted Relative change from baseline</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adjusted FEV<sub>1</sub> (% predicted) was 5.00% higher (0.24% lower to 10.24% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between groups at 24 weeks.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> L and</b> </p> <p><b>% predicted</b> </p> <p><b>Absolute change from baseline</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adjusted FEV<sub>1</sub> (% predicted) was 2.10% higher (1.13% lower to 5.33% higher) in the ivacaftor group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between groups at 24 weeks.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 2 ‐ 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The most commonly reported adverse events in the placebo group were: pulmonary exacerbation and cough. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The most commonly reported adverse events in the ivacaftor group were: pulmonary exacerbation, cough, headache, nasal congestion, oropharyngeal pain, diarrhoea and increased sputum. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no</p> <p>significant difference between groups in terms of any other adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first</b> </p> <p><b>pulmonary</b> </p> <p><b>exacerbation</b> </p> <p>Follow‐up:</p> <p>24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63% of the placebo group were exacerbation free at 24 weeks.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68% of the ivacaftor group were exacerbation free at 24 weeks.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.93</b> (95% CI 0.42 to 2.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no</p> <p>significant difference between groups at 24 weeks.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CFQ‐R:</b> Cystic Fibrosis Questionnaire‐Revised; <b>CFTR</b> : cystic fibrosis transmembrane regulator; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume at 1 second; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Presentation of the data prevented including data in analysis therefore results are presented narratively.<br/> 2. Downgraded once due to risk of bias from selective reporting.<br/> 3. Treatment effect was adjusted for baseline values of age and % predicted FEV<sub>1</sub>.<br/> 4. Downgraded once due to imprecision: few events occurred therefore CIs for occurrence of specific events are very wide (also see <a href="./references#CD009841-fig-0034" title="">Analysis 3.4</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ ivacaftor compared with placebo for cystic fibrosis with at least one R117H CFTR mutation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009841-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of mutations affecting CFTR production, structure, and function</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Example mutation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Impact on CFTR structure and function</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G542X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthesis of CFTR is critically impaired, and no functional protein is produced. This is due to the presence of a premature stop codon in the nucleotide sequence. Individuals have minimal CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ΔF508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A full length of CFTR is produced, but this is structurally abnormal and destroyed by the cell before it reaches the cell membrane. This is called a defect in the intracellular trafficking pathway. Minimal amounts of CFTR can escape being destroyed and be transported to the cell membrane. However here, class II CFTR products display defective ion transport. Individuals have minimal CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G551D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CFTR is produced and embedded in the cell membrane, but the chloride channel does not respond (‘switch on’) to normal stimulation from the cell. This means there is no significant ion transport across the protein. Individuals have some residual CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R347P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CFTR is transported to the outer cell membrane, and responds to normal stimulation, but functions at a low level because chloride ions do not cross the channel appropriately. Individuals have some residual CFTR function. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A455E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal CFTR is produced, but the amount of protein is reduced. Individuals have some residual CFTR function. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CFTR: cystic fibrosis transmembrane conductance regulator</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of mutations affecting CFTR production, structure, and function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009841-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">CFQ‐R domain scores in the phase 2 G551D study at 4 weeks (median (range))</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Domain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Day 14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Day 28</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (n = 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐770 150 mg (n = 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐770 250 mg (n = 7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (n = 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐770 150 mg (n = 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐770 250 mg (n = 7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body image</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (‐11.1 to 22.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.2 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐11.1 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐22.2 to 11.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 44.4) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Digestive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐22.2 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> <p>(0 to 22.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 33.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eating disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐11.1 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 0) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3<br/> (‐6.7 to 20.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐26.7 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐20.0 to 26.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3<br/> (0 to 20.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐6.7 to 6.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7<br/> (‐6.7 to 20.0) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health perceptions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.2 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐33.3 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐22.2 to 22.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 11.1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 4.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1<br/> (‐4.2 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2<br/> (0 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> <p>(0 to 4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> <p>(‐8.3 to 25.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 to 12.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8<br/> (‐5.6 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6<br/> (0 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8<br/> (‐5.6 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3<br/> (0 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1<br/> (‐5.6 to 33.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Role</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐8.3 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐8.3 to 8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐8.3 to 8.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Social</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8<br/> (‐5.6 to 5.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐44.4 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐16.7 to 5.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8<br/> (‐11.1 to 5.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐11.1 to 5.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐16.7 to 11.1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment burden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐11.1 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐22.2 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.2 to 22.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6<br/> (‐22.2 to 11.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐22.2 to 11.1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2<br/> (‐16.7 to 8.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2<br/> (‐8.3 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐8.3 to 16.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐8.3<br/> (‐16.7 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐16.7 to 25.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 16.7) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 33.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0 to 33.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (‐33.3 to 33.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 to 33.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 to 33.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(‐33.3 to 33.3)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CFQ‐R: Cystic Fibrosis Questionnaire‐Revised</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">CFQ‐R domain scores in the phase 2 G551D study at 4 weeks (median (range))</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009841-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Outcomes for age subgroups in R117H study at 24 weeks</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Overall</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>6 ‐ 11 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>≥18 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life (CFQ‐R) ‐ respiratory domain (pooled)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% predicted FEV<sub>1</sub> ‐ absolute change from baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% predicted FEV<sub>1</sub> ‐ relative change from baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ‐ absolute change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweat chloride ‐ absolute change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐24.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐21.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Treatment difference was adjusted for age and % predicted FEV<sub>1</sub> </p> <p>BMI: body mass index<br/> CFQ‐R: cystic fibrosis questionnaire ‐ revised<br/> FEV<sub>1</sub>: forced expiratory volume in one second </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Outcomes for age subgroups in R117H study at 24 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009841-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Absolute change in FEV1 % predicted amongst pre‐defined subgroups in the adult phase 3 G551D study at 48 weeks.</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subgroup</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline percent of predicted FEV<sub>1</sub> of less than 70% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline percent of predicted FEV<sub>1</sub> of greater or equal to 70% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants from North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants from Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants from Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less than 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greater than or equal to 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>The treatment effect represents the difference between the ivacaftor group and the placebo group with respect to the absolute change from baseline through week 48. </p> <p>FEV<sub>1</sub>: forced expiratory volume at one second </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Absolute change in FEV1 % predicted amongst pre‐defined subgroups in the adult phase 3 G551D study at 48 weeks.</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009841-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change from baseline in sweat chloride concentration in FEV1 responders and FEV1 non‐responders in the phase 3 G551D studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Paediatric phase 3 G551D study</b> <b>(</b><a href="./references#CD009841-bbs2-0003" title='AhernsR , RodriguezS , YenK , DaviesJC . VX‐770 in subjects 6 to 11 years with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):283. [Abstract no.: 203; CFGD Register: BD171a; MEDLINE: 98135729] BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD171c//BD170d; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47(S35):298. [Abstract no.: 214; CFGD Register: BD171f//BD170i; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐25. [CFGD Register: BD171g; ] DaviesJC , WainwrightCE , CannyGJ , ChilversMA , HowenstineMS , MunckA , et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine2013;187(11):1219‐1225 online. [CFGD Register: BD171h; ] DaviesKC , LiH , YenK , AhrensR , on behalf of theVX08‐770‐103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.5; CFGD Register: BD171b; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD171j//BD170j; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD171i//BD170k; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD171e//BD170g; ] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation [abstract]. Journal of Cystic Fibrosis2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; ] StalveyMS , NiknianM , HigginsM , TarnV , HeltsheSL , RoweSM . Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D‐CTFR mutation: data from the ENVISION study. Journal of Cystic Fibrosis2016;15 Suppl:S101. [Abstract no.: 197; CFGD Register: BD171o] StalveyMS , NiknianM , HigginsM , TarnVE , HeltsheSL , RoweSM . Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo‐controlled study. Pediatric Pulmonology2015;50 Suppl 41:402. [Abstract no.: 554; CENTRAL: 1092205; CFGD Register: BD171m; CRS: 5500135000001394] StalveyMS , PaceJ , NiknianM , HigginsMN , TarnV , DavisJ , et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor. Pediatrics2017;139(2):e20162522. [CFGD Register: BD171q] '>ENVISION 2013</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Adult phase 3 G551D study</b> <b>(</b><a href="./references#CD009841-bbs2-0005" title='BorowitzD , LubarskyB , WilschanskiM , MunckA , GelfondD , BodewesF , et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation. Digestive Diseases and Sciences2016;61(1):198‐207. [CFGD Register: BD170u // BD171p] BorowitzD , RamseyB , DongQ , YenK , ElbornJS . Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.3; CFGD Register: BD170d//BD171c; ] BorowitzD , RamseyB , RodriguezS , YenK , ElbornJS . Nutritional status measures among persons with CF carrying the G551D‐CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology2012;47 Suppl 35:298. [Abstract no.: 214; CFGD Register: BD170i//BD171f; ] ElbornJS , RodriguezS , LubarskyB , GilmartinG , BellS . Effect of ivacaftor in patients with cystic fibrosis and the G551D‐CFTR mutation who have baseline FEV &gt;90% of predicted. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 257; CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401] ElbornS , PlantB , KonstanM , AhernsR , RodriguezS , MunckA , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. European Respiratory Journal2013;42:1073s. [Abstract no.: 5059; CENTRAL: 1099910; CFGD Register: BD170o // BD171n ; CRS: 5500050000000278; EMBASE: 71843034] FlumeP , WainwrightCE , TullisE , RodriguezS , DaviesJ , WagenerJ . Pulmonary exacerbations in CF patients with the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2013;12 Suppl 1:S63. [Abstract no.: 58; CFGD Register: BD170j//BD171j; ] FlumePA , WainwrightCE , Elizabeth TullisD , RodriguezS , NiknianM , HigginsM , et al. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis2018;17(1):83‐8. [CFGD Register: BD170w] GrieseM , RamseyB , RodriguezS , YenK , ElbornJS , on behalf of the VX08‐770‐102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 44; CFGD Register: BD170f; ] KonstanMW , PlantBJ , ElbornJS , RodriguezS , MunckA , AhrensR , et al. Efficacy response in CF patients treated with ivacaftor: post‐hoc analysis. Pediatric Pulmonology2015;50(5):447‐55. [CFGD Register: BD170v // BD171r] McKoneE , LiH , YenK , DaviesJC , on behalf of the VX08‐770‐105 study group. Long‐term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S13. [Abstract no.: WS6.4; CFGD Register: BD170h; ] McKoneE , SawickiG , MillarS , PastaD , RubinJ , KonstanM , et al. Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor. Journal of Cystic Fibrosis2016;15 Suppl 1:S42. [Abstract no.: ePS03.4; CFGD Register: BD170s] McKoneEF , BorowitzD , DrevinekP , GrieseM , KonstanMW , WainwrightC , et al. Long‐term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp‐CFTR mutation: a phase 3, open‐label extension study (PERSIST). The Lancet. Respiratory Medicine2014;2:902‐10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995] PlantBJ , KonstanM , AhernsR , RodriguezS , MunckA , ElbornJS , et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D‐CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis2013;12 Suppl 1:S62. [Abstract no.: 53; CFGD Register: BD170k//BD171i; ] QuittnerA , RamseyB , RodriguezS , YenK , ElbornJS . Patient‐reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Pediatric Pulmonology2012;47 Suppl 35:297. [Abstract no.: 212; CFGD Register: BD170g//BD171e; ] QuittnerA , SuthoffE , Rendas‐BaumR , BaylissMS , Sermet‐GaudelusI , CastiglioneB , et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D‐CFTR mutation: patient‐reported outcomes in the STRIVE randomized, controlled trial. Health and Quality of Life Outcomes2015;13:93. [CENTRAL: 1108956; CFGD Register: BD170r; CRS: 5500050000000282; PUBMED: 26135562] QuittnerAL , RamseyB , DongQ , YenK , ElbornJS . Patient‐reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D‐CFTR mutation. Journal of Cystic Fibrosis2012;11 Suppl 1:S67. [Abstract no.: 43; CFGD Register: BD170e//BD171d; ] RamseyB , DongQ , YenK , ElbornJ . Efficacy and safety of VX‐770 in subjects with cystic fibrosis and the G551D‐CFTR mutation. Pediatric Pulmonology2011;46(S34):286. [Abstract no.: 211; CFGD Register: BD170a; MEDLINE: 98135729] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine2011;365(18):1663‐72. [CFGD Register: BD170b; ] RamseyBW , DaviesJ , McElvaneyNG , TullisE , BellSC , DrevinekP , et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine2011;365(18):1663‐1672 online. [CFGD Register: BD170c; ] SeligerVI , AccursoFJ , KonstanMW , DongQ , LubarskyB , MuellerP . Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D‐CFTR mutation. Pediatric Pulmonology2013;48 Suppl 36:298. [Abstract no.: 259; CENTRAL: 921687; CFGD Register: BD170l; CRS: 5500125000000399] SolemCT , Vera‐LlonchM , LiuS , BottemanM , CastiglioneB . Impact of pulmonary exacerbations and lung function on generic health‐related quality of life in patients with cystic fibrosis. Health and Quality of Life Outcomes2016;14:63. [CFGD Register: BD170t] SolemCT , Vera‐LlonchM , LiuS , BottemanM , LinFJ , CastiglioneB . Impact of pulmonary exacerbations on EQ‐5D measures in patients with cystic fibrosis. Value in Health2014;17(7):A535. [Abstract no.: PSY77; CENTRAL: 1055060; CFGD Register: BD170q; CRS: 5500050000000277; EMBASE: 71673604] SolemCT , Vera‐LlonchM , LiuS , BottemanMF , LaschK , RodriguezS , et al. Responsiveness of the EQ‐5D index and visual analog scale to changes in lung function in patients with cystic fibrosis. Value in Health2014;17(3):A178. [Abstract no.: PRS52; CENTRAL: 1061016; CFGD Register: BD170p; CRS: 5500050000000281; EMBASE: 71488485] '>STRIVE 2011</a><b>)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference (mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment difference (mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimal responders (less than 5% point improvement)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐55.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐46.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> responders (5% point improvement) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐53.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐49.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.0001</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>FEV<sub>1</sub>: forced expiratory volume at one second </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change from baseline in sweat chloride concentration in FEV1 responders and FEV1 non‐responders in the phase 3 G551D studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/full#CD009841-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009841-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 FEV<sub>1</sub> ‐ relative change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.4 [‐0.95, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Pulmonary exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.14, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.18, 11.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.62 [0.59, 11.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Productive cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.15, 37.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.18, 11.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.22, 13.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.13, 33.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Oropharyngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.14, 4.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Upper abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.8 [0.11, 29.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [0.17, 41.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.08, 6.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Contact dermatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.48 [0.08, 158.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.23 [0.12, 228.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.12, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.14, 9.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16 Increase in C‐reactive protein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.09, 26.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or discontinuation (severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adverse effect requiring study drug interruption (moderate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.06, 27.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Adverse effect requiring study drug discontinuation (severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.06, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 FEV<sub>1</sub> % predicted ‐ absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐0.65, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Antibiotic treatment of sinopulmonary signs or symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 At 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.24, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Weight (kg) ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.2 [‐1.18, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sweat chloride concentration ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 At 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.9 [‐5.60, ‐0.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ivacaftor (VX‐770) versus placebo in people with the F508del CFTR mutation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009841-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 CFQ‐R score (respiratory domain, child version) ‐ adjusted change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.1 [‐1.35, 13.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.1 [‐1.56, 11.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 CFQ‐R score (respiratory domain score, parent/caregiver version) ‐ adjusted change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.9 [0.41, 11.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.9 [‐0.39, 10.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 CFQ‐R score (respiratory domain score, pooled) ‐ absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.1 [4.77, 11.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.6 [5.27, 11.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 FEV<sub>1</sub> ‐ mean relative change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.9 [13.60, 20.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.8 [13.50, 20.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events occurring in greater than or equal to 5% of trial participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Pulmonary exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.30, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.27, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Productive Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.29, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Pulmonary function test decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.07, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Wheezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.28, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Rales</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.28, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Oropharyngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.52, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.55, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.46, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.74, 4.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11 Bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.13, 18.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12 Otitis media</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [0.23, 89.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13 Rhinorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.17, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.14 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.21, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.15 Ear Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.00, 10.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16 Pharyngitis streptococcal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.17 Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.40, 8.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.18 Viral Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.04, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.19 Sinus Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.26, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.20 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.66, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.21 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.55 [0.69, 162.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.22 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.35, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.23 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.23, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.24 Abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.26, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.25 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.46, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.26 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.06, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.27 Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.45, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.28 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.20, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.29 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.37, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.30 Gastrooesophageal reflux disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.31 Weight decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.05, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.32 Asparate aminotransferase increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.40, 10.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.33 Alanine aminotransferase increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.21, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.34 Eosinophil count increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [0.15, 69.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.35 C‐reactive protein increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.12, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.36 Blood glucose increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.25, 11.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.37 Hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.09, 5.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.38 white blood cell count decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.39 Bacteria sputum Identified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.39, 10.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.40 Joint Sprain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.00, 4.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.41 Breath Sounds abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.05, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.42 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.28, 6.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.43 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.44 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.17, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.45 Neck pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.46 Haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.47 Respiratory tract congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.18, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.48 Sinus Congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.39, 10.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.49 Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.04, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.50 Pleutiric pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [0.27, 21.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.51 Respiration abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.05, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.52 Pharyngeal erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.53 Culture throat positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.09, 55.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.54 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.58, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.55 Acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.30, 12.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.56 Lymphadenopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.02, 12.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.57 Excoriation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.02, 12.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.58 Neutrophil count decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.59 Forced expiratory volume decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.60 Seasonal allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.02, 12.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.61 Allergic rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.41 [0.09, 312.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Cardiac Murmur</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Chest discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Pulmonary exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Respiratory tract congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.04, 30.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Cough decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Productive cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.00, 11.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Sputum abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Sputum decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 Sputum discolored</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12 Increased upper airway secretion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13 Increased bronchial secretion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.14 Rhonchi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.15 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.16 Tension headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.17 Sinus headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.18 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.19 Chronic sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.20 Sinus congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.21 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.22 Nasal oedma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.23 Nasal dryness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.24 Nasal turbinate abnormality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.25 Nasal septum disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.26 Mucosal erosion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.27 Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.28 Oral candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.29 Pharyngeal oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.30 Pharyngeal erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.31 Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.32 Tonsillar hypertrophy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.33 Abdominal distension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.34 Upper abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.35 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.36 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.37 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.38 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.01, 16.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.39 Flatulence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.40 Pyuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.41 White blood cells in urine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.42 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.02, 114.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.43 Contact dermatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.44 Erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.45 Excoriation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.46 Pruritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.47 Genital pruritis (female)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.48 Vulvovaginal mycotic infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.49 Photosensitivity reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.50 Allergy to arthropod bite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.51 Skin laceration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.52 Injection site oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.53 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.54 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.55 Joint crepitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.56 Lymphadenopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.57 Blood creatinine increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.01, 78.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Severity of adverse effects of therapy with regards to study drug interruption (moderate) or discontinuation (severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Adverse effect requiring study drug interruption (moderate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.14, 9.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Adverse effect requiring study drug discontinuation (severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.04, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.00, 10.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Complete atrioventricular block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Pulmonary exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.13, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Gastrooesophageal reflux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Pancreatic pseudocyst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Pancreatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.04, 222.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.00, 22.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.11 Weight decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12 Anaphylactic shock</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13 Catheter related complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.14 Implant site infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.15 Influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.16 Pseudomonal lung infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.02, 6.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.17 Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.18 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.19 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.20 Pleuritic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.21 Pulmonary embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.22 Respiratory distress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.23 Productive cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.02, 41.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.24 Respiratory failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.25 Pulmonary function test decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.00, 22.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.26 Lung consolidation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.00, 22.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.27 Myringitis bullous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.28 Hepatic enzyme increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.29 Cervix carcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.30 Musculoskeletal chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.31 Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.32 Spontaneous abortion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.33 Haematuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.34 IgA nephropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.04, 195.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.35 Nephrolithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.36 Renal Colic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.37 Testicular torsion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.00, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.38 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.04, 222.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.39 Muscle strain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.04, 222.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.40 Hepatic enzyme increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.04, 222.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.41 Adjustment disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.00, 22.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.42 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.00, 22.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.43 Affective disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.00, 22.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.44 Conversion disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.04, 222.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 The number of G551D participants who developed episodes of pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 At 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.07, 41.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.36, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Time to first pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.28, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.29, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Maximum liver function test abnormalities in adolescents/adults at 48 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 2x to 3x ULN AST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.57, 6.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 2x to 3x ULN ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.23, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 2x to 3x ULN Bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.17, 21.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 3x to 5x ULN AST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.04, 5.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 3x to 5x ULN ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 3x to 5x ULN Bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 5x to 8x ULN AST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.11, 71.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8 5x to 8x ULN ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9 5x to 8x ULN Bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.10 8x AST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 15.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.11 8x ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.83 [0.35, 134.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.12 8x Bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Duration of hospitalisation for pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐3.74, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of hospitalisations for pulmonary exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.16, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 FEV<sub>1</sub> (% predicted) ‐ mean absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.80 [8.91, 12.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.44 [8.56, 12.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 FEV<sub>1</sub> (litres) ‐ mean absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.17, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.11, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Change from baseline through week 24 in percent of predicted FEV<sub>1</sub> according to subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Subgroup 1: Baseline FEV1 of less than or equal to 90% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.9 [7.30, 22.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Subgroup 2: Baseline FEV1 of more than 90% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.9 [‐3.80, 17.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Subgroup 3: North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.8 [‐2.60, 14.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Subgroup 4: Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.60 [6.40, 42.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 Subgroup 5: Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.2 [‐3.70, 12.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 Subgroup 6: Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.2 [‐2.20, 12.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7 Subgroup 7: Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.8 [4.20, 23.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Number of pulmonary exacerbations requiring intravenous antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.18, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Days with intravenous antibiotics administered for pulmonary exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.35 [‐10.51, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Weight ‐ change from baseline (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.68, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 at 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.75 [1.74, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Sweat chloride level ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.19 [‐56.20, ‐44.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 At 48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.74 [‐54.61, ‐44.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ivacaftor (VX‐770) versus placebo in people with at least one G551D CFTR mutation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009841-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 CFQ‐R score (respiratory domain score, pooled) ‐ absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.4 [2.17, 14.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 FEV<sub>1</sub> relative change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [‐0.24, 10.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.16, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Adverse event leading to discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events in &gt; 15% of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Pulmonary exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.35, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.42, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.35, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Increased sputum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.33, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.33, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Oropharyhgeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.51, 15.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.33, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.48 [0.54, 202.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Wheezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.53 [0.48, 42.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Cystic fibrosis lung pathogen colonisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [0.32, 33.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Summary of pulmonary exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 All pulmonary exacerbations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.30, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Number of hospitalisations for pulmonary exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.06, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Number of pulmonary exacerbations requiring intravenous antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.06, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Time to first pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.42, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 FEV<sub>1</sub> predicted % absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.1 [‐1.13, 5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 BMI absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐1.57, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Sweat chloride concentration ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.00 [‐28.01, ‐19.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ivacaftor (VX‐770) versus placebo in people with at least one R117H CFTR mutation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009841.pub3/references#CD009841-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009841.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009841-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009841-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009841-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD009841-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009841-note-0016">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009841\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009841\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009841\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009841\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009841\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009841.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009841.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009841.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009841.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009841.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726020460"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009841.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726020464"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009841.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e896c59689379',t:'MTc0MDcyNjAyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 